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MicroRNAs are short endogenous non-coding RNAs that play pivotal roles in a 
diverse range of cellular processes. The miR-181 family is important in T cell 
development, proliferation and activation. In this study, we identified BRK1 as a 
novel target of miR-181c using a dual selection functional assay. Given the 
importance of miR-181 in T cell functions and the potential role of BRK1 in the 
WAVE2 complex as well as actin polymerisation in T cells, we therefore 
investigated the influence of the miR-181c-BRK1 axis in T cell functions. 
Stimulation of PBMC derived CD3+ T cells resulted in reduced expression of miR-
181c and upregulation of BRK1 protein expression, suggesting that the miR-181c-
BRK1 axis might be important in T cell activation. To further assess the role of miR-
181c-BRK1 axis in T cell activation, we overexpressed miR-181c in Jurkat T cells 
and suppressed BRK1 in Jurkat and primary T cells. We showed that overexpression 
of miR-181c or suppression of BRK1 resulted in reduction in T cell activation and 
actin polymerisation coupled with impairment in lamellipodia generation and 
immunological synapse formation. Additionally, we found that BRK1 silencing led to 
reduced expressions of other proteins in the WAVE2 complex including WAVE2, 
ABI1 and SRA1, suggesting that impairment of actin polymerisation-dependent T 
cell functions were a result of the instability of the WAVE2 complex following 
BRK1 depletion. We also demonstrated a reciprocal relationship of miR-181c and 
BRK1 in BM derived CD3+ T cells from MDS patients associated with T-LGL 
leukaemia, suggesting the regulation of BRK1 protein expression by miR-181c in 
this group of MDS patients. Collectively, we demonstrated that BRK1 is a novel 
downstream target of miR-181c and highlighted the important role of miR-181c-
BRK1 axis in T cell activation and actin polymerisation-mediated T cell functions.   
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1 Chapter 1 – Introduction 
1.1 MicroRNA 
1.1.1 Background of MicroRNA 
microRNAs (miRNAs) are short endogenous non-coding RNAs of 18-25 nucleotides 
in length which play an important role as negative regulators of gene expression 
either through mRNA degradation or translational repression (Ambros, 2001; Bartel, 
2004). The first miRNA, which is Lin-4, was discovered in 1993 and it was shown to 
be involved in the development of nematodes (Lee et al., 1993; Wightman et al., 
1993). In 2000, Let-7 was reported as a second miRNA discovered and similarly, it 
took part in the temporal development of C. elegans (Reinhart et al., 2000). A year 
later, more miRNAs were found and it is believed that miRNAs participate in 
regulatory functions in both vertebrates and invertebrates (Lagos-Quintana et al., 
2001). Sequences of miRNA are highly conserved among species and they have been 
shown to play critical roles in controlling a variety of biological processes, including 
cell differentiation, proliferation and apoptosis of haematopoietic progenitors 
(Almeida et al., 2011; Chen et al., 2004b; Cheng et al., 2005; Karp and Ambros, 
2005). According to miRBase Sequence Database (Release 21, June 2014), there are 
1881 identified human hairpin precursor miRNAs and 2603 identified human mature 
miRNAs, although the functional importance of many of these miRNA annotations 
remains to be determined.  
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1.1.2 MicroRNA Biogenesis 
The canonical biogenesis pathway of mammalian miRNAs is a two-step (nuclear and 
cytoplasmic) enzymatic processing of their precursors, which are encoded in the 
genome [reviewed in (Ha and Kim, 2014; Lin and Gregory, 2015; Milunović et al., 
2016; Stroynowska-Czerwinska et al., 2014)]. miRNAs are evolutionarily conserved 
and most of the human miRNAs are encoded within protein coding genes or in the 
intergenic regions (Rodriguez et al., 2004). The miRNA genes are typically 
transcribed by RNA polymerase II (Lee et al., 2004), or less frequently by RNA 
polymerase III (Borchert et al., 2006) into long, capped and poly-adenylated 
immature primary miRNA (pri-miRNA) containing a stem-loop structure. Pri-
miRNAs are co-transcriptionally recognised by a large protein complex, called the 
Microprocessor, the main components of which are the RNase III DROSHA and 
DiGeorge syndrome critical region 8 (DGCR8) (Denli et al., 2004; Gregory et al., 
2004; Han et al., 2004; Lee et al., 2003; Morlando et al., 2008). DROSHA is 
responsible for processing the pri-miRNAs into hairpin precursor molecules (pre-
miRNAs) of 70-100 nucleotides in length in the nucleus (Kim and Kim, 2007; Lee 
et al., 2003). Pre-miRNAs are then actively transported from the nucleus into the 
cytoplasm by Exportin 5 (Lund et al., 2004). In the cytoplasm, another RNase III, 
DICER, functioning with its protein partners, Argonaute (AGO), TRBP and/or 
PACT (Chendrimada et al., 2005; Koscianska et al., 2011; Lee et al., 2006) 
recognises the pre-miRNAs and cleaves them into miRNA/miRNA* duplexes of 
approximately 22 nucleotides in length (Koscianska et al., 2011; MacRae et al., 
2007). Subsequently, miRNA/miRNA* duplexes are loaded onto AGO protein to 
form an effector complex called miRNA-induced silencing complex (miRISC). The 
duplex is then unwound in which the N-terminal domain of AGO actively wedges 
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between miRNA strands and the PAZ domain unwinds the miRNA duplex. The 
AGO protein consists of four domains: PAZ (binds the 3’ end of the miRNA 
strand), middle (MID, binds the 5’ phosphate group of the miRNA), C-terminal 
PIWI (may possess endonucleolytic activity) and N-terminal domain (facilitates 
duplex unwinding). The passenger strand (miRNA*) is removed from miRISC and 
undergoes rapid degradation. miRNA within the mature miRISC is then bound to 
potential mRNA targets and regulates RNA levels either through mRNA degradation 
or translational repression [reviewed in (Ha and Kim, 2014; Lin and Gregory, 2015; 
Milunović et al., 2016; Stroynowska-Czerwinska et al., 2014)].  
Apart from the canonical pathway of miRNA biogenesis described above, various 
alternative mechanisms can generate miRNA that are independent of DROSHA 
(wherein miRNAs are generated from pre-miRNA-like introns, called mirtrons) or 
DICER activity (Cheloufi et al., 2010; Ha and Kim, 2014; Ruby et al., 2007). The 









Figure 1.1: Biogenesis of miRNA in human. (a) miRNA genes are first transcribed 
as primary miRNA (pri-miRNA) by polymerase II. The pri-mRNA is then processed 
by DROSHA into hairpin precursor miRNA (pre-miRNA). The pre-miRNA is 
exported from nucleus into cytoplasm by Exportin 5 (Exp5) and then further 
processed by DICER to form a miRNA/miRNA* duplex. The alternative DROSHA-
independent biogenesis pathway (mirtron pathway) is indicated by the orange dashed 
line. (b) miRNA/miRNA* duplex is then incorporated into miRISC loading complex 
(RLC). The duplex is unwound and the passenger strand (miRNA*) is degraded. 
Mature miRNA strand within the miRISC binds to its mRNA target for gene 
regulation [Taken from (Stroynowska-Czerwinska et al., 2014)]. 
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1.1.3 MicroRNA Regulation 
According to computational predictions and genome-wide identification of miRNA 
targets, each miRNA is estimated to regulate hundreds of different mRNAs, 
suggesting that more than half of the protein coding genes is modulated by miRNA 
in human (Friedman et al., 2009). The first mechanism by which miRNA regulates 
gene expression is through translational repression (Figure 1.2a). Translation 
repression can occur during the initiation or post-initiation step of translation. 
miRISC inhibits the initiation of translation by interfering with the recognition of the 
5’ terminal cap of mRNA by eukaryotic initiation factor 4F (eIF4F) complex and the 
recruitment of 40S small ribosomal subunit. miRISC can also block the translational 
initiation by preventing 60S subunit from joining the translational complex and 
inhibiting 80S ribosomal complex formation. In addition, the miRISC might also 
repress the translation at post-initiation steps by inhibiting protein elongation. 
Multiple proteins in the miRISC complex, such as AGO, GW182 and poly(A)-
binding protein (PABP), might be involved in the process of translational inhibition, 
but the exact mechanism of how this complex initiates translation block is currently 
unknown. The second mechanism of miRNA-mediated gene silencing is through 
mRNA decay via deadenylation (Figure 1.2b). The deadenylation process is 
characterised by two phases, which are rapid deadenylation mediated by PAN2-
PAN3 and poly(A) tail shortening mediated by CCR4-NOT complex. Following 
deadenylation, the 5’ terminal cap is removed by the decapping complex, DCP1-
DCP2 and the mRNA is degraded by cytoplasmic nuclease 5’-3’ exoribonuclease 1 
(XRN1). Alternatively, targeted mRNA can be directly degraded by 3’-5’ 
cytoplasmic exonuclease without undergoing the decapping process [reviewed in 
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(Fabian and Sonenberg, 2012; Jonas and Izaurralde, 2015; Milunović et al., 2016; 
Stroynowska-Czerwinska et al., 2014)]. 
In humans, partial pairing between miRNA and mRNA target sites is sufficient for 
gene regulation. It is believed that the most effective mRNA targeting is through 
seed-match pairing, which is the perfect pairing of the miRNA seed sequence 
(nucleotide 2 to 7 at the 5’ end of miRNA) to the target sites in 3’ untranslated region 
(3’UTR) of mRNA. In some cases, base pairing between the seed sequence in 
miRNA plus the miRNA nucleotide 8 and the 3’UTR of mRNA has also been 
observed. Seed-match pairing was believed to be both necessary and sufficient to 
confer mRNA recognition by miRNA and thus leads to the suppression of gene 
expression (Bartel, 2009; Voinnet, 2009). Nevertheless, there are a number of studies 
reporting that miRNA could regulate gene expression without pairing between 
miRNA seed sequence and 3’UTR of mRNA. For instance, Lytle et al. suggested 
that miRNA could bind to any part of their target mRNA such as the 5’UTR of target 
mRNA, resulting in repression of gene expression (Lytle et al., 2007). In addition, 
Grimson et al. have demonstrated that mRNA binding sites are present in the 3’ end 
of miRNA (Grimson et al., 2007) and Shin et al. have reported the binding sites at 
the central region of miRNA (Shin et al., 2010). Furthermore, miR-24 was shown to 
regulate several genes (E2F2, MYC, AURKB, CCNA2, CDC2, CDK4 and FEN1) by 
binding to seedless 3’UTR miRNA recognition elements (Lal et al., 2009) and miR-










Figure 1.2: The mechanisms of miRNA-mediated gene silencing in human. (a) 
miRNA-mediated translational repression: the miRISC inhibits translation initiation 
by interfering with eIF4F-cap recognition and 40S small ribosomal subunit 
recruitment. Alternatively, miRISC can also inhibit translation at the initiation step 
by antagonising 60S subunit joining and preventing 80S ribosomal complex 
formation. The miRISC might also inhibit translation at post-initiation steps by 
inhibiting ribosome elongation. (b) miRNA-mediated mRNA decay: the miRISC 
interacts with the CCR4-NOT and PAN2-PAN3 deadenylase complexes to facilitate 
deadenylation of the poly(A) tail (indicated by A(n)). Following deadenylation, the 5’ 
terminal cap (indicated by m7G) is removed by the DCP1-DCP2 decapping complex, 






1.2.1 Background of miR-181  
The miR-181 family is composed of four members, miR-181a, miR-181b, miR-181c 
and miR-181d, which are encoded by three independent paralog precursor transcripts 
on three separate chromosomes. miR-181a and miR-181b are located on chromosome 
1q32.1 (miR-181a-1 and miR-181b-1) and chromosome 9q33.3 (miR-181a-2 and 
miR-181b-2), while miR-181c and miR-181d are located on chromosome 19p13.12 
(Figure 1.3). In terms of sequence homology, the mature forms of miR-181a-1 and 
miR-181a-2, as well as miR-181b-1 and miR-181b-2, are identical. All four members 
of the miR-181 family have the same sequence at the 5’ seed region (nucleotide 2 to 
8), suggesting a significant degree of functional redundancy, but they differ either in 
the centre or 3’ end by no more than four nucleotides (Figure 1.4) (Ji et al., 2009).  
Although sequence variations are evident among the four mature miR-181s, each 
miR-181 is highly conserved among species and each transcript contains two miR-
181 paralogs in most species. In addition, it has been shown that miR-181a and miR-
181c are closely linked, while miR-181b and miR-181d are closely related (Figure 
1.3) (Ji et al., 2009). Albeit the seed region of the four members of miR-181 family 
are the same and most of their predicted target genes are overlapping, they might 
have different functions in different types of cancer (Lin et al., 2013). As reported by 
Liu et al., the different biological activities of miR-181a-1 and miR-181c are not 
determined by their mature sequences but largely rely on their unique loop 




Figure 1.3: Location of miR-181 family on chromosome. miR-181a and b are 
located on chromosome 1 and chromosome 9 while miR-181c and d are located on 
chromosome 19. There are two paralog groups of precursor miR-181, which are miR-
181a-1/a-2/c (yellow) and miR-181b-1/b-2/d (green), suggesting that miR-181a is 
closely linked to miR-181c while miR-181b is closely related to miR-181d. The 




Figure 1.4: Mature miR-181 sequences. The underlined nucleotides show the 
conserved bases among the four members of miR-181 family. The red letters indicate 






5’ AACAUUCAACGCUGUCGGUGAGU 3’ 
5’ AACAUUCAUUGCUGUCGGUGGGU 3’ 
5’ AACAUUCAAC - CUGUCGGUGAGU 3’ 
5’ AACAUUCAUUGUUGUCGGUGGGU 3’ 
 28 
1.2.2 Role of miR-181 in Haematopoiesis 
There is accumulating data providing evidence for the critical roles of miR-181 as 
regulators of the haematopoiesis. Firstly, miR-181 was suggested to be a positive 
regulator of B cell differentiation as miR-181 was found to be preferentially 
expressed in B lymphoid cells in mouse bone marrow (BM) and its overexpression in 
haematopoietic stem/progenitor cells (HSPC) resulted in an elevated fraction of B 
lineage cells both in vitro and in vivo (Chen et al., 2004a). Besides that, both Lu et al. 
and Choong et al. reported that miR-181a and miR-181b were overexpressed during 
erythroid differentiation in human umbilical cord blood-derived CD34+ cells 
(Choong et al., 2007; Lu et al., 2005). Furthermore, Li et al. demonstrated that in 
both K562 cells and human umbilical cord blood-derived CD34+ progenitor cells, 
miR-181 overexpression promoted megakaryocytic differentiation by repressing 
Lin28 expression, disrupting the Lin28-Let-7 reciprocal regulatory loop and in turn 
upregulating Let-7 (Li et al., 2012a). However, this finding contradicts Garzon et al. 
study where they reported that miR-181b and miR-181c were downregulated during 
in vitro megakaryocytic differentiation in CD34+ BM progenitors (Garzon et al., 
2006). Moreover, miR-181 family has also been shown to inhibit granulocytic and 
macrophage-like differentiation in HL-60 cells and CD34+ HSPC (Su et al., 2015). 
Additionally, miR-181a was suggested to regulate molecules that are critical to very 
early steps in haematopoiesis, blocking the differentiation of all haematopoietic 
lineages. Using computational analysis, this study predicted that miR-181a regulates 
various genes that are important in erythroid (MYB, CREBBP and AGTR2), myeloid 
(ERI-1, ETS, MEIS-1 and HOXA5) and lymphoid (PU.1, MEF, SPI-B and MYB) 
differentiation in CD34+ HSPC. Also, CXCR4 was found to be modulated by miR-
181a using a reporter assay (Georgantas et al., 2007). Moreover, miR-181a has been 
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shown to be involved in T cell related immune responses by regulating the T cell 
receptor (TCR) signalling strength and the sensitivity of T cells to antigens. miR-
181a was shown to repress the expression of multiple negative regulators in TCR 
signalling pathway (phosphatases PTPN22, SHP-2, DUSP5 and DUSP6) and 
increase the basal level of LCK and ERK activation. This enhances the TCR 
signalling strength and sensitivity of T cells to antigens, thereby augmenting the 
TCR-mediated T cell activation (Li et al., 2007). In addition, Cichocki et al. 
demonstrated that miR-181a and miR-181b promoted the development of natural 
killer (NK) cells from umbilical cord blood-derived CD34+ haematopoietic 
progenitor cells and enhanced the NK cell function as shown by increased IFN-γ 
production in primary CD56+ NK cells. Also, miR-181a and miR-181b were found to 
modulate the expression of nemo-like kinase (NLK), an inhibitor of NOTCH 
signalling, suggesting that miR-181a and miR-181b promote NK cell development 
through the regulation of NOTCH signalling pathway (Cichocki et al., 2011). The 
role of miR-181 in NK cell development was confirmed later in another study where 
they showed that miR-181a/b-deficient mice exhibited a complete absence of mature 
NKT cells in thymus and periphery. miR-181a/b was subsequently found to modulate 
the expression of the phosphatase PTEN, a regulator of phosphoinositide 3-kinase 
(PI3K) signalling pathway. miR-181a/b-deficient mice were also shown to exhibit 
other haematological defects including defects in T cell proliferation and 
development as well as early B cell development, associated with impaired PI3K 
signalling (Henao-Mejia et al., 2013). Besides that, miR-181c has been reported to 
modulate both T cell activation and proliferation by regulating the expression of IL-2. 
Exogenous overexpression of miR-181c reduced the IL-2 expression, and decreased 
both the T cell activation and proliferation (Xue et al., 2011).  
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1.2.3 Differential Expression of miR-181 in Haematological Malignancies 
Due to the crucial roles of miR-181 in haematopoiesis, it is not surprising that 
increasing evidence supports the notion of the involvement of miR-181 in 
haematological malignancies. There are multiple studies reporting the differential 
expression of miR-181 in different types of leukaemia and their potential role in the 
diagnosis and prognosis of leukaemia and the development of novel therapeutic 
approaches. 
In acute myeloid leukaemia (AML), Debernardi et al. found that the expression of 
miR-181a was elevated in M1 and M2 subtypes as compared to the M4 and M5 
subtypes in a miRNA expression study of 30 AML samples with normal karyotype 
(Debernardi et al., 2007). This was then confirmed by Isken et al. who observed the 
same differential expression in 14 normal karyotype AML samples and found miR-
181b to be overexpressed in AML M1 and M2 subtypes (Isken et al., 2008). These 
findings were further supported by another more recent study performed by Su et al. 
reporting that miR-181 family was upregulated in M1, M2 and M3 subtypes of adult 
AML patients (Su et al., 2015). Moreover, higher miR-181a expression has been 
reported in cytogenetically normal AML (CN-AML) patients with the presence of 
CEBPA mutations, associated with favourable clinical outcomes (Marcucci et al., 
2008a). Hickey et al. have also shown that in xenograft mouse models, either forced 
expression of miR-181a or lenalidomide treatment significantly inhibited the tumour 
growth in AML (Hickey et al., 2013). In addition, Butrym et al. showed that miR-
181 expression was increased in AML patients as compared to healthy controls. The 
elevated expression of miR-181 at diagnosis was positively correlated with better 
prognosis but negatively correlated with the higher risk of disease relapse (Butrym et 
al., 2016). In cytogenetically abnormal AML (CA-AML), Li et al. showed the 
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elevated expression of miR-181 family in CA-AML patients with favourable 
cytogenetic abnormalities such as t(8;12), inv(16) and t(15;17). On the contrary, 
downregulation of miR-181a and miR-181b was observed in CA-AML patients with 
unfavourable cytogenetic abnormalities such as MLL-rearrangements and this was 
associated with upregulation of a HOXA-PBX3 homeobox-gene signature (Li et al., 
2012b). Furthermore, reduced expression of miR-181a and miR-181b has also been 
found in a molecular subset of high risk CN-AML patients (FLT3-ITD positive 
and/or NPM1 wild-type) (Marcucci et al., 2008b; Schwind et al., 2010). It was 
believed that decreased expression of miR-181 family contributed to the aggressive 
leukaemia phenotype in high risk CN-AML and the downregulation was inversely 
correlated with the expression level of proteins involved in the toll-like receptor 
(TLR) and IL-1β innate immune response pathways (Marcucci et al., 2008b). In 
another study, Lu et al. showed that miR-181b was downregulated in human 
multidrug-resistant leukaemia cells and relapsed/refractory AML patient samples. 
Ectopic expression of miR-181b sensitised these leukaemia cells to cytotoxic 
chemotherapeutic drugs and promoted drug-induced apoptosis by targeting HMGB1 
(Lu et al., 2014). This finding is consistent with Nanbakhsh et al. study where they 
found that downregulation of miR-181a was associated with the acquisition of 
resistance to daunorubicin and cross-resistance of NK cell-mediated cytotoxicity in 
AML cell lines (U937 and KG1) through regulation of the tyrosine kinases, 
MAP3K10 and MAP2K1, and the BCL2 (BCL2 and MCL1) family. Reduced 
expression of miR-181a was also observed in refractory primary AML blasts and 
overexpression of miR-181a in AML blasts attenuated their resistance to 
daunorubicin and to NK cell-mediated killing (Nanbakhsh et al., 2015). In a more 
recent study, downregulation of miR-181 was seen in older AML patients treated 
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with the hypomethylating drug azacitidine and the lower miR-181 expression was 
shown as an independent predictor for good response to treatment and prolonged 
survival in this patient group (Butrym et al., 2016).  
Furthermore, miR-181 has also been implicated in chronic myeloid leukaemia 
(CML). Mosakhani et al. reported the decreased expression of miR-181c in CML 
patients who are resistant to imatinib as compared to imatinib-responders, suggesting 
that reduced miR-181c expression is associated with imatinib resistance in CML 
(Mosakhani et al., 2013). A more recent study showed that the expression level of 
miR-181a was significantly reduced in K562 cells and in patients with CML as 
compared to healthy controls. Overexpression of miR-181a in K562 cells inhibited 
cell growth and induced cell apoptosis and differentiation, in turn enhancing the 
sensitivity of these cells to imatinib (Wang et al., 2015). This finding is in line with 
Fei et al. who showed that in K562 cells, miR-181a overexpression suppressed cell 
growth, induced G2 arrest and promoted apoptosis by targeting RALA, suggesting 
that miR-181a is a tumour suppressor in CML (Fei et al., 2012). 
Moreover, differential expression of miR-181 has also been revealed in acute 
lymphocytic leukaemia (ALL). miR-181b has been found to be upregulated in 
patients with ALL in a miRNA expression profiling study performed by Zanette and 
colleagues (Zanette et al., 2007). Besides that, a more recent study reported that miR-
181a acts as an oncogene in ALL by reducing the expression of tumour suppressor 
gene, EGR1. In this study, they performed miRNA/mRNA expression profiling in 20 
ALL patients and observed a negative correlation between miR-181a and EGR1. 
Also, overexpression of miR-181a in Jurkat T-ALL cells reduced the expression of 
EGR1 and enhanced cell proliferation (Verduci et al., 2015).  
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In addition, dysregulation of miR-181 has also been demonstrated in chronic 
lymphocytic leukaemia (CLL). Pekarsky et al. showed the downregulation of miR-
181b in aggressive B cell CLL patients carrying 11q deletion, correlated with 
increased expression of TCL1 (Pekarsky et al., 2006). Moreover, reduced expression 
of miR-181 family was seen in CLL 17p-aggressive groups (patients carrying 17p 
deletion received a treatment over time periods ranging from 0 to 24 months) as 
compared to CLL 17p-indolent groups (patients carrying 17p deletion treated or not 
in a time longer than 24 months), suggesting that the downregulation of miR-181 is 
associated with disease progression in CLL bearing 17p deletion. In contrast, in CLL 
patients harbouring trisomy 12, increased expression of miR-181a was observed and 
the upregulation was associated with a shorter time interval before treatment, 
suggesting that the upregulation of miR-181a is correlated with more aggressive 
disease in this group of CLL patients (Visone et al., 2009). Zhu et al. reported the 
downregulation of miR-181a and miR-181b in CLL patients as compared to healthy 
controls. The expression levels of miR-181a and miR-181b were shown to be 
significantly lower in poor prognosis subgroups of CLL (unmutated IGHV gene and 
p53 aberrations). The downregulation of miR-181a and miR-181b was also 
associated with shorter overall survival and treatment-free survival in CLL patients. 
Enforced expression of miR-181a and miR-181b in primary CLL cells from p53 
wild-type patients sensitised these cells to fludarabin-induced apoptosis but miR-
181a and miR-181b overexpression in CLL cells from p53-mutant patients did not 
promote apoptosis, suggesting that apoptosis-inducing effects of miR-181a and miR-
181b may require p53 activation. miR-181a and b were also found to regulate anti-
apoptosis genes, BCL-2, MCL-1 and XIAP, which are characteristically associated 
with leukaemic cell resistance to chemotherapeutic agents (Zhu et al., 2012).   
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1.3 WAVE Protein  
WAVE protein [Wiskott-Aldrich Syndrome Protein (WASP) Family Verprolin-
Homologous Protein] is a member of the WASP family, which are well known as 
regulators of actin cytoskeletal dynamics (Campellone and Welch, 2010; Padrick and 
Rosen, 2010; Pollitt and Insall, 2009b). The WASP family consists of eight members, 
namely WASP, neural-WASP (N-WASP), WAVE1, WAVE2, WAVE3, WASP and 
WAVE homolog (WASH), junction mediating regulating protein (JMY), and WASP 
homolog associated with actin, membrane and microtubules (WHAMM) 
(Campellone and Welch, 2010; Kurisu and Takenawa, 2009). In mammals, there are 
three isoforms of WAVE, which are WAVE1, WAVE2 and WAVE3 (Suetsugu et al., 
1999). WAVE1 and WAVE3 are predominantly expressed in neuronal cells while 
WAVE2 is ubiquitously distributed (Kurisu and Takenawa, 2009; Oda and Eto, 
2013). WAVE proteins are essential in actin polymerisation, which is necessary to 
carry out diverse roles in physiological and pathological processes, ranging from 
embryogenesis, tissue morphogenesis and plasticity, pathogen infection, immune cell 
activation and chemotaxis, to cancer invasion and metastasis (Pollitt and Insall, 
2009b; Takenawa and Suetsugu, 2007).  
Structurally, the WAVE protein consists of a WAVE/SCAR homology domain 
(WHD/SHD) at their N-terminal, followed by a basic (B) domain, a proline-rich 
region (PRR) and a C-terminal VCA (V for verprolin-homology; C for cofilin-
homology; A for acidic) domain. At the N-terminal, WAVE protein is constitutively 
incorporated into a conserved, heteropentameric complex of around 400kDa, named 
WAVE regulatory complex. The WAVE regulatory complex consists of 
WAVE1/SCAR (or the orthologs WAVE2 and WAVE3), SRA1/CYFIP1 (or the 
ortholog PIR121/CYFIP2), NAP1/HEM2/Kette/NAP125/NCKAP1 (or the ortholog 
 35 
HEM1), ABI1 (or the orthologs ABI2 and ABI3) and BRK1/HSPC300 (Chen et al., 
2010; Gautreau et al., 2004). Different WAVE regulatory complex isoforms can be 
assembled from combinations of different orthologs of each component (Takenawa 
and Suetsugu, 2007). The WAVE regulatory complex can be viewed as two sub-
complexes, a dimer formed by pseudosymmetric association of the two large 
homologous proteins SRA1 and HEM1, and a trimer formed by the N-terminal of 
WAVE, ABI and BRK1 forming a four-helix bundle (Chen et al., 2010). It has been 
shown that the WAVE protein exists in a basal inactive state, where its activity 
towards the actin-related proteins 2/3 (ARP2/3) complex is inhibited by intracomplex 
sequestration of the C-terminal VCA domain, in which the VCA region is bound to 
SRA1 and therefore it is inaccessible for the ARP2/3 complex (Chen et al., 2010; 
Derivery et al., 2009; Eden et al., 2002; Ismail et al., 2009). In response to upstream 
signals, the WAVE regulatory complex is recruited to the membrane where it is 
triggered to release the inhibition, leading to the activation of WAVE protein. The 
Rho family GTPase, RAC1 was believed to play a crucial role in activation of 
WAVE proteins by two cooperative mechanisms. Firstly, interaction of the GTP-
loaded form of RAC1 with WAVE regulatory complex via SRA1 activates the 
WAVE protein by allosterically releasing the bound VCA domain (Chen et al., 2010). 
Second, the proline-rich region of WAVE protein interacts with the SH3 domain of 
the membrane-associated insulin receptor substrate p53 (IRSp53) and simultaneously, 
activated RAC1 binds to the RCB (RAC binding)/IMD (IRSp53-MIM homology 
domain) domain of IRSp53, contributing to the localisation and activation of WAVE 
proteins (Miki et al., 2000; Suetsugu et al., 2006). Through its basic domain, WAVE 
proteins bind to acidic phospholipids (phosphatidylinositol (3,4,5)-triphosphate, 
PIP3), which enhances its association with membranes (Oikawa et al., 2004). In 
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addition, the phosphorylation of the WAVE proteins by kinases, such as ABL, 
CDK5 and ERK2 leads to its activation by destabilising VCA sequestration and its 
regulation of the association of proteins in the WAVE regulatory complex 
(Takenawa and Suetsugu, 2007). Hence, the activation of WAVE proteins is a highly 
cooperative process which requires the simultaneous interaction of WAVE with 
activated RAC1 and acidic phospholipids, as well as a specific state of 
phosphorylation of the WAVE proteins achieved by kinases (Chen et al., 2010; 
Lebensohn and Kirschner, 2009). Following activation, the bound VCA region is 
released from SRA1 and is now able to carry out actin polymerisation. During actin 
filament nucleation, the V region at the C-terminal recruits actin monomer (G-actin) 
to the nascent filaments, while the C and A regions bind ARP2/3 complex, inducing 
conformational changes in the ARP2/3 complex, in turn promoting production of 
branched networks of filamentous actin (F-actin) (Goley and Welch, 2006; 
Takenawa and Suetsugu, 2007). The structure of the WAVE protein and the 




Figure 1.5: The structure of WAVE protein and the regulation of its 
activation.WAVE protein consists of an N-terminal WAVE/SCAR homology 
domain (WHD/SHD), followed by a basic (B) domain, a proline-rich region (PRR) 
and a C-terminal VCA domain. WAVE regulatory complex at its N-terminal consists 
of WAVE (1, 2 or 3), SRA1, HEM (1 or 2), ABI (1, 2 or 3) and BRK1. The WAVE 
protein exists in an inactive form where VCA domain is bound to SRA1 protein. The 
activation of WAVE protein is stimulated by the binding of activated RAC1 to 
WAVE regulatory complex through SRA1 or to PRR through insulin receptor 
substrate p53 (IRSp53), the binding of phosphatidylinositol (3,4,5)-triphosphate 
(PIP3) to the B domain, and the phosphorylation of WAVE by kinases. Upon 
activation, VCA domain is released from SRA1 and subsequently, actin monomer 
(G-actin) is recruited to the V region and ARP2/3 complex is able to bind to the C 
and A regions. This causes conformational changes in the ARP2/3 complex, thereby 































1.3.1 BRK1 – A Component of WAVE Complex 
BRK1 (BRICK1, SCAR/WAVE Actin-Nucleating Complex Subunit), a small 
protein of 9kDa, is located on chromosome 3p25.3 and is a component of the WAVE 
complex that plays a critical role in actin nucleation (Takenawa and Suetsugu, 2007). 
BRK1 is the only subunit in WAVE complex for which no paralogous gene has been 
identified and is also the most conserved subunit in the complex (Derivery et al., 
2008). Interestingly, BRK1 is a homotrimer that remains stable as a free sub-
complex in the absence of other WAVE regulatory complex subunits (Derivery et al., 
2008; Gautreau et al., 2004). This free pool of BRK1 homotrimers dissociate to form 
monomers before directly binding and stabilising the WAVE and ABI subunits to 
form a WAVE-ABI-BRK1 heterotrimeric complex. This heterotrimer in turn 
associates with SRA1-HEM1 dimer, mainly via interaction between BRK1 and 
conserved surface of SRA1 (Chen et al., 2010; Linkner et al., 2011). Thus, in the 
assembly of WAVE regulatory complex, BRK1 acts as an adaptor protein to stabilise 
and coordinate the assembly of the WAVE-ABI-BRK1 heterotrimer and the 
subsequent binding of WAVE-ABI-BRK1 heterotrimer to SRA1-HEM1 dimer 
platform (Derivery et al., 2008; Linkner et al., 2011). 
Whereas most members of the WAVE complex have been widely studied in recent 
years, the function of BRK1 is less well understood. The maize Brk1 orthologue was 
first shown, by genetic screening, to be responsible for morphologic defects in leaf 
epithelia due to a recessive mutation (Frank and Smith, 2002). Subsequently, a 
Arabidopsis Brk1 mutant was found to cause severe defects in trichome 
morphogenesis, and the participation of Brk1 in actin reorganisation in Arabidopsis 
is well documented (Djakovic et al., 2006; Le et al., 2006; Szymanski, 2005). RNA 
interference studies have suggested similar roles for Brk1 in Drosophila as 
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knockdown of Brk1 in cultured Drosophila cells resulted in a reduction of cortical F-
actin and alterations in cell morphology (Kunda et al., 2003). Additionally, Qurashi 
et al. showed for the first time, in Drosophila, that BRK1 is an indispensable 
component of the WAVE complex and plays an important role in the development of 
the nervous system. The authors showed that the Drosophila Brk1 expression profile 
resembled that of other members in WAVE complex and BRK1 protein was co-
immunoprecipated with WAVE and SRA1. Also, in Drosophila, Brk1 mutation as 
well as mutations in the other WAVE complex subunits led to defects in axonal and 
neuromuscular junction growth in vivo (Qurashi et al., 2007). In Dictyostelium, loss 
of Brk1 caused reduction in WAVE protein expression and Wave mutant-like 
phenotypes such as slow migration, roundness and lack of large pseudopods were 
observed (Pollitt and Insall, 2009a). 
In humans, it is evident that BRK1 plays a key role in cellular processes that are 
dependent on actin filaments, such as cell attachment, stretching, endocytosis, cell 
division and mobility (Li et al., 2014). Depletion of BRK1 in HeLa cells has been 
shown to cause defective lamellipodia formation (Derivery et al., 2008; Eden et al., 
2002). Furthermore, gene expression profiling of non-small cell lung carcinoma 
(NSCLC) revealed that BRK1 is one of the genes upregulated in tumour tissues as 
compared to adjacent normal tissues (Liu et al., 2007b; Sun et al., 2004). The same 
group subsequently delineated the exact roles of BRK1 in the development of 
NSCLC. They found that suppression of BRK1 caused actin filament reorganisation, 
inhibited pseudopodia formation and blocked cell migration in PG NSCLC cell line, 
suggesting the metastatic role of BRK1 in the carcinoma (Cai et al., 2009). Moreover, 
Escobar et al. reported that loss of BRK1 resulted in abnormal actin stress fibre 
formation and vinculin distribution as well as loss of ARP2/3 and WAVE proteins at 
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the cellular protrusions. They also showed that downregulation of BRK1 led to 
defective directional migration and invasive growth, coupled with reduced 
proliferation in SN12C and U031 renal cell carcinoma cell lines as well as U2OS 
osteosarcoma cell line. Interestingly, the authors also revealed that genetic ablation 
of Brk1 in mice resulted in dramatic defects in embryo compaction and development, 
suggesting an essential role for this protein in actin dynamics and cell survival during 
embryo development (Escobar et al., 2010). In addition, BRK1 has also been shown 
to regulate actin dynamics during the processes of neurite outgrowth in human IMR-
32 neuroblastoma cell line and primary rat hippocampal neurons as knockdown of 
BRK1 increased neurite outgrowth (Wang et al., 2013a). 
Strikingly, the clinical relevance of BRK1 in Von Hippel-Lindau (VHL) syndrome, 
an autosomal dominant familial cancer syndrome, has been reported by multiple 
studies. In VHL patients, the VHL tumour suppressor gene is partially or completely 
deleted and thus is predisposed to multiple tumours, primarily of the central nervous 
system, eyes, adrenals and kidney. The BRK1 gene is located 30kb downstream of 
VHL on chromosome 3p and large VHL gene deletions involving BRK1 are 
associated with a significant lower risk of developing tumours. This is due to the 
compromised proliferation, polarisation and motility in BRK1-deficient cells which 
leads to the inability of the cells to properly support tumour development. On the 
contrary, retention of the BRK1 gene is correlated with the development of tumours 
in VHL patients (Cascón et al., 2007; Franke et al., 2009; Maranchie et al., 2004; 
McNeill et al., 2009). 
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1.4 T Cell Activation 
T cells play a central role in adoptive immunity, both in cell-mediated cytotoxicity 
and in the activation of the humoral immune response, and hence it is important to 
understand how they are activated and regulated. Ligation of TCR to peptide-major 
histocompatibility complex (peptide-MHC) molecules, either from endogenously 
encoded self molecules or exogenously encoded pathogen molecules, on antigen 
presenting cell (APC) is a prerequisite for T cell activation. The mutual recognition 
of the T cell and APC results in the engagement and clustering of the TCR, and the 
formation of the T cell-APC interface, known as the immunological synapse. 
Signalling molecules are recruited to this site, resulting in activation of multiple 
signalling pathways that lead to calcium flux, gene transcription, actin 
polymerisation and affinity maturation of integrins, which are all required to initiate 
and sustain T cell activation (Huang et al., 2013; Manz et al., 2011; O'Donoghue et 
al., 2013). Interestingly, studies from the past decade suggest that T cell signal 
transduction is an intricately branching network, rather than a top-down signalling 
pathway (Brownlie and Zamoyska, 2013). 
The TCR consists of a single αβ heterodimer and associates with several 
immunoreceptor tyrosine-based activation motifs (ITAMs) (γ-chain, δ-chain, ε-
chains and ζ-chains) in the CD3 subunits. The recognition of peptide-MHC class I 
and II by TCR αβ heterodimer is assisted with the co-receptors CD8 and CD4, 
respectively. The co-receptors bring the SRC family kinase (SFK), LCK which is 
associated with their cytoplasmic regions, into close proximity to the TCR-associated 
CD3 and the ζ-chain ITAMs (Artyomov et al., 2010). LCK phosphorylates the 
tyrosine residues in the ITAMs of TCR-associated γ-chain, δ-chain, ε-chains and ζ-
chains, thereby allowing the recruitment and phosphorylation of the SYK family 
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kinase, ZAP70 (ζ-chain associated protein kinase of 70kDa) (Acuto et al., 2008). The 
phosphorylation causes conformational changes in ZAP70, which promotes its 
kinase activity (Deindl et al., 2007), leading to phosphorylation of the 
transmembrane adapter protein, LAT (linker for the activation of T cell) and the 
cytosolic adapter protein, SLP76 [SRC homology 2 (SH2) domain-containing 
leukocyte protein of 76kDa] (Wardenburg et al., 1996; Zhang et al., 1998). The 
phosphorylated residues of LAT, in turn, recruit multiple downstream adaptors and 
signalling molecules, allowing assembly of a multiprotein complex called LAT 
signalosome. The molecules that constitute this complex include SLP76, PLCγ1 
(phospholipase Cγ1), GRB2 (growth factor receptor-bound protein 2), GADS 
(GRB2-related adaptor protein), ADAP (adhesion- and degranulation-promoting 
adaptor protein), ITK (interleukin-2-inducible T cell kinase), NCK1 (NCK adaptor 
protein 1) and VAV1 (Vav guanine nucleotide exchange factor 1). This complex 
plays a pivotal role in propagating the TCR signals into multiple and diverse distal 
signalling pathways, including the PLCγ1-dependent pathways [diacylglycerol 
(DAG)- and Ca2+-induced signalling pathways] as well as the cytoskeletal 
rearrangements and integrin activation pathways (Brownlie and Zamoyska, 2013; 
Roncagalli et al., 2014). 
The major TCR signalling pathways that are PLCγ1-dependent and result from 
induction of DAG and Ca2+ include the NFAT (nuclear factor of activated T cell), 
the MAPK (mitogen-activated protein kinase) and the NF-κB (nuclear factor kappa-
light-chain-enhancer of activated B) signalling. The activation of these three 
pathways lead to the coordinated mobilisation of transcription factors that are crucial 
for the expression of genes necessary for T cell growth and differentiation. 
Following TCR ligation, the phosphorylated LAT and SLP76 form a complex via the 
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GADS. Phosphorylated SLP76 in turn interacts with PLCγ1, where PLCγ1 is 
phosphorylated and activated by ITK. Activated PLCγ1 thereby hydrolyses the 
membrane lipid, Ptdlns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) producing 
second messengers, DAG and IP3 (Smith-Garvin et al., 2009). The TCR-induced 
production of DAG results in the activation of two major pathways involving RAS 
and protein kinase Cθ (PKCθ). RAS, a guanine nucleotide-binding protein, is 
required for the activation of the serine-threonine kinase RAF-1, a MAPK kinase 
kinase (MAPKKK), which initiates a MAPK phosphorylation and activation 
cascade. RAF-1 phosphorylates and activates MAPK kinase (MAPKK), which result 
in the phosphorylation and activation of ERK1 (extracellular signal-regulated kinase 
1) and ERK2. ERK kinase activity leads to the activation of the transcription factor 
ELK1, which in turn contributes to the activation of AP-1 (activator protein-1) and 
STAT3 (signal transducer and activator of transcription 3) [reviewed in (Genot and 
Cantrell, 2000)]. RAS is only active in the GTP-bound state, and it is activated by 
RAS GEF (RAS guanine nucleotide-exchange factor) and suppressed by GAP 
(GTPase-activating protein). There are two RAS GEFs present in T cells, which are 
SOS (son of sevenless) and RASGRP (RAS guanyl nucleotide-releasing protein) 
(Dower et al., 2000; Ebinu et al., 2000; Egan et al., 1993). RASGRP is inducibly 
recruited to the membrane through a DAG-binding domain (Ebinu et al., 1998), 
where it is phosphorylated by PKC (Roose et al., 2005). SOS is constitutively bound 
to the adapter protein GRB2, and upon TCR stimulation, the GRB2 SH2 domain is 
recruited to and binds phosphorylated tyrosines on LAT, thereby bringing SOS into 
the proximal signalling complex, where it can facilitate the localised activation of 
RAS (Finco et al., 1998). Besides RAS pathway, the second signalling pathway 
regulated by DAG is mediated by PKCθ, a member of the PKC family that contains 
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a lipid-binding domain specific for DAG, which is important for recruiting PKCθ to 
the plasma membrane following T cell activation. One of the critical pathways that 
PKCθ regulates is NF-κB activation. In resting cells, NF-κB is found in the cytosol 
associated with inhibitor of NF-κB (IκB) family members that prevent NF-κB 
translocation into the nucleus. However, following T cell activation, IκB is 
phosphorylated by the IκB kinase (IKK) complex, ubiquitylated, and degraded, 
which allows NF-κB to translocate into the nucleus, where it activates genes 
involved in the T cell function, survival and homeostasis [reviewed in (Schulze-
Luehrmann and Ghosh, 2006)]. Apart from DAG, TCR-stimulated PLCγ1 activity 
also generates IP3 which stimulates Ca2+-permeable ion channel receptors (IP3R) on 
the endoplasmic reticulum (ER) membrane, resulting in the release of ER Ca2+ stores 
into the cytoplasm [reviewed in (Oh-Hora and Rao, 2008)]. TCR signalling induces 
an increase in the intracellular Ca2+ levels, leading to the activation of Ca2+ and 
calmodulin-dependent transcription factors such as MEF2 (myocyte-enhancing 
factor 2) and DREAM (downstream regulatory element antagonist modulator), as 
well as signalling proteins, including the phosphatase calcineurin and the CaMK 
(Ca2+-calmodulin-dependent kinase), that in turn activate a variety of transcription 
pathways [reviewed in (Savignac et al., 2007)]. Activated calcineurin 
dephosphorylates members of the NFAT family, which allows them to translocate 
into the nucleus. In the nucleus, NFAT isoforms form complexes with a variety of 
transcription factors, thereby integrating signalling pathways, which lead to 
differential gene expression patterns and functional outcomes, depending on the TCR 
signal. One of the interaction is between NFAT and AP-1, which integrates Ca2+ and 
RAS signals, resulting in the expression of genes such as IL-2 that is important for T 
cell activation (Macián et al., 2002). 
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In addition to the PLCγ1-dependent pathways, the LAT signalosome also propagates 
signals that are initiated from TCR ligation, to the integrin activation which promotes 
cell adhesion, and the actin reorganisation which is essential for T cell activation, 
proliferation and adhesion. Integrins are αβ heterodimeric receptors that play an 
important role in mediating cell-cell or cell-matrix adhesion. Integrins that are 
expressed on T cells include leukocyte function-associated antigen-1 (LFA-1) and 
very late antigen-4 (VLA-4), which bind to ligands, intercellular adhesion molecule 
(ICAM) and vascular cell adhesion molecule (VCAM), respectively. They also bind 
to fibronectin on other immune cells, endothelial cells and fibroblasts, as well as 
extracellular matrix proteins. Activation of integrins (increasing their affinity and 
avidity for ligands) is crucial for T cell activation and critically dependent upon the 
biochemical events initiated by TCR in a process called inside-out signalling 
(Ménasché et al., 2007). Signalling molecules that are essential for this process 
include LCK, ZAP70 and SLP76 (Epler et al., 2000), as well as complexes 
containing RAP1, either RAPL (also known as RASSF5) or RIAM (RAP1-GTP-
interacting adaptor molecule, also known as APBB1IP), SKAP55 (SRC kinase-
associated phosphoprotein of 55kDa, also known as SKAP1) and ADAP (Hogg et 
al., 2011; Raab et al., 2010). The phosphorylation of LAT recruits SLP76-VAV1 and 
ADAP, resulting in the activation of RAP1 and the initiation of signalling to LFA1. 
The inside-out signals induce a conformational change in LFA-1, increasing its 
affinity to ICAM1, allowing the formation of stable conjugates, which are required 
for the prolonged signalling for the full activation of T cell. Besides integrin 
activation, assembly of LAT signalosome also leads to actin reorganisation in T 
cells. Following TCR engagement, phosphorylated SLP76 regulates actin 
polymerisation by bringing the Rho family GTPase exchange factor VAV1, the 
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adaptor protein NCK1 and actin nucleation-promoting factor (NPF), such as the 
WASP and WAVE proteins, into close proximity. Rearrangement of the actin 
cytoskeleton is important in several aspects of T cell activation, including the 
engagement of TCR (Monks et al., 1998), the formation of immunological synapse 
(Delon et al., 1998) and its function as a scaffold for the further assembly and 
stabilisation of signalling complexes (Dustin and Cooper, 2000). 
Taken together, the TCR signalling pathways need to be properly coordinated and 
regulated in order to initiate and sustain T cell activation. An overview of TCR 




Figure 1.6: Overview of TCR signalling. TCR signal transduction is initiated by 
the recognition of cognate peptide-MHC molecules. The first molecule to be 
recruited to the TCR-CD3 complex is the SRC family kinase (SFK) member LCK, 
which phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) of 
the CD3 γ-chain, δ-chain, ε-chains and ζ-chains. Phosphorylation of the ITAMs 
enables the recruitment of ZAP70 (ζ-chain associated protein kinase of 70kDa), its 
phosphorylation by LCK and its activation. Activated ZAP70 phosphorylates four 
key tyrosine residues on LAT (linker for activation of T cell), which recruits 
numerous signalling molecules to form a multiprotein complex, termed LAT 
signalosome. Important molecules that constitute this complex include PLCγ1 
(phospholipase Cγ1), GRB2 (growth factor receptor-bound protein 2), GADS 
(GRB2-related adaptor protein), SLP76 (SH2 domain-containing leukocyte protein 
of 76kDa), ADAP (adhesion- and degranulation-promoting adaptor protein), ITK 
(interleukin-2-inducible T cell kinase), NCK1 (NCK adaptor protein 1) and VAV1 
(Vav guanine nucleotide exchange factor 1 protein). The LAT signalosome 
propagates signal branching to three major signalling pathways, NFAT (nuclear 
factor of activated T cell), MAPK (mitogen-activated protein kinase) and NF-κB 
(nuclear factor kappa-light-chain-enhancer of activated B), leading to the 
mobilisation of transcription factors that are critical for gene expression and essential 
for T cell growth and differentiation. Signals initiated from the TCR through LAT 
signalosome also result in actin reorganisation and the activation of integrins by 
inside-out signalling [Taken from (Brownlie and Zamoyska, 2013)]. 
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1.4.1 The Actin Cytoskeleton in T Cell Activation 
Reorganisation of the actin cytoskeleton is a requisite event in controlling T cell 
activation and it is important in multiple aspects of T cell function (Holsinger et al., 
1998). To become activated, T cells must first efficiently recognise APC, thereby 
translating external cues through tightly regulated intracellular signalling pathways, 
into specific T cell effector responses. Several cellular processes, including cellular 
polarisation, receptor sequestration and signalling, integrin-mediated adhesion, 
immunological synapse formation, and releases of cytokines and lytic granules, are 
required to initiate and sustain T cell activation. All these cellular processes in T 
cells are dependent upon the lymphocyte cytoskeleton. The actin cytoskeleton 
controls T cell shape, which changes dramatically depending on whether the cell is 
circulating in the bloodstream, migrating through tissues, or interacting with APC. At 
the immunological synapse, actin is likely to provide a scaffold for clustering, 
translocation and spatial segregation of proteins and signalling molecules, amplifying 
and sustaining the T cell signalling. Therefore, actin dynamics have been envisaged 
to participate extensively from the very first step of TCR triggering to the completion 
of a successful T cell activation, serving as a highly versatile machinery (Billadeau et 
al., 2007; Burkhardt et al., 2008; Kumari et al., 2014; Yu et al., 2013).  
Engagement of the TCR activates multiple actin-regulatory proteins that work 
together to drive actin polymerisation at the immunological synapse. The primary 
signalling pathway leading from TCR ligation to actin remodelling involves 
signalling through LCK and ZAP70, which results in phosphorylation of LAT and 
SLP76. Phosphorylated LAT and SLP76 in turn serve as a scaffold for other actin-
regulatory proteins, PLCγ1, NCK1, ITK and VAV1. These proteins stabilise one 
another at the sites of TCR engagement, and loss of any of these molecules causes 
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disruption in actin polymerisation at the immunological synapse (Fuller et al., 2003). 
PLCγ1 activity leads to calcium mobilisation, which is essential for F-actin 
remodelling in T cells (Bunnell et al., 2001). VAV1 catalyses the exchange of GDP 
for GTP on the small Rho GTPases CDC42 and RAC1, thereby activating them 
(Turner and Billadeau, 2002). GTP-bound CDC42 and RAC1 in turn activate WASP 
and WAVE respectively, promoting actin polymerisation (Dombroski et al., 2005; 
Labno et al., 2003).  
Accumulation of F-actin at the immunological synapse is the result of TCR-induced 
activation of multiple actin regulatory and polymerising pathways. The most 
extensive studied pathway involves the ARP2/3 complex, in which its activation 
requires interaction with NPF. The ARP2/3 complex, containing two actin-related 
proteins, ARP2 and ARP3, binds to the side of an existing actin filament, where 
ARP2 and ARP3 mimic two actin monomers as part of the core nucleus. NPF then 
binds to the ARP2/3 complex and present an actin monomer, allowing elongation of 
actin filaments to take place. Suppression of either ARP2 or ARP3 in Jurkat T cells 
has been shown to impair F-actin polymerisation at the immunological synapse and 
lamellipodia formation, demonstrating that the ARP2/3 complex and its upstream 
activators (NPF) are central effectors of actin polymerisation at the immunological 
synapse (Gomez et al., 2007).  
The best-characterised activator of the ARP2/3 complex is WASP, one of the NPF. 
WASP is recruited to the site of TCR activation through its interaction with the 
SLP76-associated adapter protein NCK, where it is activated via VAV1-dependent 
stimulation of the Rho family GTPase CDC42 (Zeng et al., 2003). Several studies 
showed that T cells from patients with Wiskott-Aldrich syndrome (WAS), an X-
linked immunodeficiency disorder resulting from mutations in the WAS gene, 
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exhibits cytoskeletal defects, aberrant morphology and impaired proliferation in 
response to TCR activation (Calvez et al., 2011; Cianferoni et al., 2005; Molina et 
al., 1993). Furthermore, it has been shown that T cells from WASP-knockout mice 
are proliferation deficient in response to antigenic stimulus, have unstable synapses, 
reduced Ca2+ influx and decreased IL-2 production (Cannon and Burkhardt, 2004; 
Sims et al., 2007; Snapper et al., 1998; Zhang et al., 1999). However, multiple 
studies have reported that under certain experimental condition, WASP-deficient T 
cells are still able to polymerise F-actin normally at the immunological synapse, 
forming conjugates and exhibiting normal TCR-mediated integrin activation 
(Cannon and Burkhardt, 2004; Krawczyk et al., 2002; Nolz et al., 2006). A possible 
explanation for these findings is that other proteins, including the close homolog N-
WASP, as well as less closely related proteins such as WAVE and haematopoietic 
cell-specific protein 1 (HS1), might have partially overlapping functions. 
Interestingly, impairment in T cell development has been observed in mice with both 
WASP and N-WASP knockout, but T cells develop normally in WASP-knockout 
mice, suggesting that WASP has a redundant role with N-WASP in T cell 
development (Cotta-de-Almeida et al., 2007).  
The WAVE protein, which similar to WASP, regulates ARP2/3-dependent F-actin 
remodelling through its VCA region. WAVE protein, activated through VAV1-
mediated activation of Rho family GTPase RAC1, has emerged as a central regulator 
of F-actin polymerisation downstream of the TCR (Burkhardt et al., 2008). WAVE2 
has been shown to be required for proper conjugate formation and F-actin 
accumulation at the immunological synapse (Nolz et al., 2006; Zipfel et al., 2007). 
WAVE2 has also been implicated in lamellipodia formation and regulation of 
CRAC-mediated calcium entry (Nolz et al., 2006). In addition, WAVE2 has also 
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been demonstrated to play a role in IL-2 production (Nolz et al., 2006; Nolz et al., 
2008) and the inside-out signalling for activation of integrins in T cells (Nolz et al., 
2006; Nolz et al., 2007; Nolz et al., 2008). 
WASH, the most recent NPF identified in T cells, localises at the plasma membrane 
and intracellular vesicles, and regulates endosome-associated ARP2/3 activity 
(Gomez and Billadeau, 2009). Although T cells derived from WASH-knockout mice 
showed normal T cell signalling and activation, they showed a reduction in T cell 
proliferation and impairment in trafficking of TCR. Also, WASH has been shown to 
regulate T cell endomembrane trafficking via maintenance of actin dynamics at the 
endosomes (Gomez et al., 2012).  
HS1, the haematopoietic lineage-restricted homolog of the actin-binding protein 
cortactin, functions primarily to stabilise existing branched actin filaments by 
bridging the ARP2/3 complex with F-actin (Billadeau and Burkhardt, 2006). Studies 
demonstrated that HS1-deficient T cells show defects in lamellipodia formation and 
F-actin polymerisation at the immunological synapse as well as impairment in Ca2+ 
influx and T cell proliferation (Gomez et al., 2006; Taniuchi et al., 1995). Although 
the exact role of HS1 in T cell activation is not clear, existing data indicate that it 
regulates PLCγ1 dynamics at the immunological synapse. TCR engagement induces 
ZAP70-dependent tyrosine phosphorylation and ITK-dependent recruitment of HS1 
at the immunological synapse. Phosphorylated HS1 in turn interacts with PLCγ1 and 
regulates its association with F-actin (Carrizosa et al., 2009; Gomez et al., 2006). In 
addition, phosphorylated tyrosine residues on HS1 also serve as docking sites for 
VAV1 which stabilises it and leads to actin accumulation at the immunological 
synapse (Gomez et al., 2006). Moreover, another study reported the interaction 
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between HS1 and WASP, further supporting the notion of HS1 involvement in actin 
remodelling in T cells (Dehring et al., 2011).  
In addition to pathways that promote actin nucleation in T cells, mechanisms for the 
negative regulation of F-actin assembly must also concomitantly occur for the 
cytoskeleton to function dynamically. Accordingly, several studies reported that 
actin-severing proteins such as cofilin and coronin-1 are important in T cell function. 
Cofilin has been shown to be crucial in regulating actin dynamics at the 
immunological synapse. Cell-permeable peptides that block the costimulation-
induced cofilin/F-actin interaction in human T lymphocytes blocked T cell 
proliferation, reduced cytokine (IL-2, IFN-γ, TNF-α, TNF-β, IL-10, IL-4 and IL-13) 
production, impaired receptor capping and decreased T cell-APC conjugate 
formation (Eibert et al., 2004). In addition, coronin-1, which binds and inhibits 
ARP2/3-mediated F-actin polymerisation, has emerged as a regulator of steady-state 
F-actin formation in T cells. Although T cells from coronin-1-deficient mice showed 
normal F-actin accumulation at the immunological synapse, these cells exhibited 
defects in migration and homing in response to chemokines and failed to generate 
uropod and accumulate talin beneath the membrane on the leading edge. 
Furthermore, naive T cells from coronin-1-deficient mice also showed increase in 
apoptosis, coupled with a decreased pool of G-actin which is dependent on the ability 
of coronin-1 to interact with the ARP2/3 complex (Föger et al., 2006). 
Additionally, the large GTPases dynamin-2, recruited by VAV1 to the 
immunological synapse, has been shown to regulate F-actin reorganisation. 
Dynamin-2 is able to recruit several actin-regulatory proteins such as the adaptor 
protein NCK1 and ABI1/2, thereby linking dynamin-2 to WASP- and WAVE-
mediated actin dynamics, respectively (Gomez et al., 2005). Moreover, the EZH2 
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(enhancer of zeste homologue-2) methyltransferase, a VAV1-interacting protein, has 
also emerged as a regulator of TCR-induced F-actin assembly. A study by Su et al. 
indicated that some of the F-actin regulators might require methylation by EZH2 for 
their activation (Su et al., 2005). It has also been suggested that the actin-binding 
adaptor protein HIP55 (haematopoietic progenitor kinase-1-interacting protein of 
55kDa) has a role in the regulation of TCR internalisation at the immunological 
synapse by connecting the TCR to actin and therefore the endocytic machinery (Han 
et al., 2005; Le Bras et al., 2004).  
Collectively, the regulation of F-actin polymerisation and depolymerisation at the 
immunological synapse is a complex and integrated process. Therefore, the activity 
of actin dynamics in T cells needs to be tightly controlled for proper T cell 
activation. The regulation of F-actin polymerisation during T cell-APC interaction is 





Figure 1.7: Regulation of F-actin polymerisation during the T cell-APC 
interaction. Following TCR ligation, LCK and ZAP70 are activated. LAT is then 
phosphorylated by ZAP70 and SLP76 is recruited by LAT. LAT and SLP76 serve as 
a scaffold for actin-regulatory proteins, PLCγ1, NCK1, ITK and VAV1. PLCγ1 
activity leads to calcium mobilisation, which is essential for F-actin remodelling in T 
cells. VAV1 facilitates the exchange of GDP for GTP on the small Rho GTPases 
CDC42 and RAC1, thereby activating them. VAV1 might require an interaction with 
the methyltransferase EZH2 to regulate these GTPases and F-actin polymerisation. 
GTP-bound CDC42 activates WASP, which is recruited by NCK1. The binding of 
active CDC42 to WASP releases its auto-inhibition, thereby allowing WASP to 
polymerise F-actin through its association with the ARP2/3 complex. GTP-bound 
RAC1 interacts with the WAVE2 complex and is thought to either localise or 
activate WAVE2-mediated activation of ARP2/3 complex. Moreover, through an 
interaction with VAV1, dynamin-2 (DNM2) is localised to the immunological 
synapse where it participates in regulating F-actin reorganisation, and probably 
influences membrane dynamics and recruitment of additional actin regulators. HS1 is 
phosphorylated by TCR proximal kinases and stabilises newly generated actin 
filaments. Cofilin has a role in T cell actin dynamics through F-actin severing and 
depolymerising activity [Taken from (Billadeau et al., 2007)].  
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1.5 Myelodysplastic Syndrome 
1.5.1 Background of Myelodysplastic Syndrome 
Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal 
haematopoietic stem cell malignancies. Clinically, MDS patients are characterised by 
cytopenias, myeloid cell dysplasia and defective haematopoiesis (Adès et al., 2014; 
Corey et al., 2007; Nimer, 2008). This malignancy is generally associated with 
hypercellular dysplastic BM, although it can also be normocellular or hypocellular 
(Corey et al., 2007). If untreated, patients progress toward BM failure and develop 
fatal haematological complications. Moreover, approximately one-third of MDS 
patients also develop AML (Adès et al., 2014; Greenberg et al., 1997; Walter et al., 
2012). Once thought relatively rare, MDS represents the most common 
haematological malignancies in the elderly (Corey et al., 2007).  
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1.5.2 Classification and Prognostic Scoring Systems of Myelodysplastic 
Syndrome 
The World Health Organisation (WHO) classification system is currently used for 
stratification of the MDS patients. The WHO classification was developed in 2002 
according to the previous classification system, French-American-British (FAB), 
1982 (Vardiman et al., 2002). According to the WHO classification system, MDS 
patients can be grouped into eight categories based on their biological, genetic and 
morphological features (Table 1.1).  
To predict the prognosis of MDS, the International Prognostic Scoring System 
(IPSS) was developed on the basis of findings in 816 patients with primary MDS 
(Greenberg et al., 1997). The IPSS relies on the primacy of blood cytopenias, 
cytogenetic abnormalities and percentage of blasts in BM as prognostic variables. 
The IPSS divides patients into four different risk groups: low, intermediate-1, 
intermediate-2 and high (Table 1.2). 
In 2012, the IPSS was revised (IPSS-R) to address several limitations in the IPSS 
(Greenberg et al., 2012). Although IPSS-R retained the three basic IPSS parameters, 
which are cytopenias, cytogenetic abnormalities and percentage of BM blasts, it 
applied more specific cytogenetic subgroups where the rare abnormalities were 
included and the deletion of 7q was segregated from loss of whole chromosome 7. 
Also, IPSS-R segregated the <5% BM blast category into two groups, 0 - 2% and >2 
- <5%, and the grouping of all patients with >10% blasts into the same category. In 
addition, it also separated cytopenias into haemoglobin, platelet count and absolute 
neutrophil count rather than based on the number of cytopenias, and categorised 
patients into five rather than four different risk groups: very low, low, intermediate, 
high and very high.  
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Table 1.1: WHO Classification of MDS (Vardiman et al., 2002) 




No or rare blasts 
Erythroid dysplasia only 
< 5% blasts 






Erythroid dysplasia only 
< 5% blasts 




Cytopenias (bicytopenia or 
pancytopenia) 
No or rare blasts 
No Auer rods  
< 1 x 109/L monocytes 
Dysplasia in ≥ 10% of cells in 
two or more myeloid cell lines 
< 5% blasts  
No Auer rods 
< 15% ringed sideroblasts 
Refractory anaemia 
with multilineage 
dysplasia and ringed 
sideroblasts 
(RCMD-RS) 
Cytopenias (bicytopenia or 
pancytopenia) 
No or rare blasts 
No Auer rods  
< 1 x 109/L monocytes 
Dysplasia in ≥ 10% of cells in 
two or more myeloid cell lines 
< 5% blasts 
No Auer rods 
≥ 15% ringed sideroblasts 
Refractory anaemia 
with excess blasts-1 
(RAEB-1) 
Cytopenias 
< 5% blasts 
No Auer rods  
< 1 x 109/L monocytes 
Unilineage or multilineage 
dysplasia 
5% to 9% blasts 
No Auer rods 
Refractory anaemia 
with excess blasts-2 
(RAEB-2) 
Cytopenias 
5% to 19% blasts 
Auer rods ±   
< 1 x 109/L monocytes 
Unilineage or multilineage 
dysplasia 
10% to 19% blasts 




No or rare blasts 
No Auer rods 
Unilineage dysplasia in 
granulocytes or megakaryocytes 
< 5% blasts 
No Auer rods 
MDS associated 
with isolated del(5q) 
Anaemia 
< 5% blasts 
Platelets normal or increased 
Normal to increased 
megakaryocytes with 
hypolobulated nuclei 
< 5% blasts 





Table 1.2: IPSS for MDS (Greenberg et al., 1997) 
(a) IPSS: Prognostic Variables 
Prognostic Variable 
Score 
0 0.5 1.0 1.5 2.0 
BM blasts (%) <5 5-10 - 11-20 21-30 
Cytogenetics* Good Intermediate Poor - - 
Cytopenias 0/1 2/3 - - - 
*Good: normal, -Y, del(5q), del(20q); poor: complex (≥3 abnormalities) or chromosome 7 
anomalies; intermediate: other abnormalities 
- indicates not applicable 
 
(b) IPSS: Risk Group and Clinical Outcomes 




Low 0 5.7 9.4 
Intermediate-1 0.5-1.0 3.5 3.3 
Intermediate-2 1.5-2.0 1.2 1.1 




1.5.3 Pathogenesis of Myelodysplastic Syndrome 
To date, the exact mechanisms for the pathogenesis of MDS remains to be fully 
elucidated, owing to the heterogeneity and complexity of the disorder. However, 
MDS has been shown to be caused by several factors, which include cytogenetic 
abnormalities, genetic mutations, epigenetic alterations, immune dysregulation and 
miRNA dysregulation. 
Cytogenetic abnormalities are major determinants of the pathogenesis, diagnosis and 
prognosis in MDS in addition to their importance in the selection of treatment for 
individual patients. Cytogenetic abnormalities are commonly observed in MDS, 
which have been demonstrated in approximately 50% of de novo MDS patients and 
80% of therapy-related MDS cases. Unbalanced chromosomal abnormalities 
involving loss or gain of genetic materials are commonly seen in MDS patients while 
balanced abnormalities including translocations, inversions and insertions are less 
common (Garcia-Manero, 2015; Haase, 2008; Haase et al., 2007; Schanz et al., 
2012). As MDS progresses, increased cytogenetic abnormalities are observed which 
is accompanied by the malignant transformation into AML (Greenberg et al., 1997). 
The three most common cytogenetic defects in MDS are del(5q), trisomy 8 and 
monosomy 7/ del(7q), with good, intermediate and poor prognosis, respectively 
(Greenberg et al., 1997; Haase, 2008; Haase et al., 2007).  
Over the past decade, the development of single nucleotide polymorphism (SNP) 
array analysis and next generation sequencing has led to new insights into the genetic 
basis of MDS. According to recent large cohort studies of MDS, 72 - 90% of MDS 
patients carried at least one mutation, with an average of three per cases (Cazzola et 
al., 2013; Haferlach et al., 2014; Papaemmanuil et al., 2013). Although over 60 genes 
have recently been identified to be mutated in MDS, only six genes, TET2, SF3B1, 
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ASXL1, SRSF2, DNMT3A and RUNX1, are found to be consistently mutated in 10% 
or more of MDS patients (Cazzola et al., 2013; Haferlach et al., 2014; Kulasekararaj 
et al., 2013). Genes that are commonly mutated in MDS are involved in pathways 
important in epigenetic regulation (TET2, DNMT3A, IDH1, IDH2, ASXL1 and 
EZH2), transcriptional regulation (RUNX1, BCOR, ETV6, SETBP1 and GATA6), 
tumour suppressor (TP53), signal transduction (JAK2, CBL, NRAS, FLT3, KIT and 
CSNK1A1), RNA splicing machinery (U2AF1, SRSF2, SF3B1 and ZRSR2) and the 
cohesin complex (STAG1, STAG2, SMC3 and RAD21) [reviewed in (Kulasekararaj et 
al., 2013; Pellagatti and Boultwood, 2015; Zhang et al., 2015)].  
Furthermore, accumulating evidence suggests that the alterations in the immune 
system play an important role in the pathogenesis of MDS. Immune dysregulation 
has been implicated in the defective haematopoiesis seen in MDS, owing to an 
abnormal susceptibility to apoptosis in haematopoietic precursors and limited 
responsiveness of these cells to growth factors (Ganan-Gomez et al., 2015). In 
accordance to this, many MDS patients seem to benefit from immunosuppressive 
therapy (Olnes and Sloand, 2011). Dysregulation of the expression and secretion of 
multiple cytokines has been reported in MDS including TNF-α, TRAIL, IFN-γ, 
TGF-β, IL-4, IL-6, IL-10 and IL-7 (Serio et al., 2014). Moreover, in MDS, 
cytotoxic (CD8+) and helper (CD4+) T cells are activated by MHC molecules on 
malignant MDS stem cells, which leads to T cell expansion in both peripheral blood 
(PB) and BM, in turn suppressing haematopoiesis [reviewed in (Glenthøj et al., 
2016)]. In addition, the TLR signalling pathway is hyperactive in MDS, attributed to 
the upregulation of activators including MYD88, TIRAP, IRAK1/4 and TRAF, 
coupled with the downregulation or allelic deletion of inhibitory factors such as miR-
145 and miR-146a. The TLR signalling activates NF-κB and MAPK pathways which 
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in turn induces the transcription of pro-inflammatory cytokines (Ganan-Gomez et al., 
2015; Starczynowski et al., 2010). It has also been demonstrated that the 
immunosuppressive capacity of mesenchymal stem cells (MSC) is decreased in MDS 
patients and these cells failed to efficiently inhibit dendritic cell maturation in low 
risk MDS patients, suggesting that the functionality of MSC is altered in MDS and 
may favour the expansion of cytotoxic T cells in the early stages of the disease 
(Wang et al., 2013b). Intriguingly, Chen et al. demonstrated that myeloid-derived 
suppressor cell (MDSC), a group of inflammation-associated immature cells, are 
markedly expanded in the local BM of MDS patients. Increased numbers of MDSC 
causes defective myeloid and erythroid differentiation, coupled with reduction in T 
cell proliferation and functionality, as well as induces the secretion of suppressive 
cytokines including IL-10 and TGF-β, and inflammatory intermediates such as 
reactive oxygen species (ROS), arginase, cytokines and inducible nitric oxide 
synthase (iNOS), thereby inducing DNA instability and promoting the emergence 
of mutant MDS clones (Chen et al., 2013).  
Additionally, a recent genomic analysis of AML and MDS cell lines found that 
approximately 77% (542 out of 706) of miRNAs are located in regions of leukaemia-
associated cytogenetic changes, and 18% (99 out of 542) of these miRNAs are 
relevant in myeloid malignancies (Starczynowski et al., 2011). Moreover, miRNAs 
are essential regulators of the differentiation and development of haematopoietic 
stem cells (Georgantas et al., 2007; Liao et al., 2008). Therefore, alterations of 
miRNA could affect proliferation and differentiation of haematopoietic stem cells, 
contributing to the pathogenesis of haematological malignancies, including MDS 
(Lujambio and Lowe, 2012). There are several reviews summarising the findings of 
multiple studies on the differential expression of various miRNAs and the expression 
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pattern of specific miRNAs in MDS (Kuang et al., 2016; Milunović et al., 2016; 
Rhyasen and Starczynowski, 2012). Interestingly, there is only little overlap seen in 
the dysregulated miRNAs in MDS and the comparison between studies is difficult. 
This discrepancy might be due to different approaches, sample sources and size of 
patient cohorts used. As summarised in a review by Rhyasen et al., out of the 80 
dysregulated miRNAs (30 downregulated and 50 upregulated miRNAs) in MDS, 
only 17 were commonly identified by more than a single study and only five of the 
miRNAs were common to four studies (Rhyasen and Starczynowski, 2012). 
However, progress has been made in our understanding of the involvement of 
miRNA dysregulation in the pathogenesis of MDS, but more extensive research is 
needed to clarify the role of this complex mechanism in MDS. 
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1.5.4 Differential Expression of miR-181 in Myelodysplastic Syndrome 
Aberrant expression of miR-181 in MDS has been reported in several recent studies. 
Overexpression of miR-181a has been reported in advanced MDS patients and also 
their downregulation in early MDS cases. Besides that, the authors showed that the 
expression level of miR-181a increased steadily from healthy controls to MDS to 
AML (Pons et al., 2009). Furthermore, it has been shown that the four members of 
the miR-181 family (miR-181a, miR-181b, miR-181c and miR-181d) are significantly 
upregulated in high risk MDS patients as compared with low risk patients. In 
addition, a decreased survival was observed in patients with elevated expression of 
miR-181 in low risk MDS patients when compared to patients without increased 
miR-181 levels. These findings indicate the pathogenetic overlap between high risk 
MDS and AML (Sokol et al., 2011). In a more recent study, interestingly, miR-181a 
has been shown to be downregulated in MSC from MDS patients when compared 
with normal controls (Santamaría et al., 2012).  
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1.6 Large Granular Lymphocytic Leukaemia 
1.6.1 Background of Large Granular Lymphocytic Leukaemia 
Large granular lymphocytic leukaemia (LGL leukaemia) embodies a spectrum of 
rare clonal lymphoproliferative disorders, which involve inappropriate expansion of 
large granular lymphocytes (LGLs), either cytotoxic T lymphocytes or NK cells 
(Lamy and Loughran, 2011; Watters et al., 2011). LGL leukaemia is an indolent 
disorder with good prognosis and characterised by cytopenia with neutropenia the 
most common, resulting in an increased frequency of bacterial infection (Loughran, 
1993). LGL leukaemia is frequently associated with a wide array of autoimmune 
disorders such as rheumatoid arthritis (RA), pure red cell aplasia (PRCA) and 
immune thrombocytopenic purpura (ITP), as well as BM failure syndromes 
including aplastic anaemia (AA) and MDS (Bareau et al., 2010; Dhodapkar et al., 
1994; Go et al., 2000; Kwong and Wong, 1998; Lamy and Loughran, 2011; 
Saunthararajah et al., 2001). 
In 1985, the term LGL leukaemia was first introduced as a disorder involving clonal 
invasion of the PB, BM and spleen (Loughran et al., 1985). In 1993, the distinction 
between CD3+ T cell and CD3- NK cell lineage subtypes of LGL (T-LGL and NK-
LGL respectively) leukaemia was proposed (Loughran, 1993). In 1999, the WHO 
classification included T cell and NK cell LGL leukaemia in the mature peripheral T 
cell neoplasms subgroup (Harris et al., 1999). In 2008, a provisional entity of chronic 
NK cell lymphoproliferative disorder (CLPD-NK) was created by the WHO to 
separate it from the more aggressive NK-cell leukaemia (Swerdlow et al., 2008). The 
types of LGL leukaemia with their clinical features are shown in Table 1.3. 
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Table 1.3: Types of LGL Leukaemia (Steinway et al., 2014) 
Type Median Age  Clinical Features Marker 





- Recurrent bacterial 
infections 
Autoimmune conditions 
- Rheumatoid arthritis 
- Pure red cell aplasia 
- Immune thrombocytopenic 
purpura 
CD3+ CD8+ CD16+ 
CD56- CD57+ 







CD3+ CD8+ CD57+ 
 
CLPD-NK 39 Similar to T-LGL, indolent 







58 Fulminant B symptoms 
Cytopenias 
Hepatosplenomegaly 






1.6.2 Pathogenesis of Large Granular Lymphocytic Leukaemia 
The understanding of the pathogenesis of LGL leukaemia is pivotal as it contributes 
to the development of drugs to combat the dysregulation of the disease. Several 
studies have demonstrated that LGL leukaemia is associated with dysregulation of 
the survival and apoptosis pathways including the Fas and Fas ligand (FasL), the 
interleukin-15 (IL-15), the platelet-derived growth factor (PDFG), the PI3K-AKT, 
the sphingolipid, the NF-κB, the RAS/MEK/ERK, and the JAK/STAT signalling 
pathways (Table 1.4) [reviewed in (Steinway et al., 2014; Zhang and Loughran, 
2012)]. More recently, somatic mutations in the SH2 dimerisation and activation 
domain in the STAT3 gene have been found to be associated with LGL leukaemia, 
further supporting the importance of STAT3 signalling in the pathogenesis of this 
disorder (Koskela et al., 2012).  
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Table 1.4: Known Dysregulated Signalling Pathways in LGL Leukaemia 





Signalling Pathway  
Dysregulation in LGL Leukaemia 
Fas-FasL Mediates apoptosis 
of activated CTL 
Fas-FasL machinery is blocked by soluble Fas 
that is elevated in patient sera and is capable of 
blocking Fas-mediated cell death of leukaemia 
LGLs 
IL-15 Promotes survival of 
T and NK cells 
IL-15 prevents apoptosis of leukaemic LGLs 
by enhancing degradation of Bid, a critical 
apoptotic factor; higher level of soluble IL-
15Rα may lower the IL-15 response threshold 
in leukaemic LGL cells 
PDGF Regulates cell 
growth and division 
Elevated PDGF regulates long-term survival of 
leukaemic LGL cells through PI3K-AKT and 
MER/ERK pathways 
PI3K-AKT Promotes cell 
proliferation, 
survival and cancer 
progression 
PI3K-AKT signalling is constitutively 
activated in T-LGL leukaemia, due to 
overactive Src family kinases, which leads to 
inhibition of pro-apoptotic signalling, 
promoting survival of T cells 
Sphingolipid 
rheostat 
Determines cell fate Pro-apoptotic ceramide is decreased and anti-
apoptotic sphingosine-1-phospshate (S1P) is 
elevated. S1P receptor 5 is overexpressed in 
leukaemic LGLs 
NF-κB Plays critical role in 
haematopoiesis and 
survival of immune 
cells 
NF-κB has been shown to be activated in 
leukaemic LGLs downstream of AKT and 
promotes the expression of anti-apoptotic 
BCL-2 proteins 
RAS/MEK/ERK Regulates cell 
proliferation and 
differentiation in 
response to various 
growth factors 
RAS and ERK are constitutively activated in 
NK-LGL leukaemic cells 
JAK/STAT Regulates cell 
proliferation, 
survival and immune 
response 
Persistent activation of STAT3 in LGL 
leukaemia; somatic activating mutations in the 
SH2 dimerisation and activation domain in the 
STAT3 gene in 30-40% of NK and T-LGL 
patients 
LGL: large granular lymphocyte; CTL: cytotoxic T lymphocyte 
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1.7 Association of Myelodysplastic Syndrome with T Cell Large Granular 
Lymphocytic Leukaemia  
Clonal proliferations of T cell large granular lymphocytes (T-LGLs) have been 
documented in patients with BM failure syndromes including AA (Go et al., 2000), 
paroxysmal nocturnal hemoglobinuria (PNH) (Boyer et al., 2015; Karadimitris et al., 
2001; Lamy and Loughran, 1999; Risitano et al., 2005) and MDS (Dhodapkar et al., 
1994; Huh et al., 2009; Saunthararajah et al., 2001).  
It is noted that clonal T-LGL proliferation associated with MDS is not uncommon 
and the coexistence of T-LGL and MDS has been reported by several studies. 
Dhodapkar and colleagues identified five patients with T-LGL and concomitant 
MDS out of 68 patients with T-LGL (Dhodapkar et al., 1994). Subsequently, 
Saunthararajah et al. described nine patients with coexistence of T-LGL and MDS 
(Saunthararajah et al., 2001). In addition, Huh et al. reported nine patients with T-
LGL who also had MDS (Huh et al., 2009). Although the coexistence of T-LGL and 
MDS is rare, it seems likely that the simultaneous occurrence of T-LGL and MDS 
may be causally related rather than a chance event. Saunthararajah et al. have 
proposed two possible mechanisms of the association of T-LGL with MDS. Firstly, 
T-LGL might arise from a clonally rearranged MDS stem cell or alternatively, the T-
LGL could represent an autoimmune response to an antigen presented by normal or 
MDS marrow cells (Saunthararajah et al., 2001). It has been suggested that T-LGL 
proliferation may have pathogenic roles in the development of cytopenias in MDS, in 
which the expanded cytotoxic CD8+ T cells suppress the autologous progenitor cell 
growth in vitro (Molldrem et al., 1997). This is supported by a report which showed 
that a subgroup of MDS patients responded to immunosuppressive treatment with 
cyclosporine or anti-thymocyte globulin (ATG) (Saunthararajah et al., 2001). Several 
studies have reported the favourable factors in MDS patients associated with T-LGL, 
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which include BM hypocellularity, presence of HLA-DR15 expression, younger age, 
lower platelet count and blast percentage, and shorter duration of transfusion 
requirement (Epling-Burnette et al., 2007; Molldrem et al., 2002; Saunthararajah et 
al., 2002; Saunthararajah et al., 2003; Zhang et al., 2016). Nonetheless, the 
clinicopathological features as well as the prognostic and predictive value of the 
presence of T-LGL proliferation in MDS patients is still unclear and no treatment 
guideline has been established so far for these patients. 
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1.8 Project Aims 
The miR-181 family has been shown to be important in haematopoiesis including T 
cell development, differentiation, proliferation and activation, and hence its aberrant 
expression has been implicated in haematological malignancies. Therefore, the aim 
of this study was to identify biologically relevant targets of the miR-181 family 
members using a functional assay, developed in-house (Gäken et al., 2012). We 
identified and validated one of the targets of miR-181c which was BRK1, a 
component of the WAVE complex that regulates actin polymerisation. Given the 
importance of miR-181 family in T cell functions and the potential roles of BRK1 in 
the involvement of the WAVE complex and the regulation of actin dynamics in T 
cells, this study was subsequently aimed to delineate the influence of the miR-181c-
BRK1 axis in T cell functions. In addition, as multiple studies reported the aberrant 
expression of the miR-181 family in MDS and various leukaemia, we also aimed to 
investigate the expression level of miR-181c and its target BRK1 in MDS patients 
associated with T-LGL leukaemia. 
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2 Chapter 2 – Methods 
2.1 PCR and Gel Electrophoresis 
2.1.1 Design of Primers for miRNA Target Identification Functional Assay 
The miRNA primers (for miR-181a, miR-181b, miR-181c and miR-181d) were 
designed based on the primary sequences which were obtained from miRBase web 
resource (http://www.mirbase.org/). The obtained miRNA sequences were aligned 
against human genomic DNA database in NCBI Nucleotide Blast 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) to obtain the complementary genomic 
region and sequences of approximately 4kb covering the miRNA sequences was 
selected. These selected sequences were further used to design primers using Primer 
3 Software (http://primer3.ut.ee/). Primers amplifying miR-181a, miR-181b, miR-
181c/d were designed, producing PCR products ranging from 600bp to 800bp in size. 
miR-181c and miR-181d were amplified by one pair of primers as they are located 
close to each other on chromosome 19. Restriction enzyme sites were incorporated in 
front of the primer sequences to facilitate the subsequent cloning experiments. 
Restriction sites were selected by using NEBcutter V2.0 
(http://nc2.neb.com/NEBcutter2/) based on the criteria that there should be no 
internal restriction site in the PCR products. Sequences of the primers are listed in 
Appendix B1. Oligonucleotide primers were dissolved in nuclease free water to give 
a stock concentration of 100µM and stored at -20°C. 
2.1.2 Standard PCR  
PCR was carried out using GoTaq® Hot Start Colourless Master Mix (Promega) or 
DreamTaq PCR Master Mix (Thermo Scientific) and PCR reaction composition was 
set up as shown in Table 2.1. PCR reactions were run on a programmable thermal 
cycler (Applied Biosystems), with standard cycling conditions as shown in Table 2.2. 
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Table 2.1: Standard PCR Reaction Composition 
Reagent Concentration Volume (µl) 
Template DNA  10-100ng/µl - 
Go Taq or DreamTaq Master Mix  2× 10 
Forward primer 10µM 0.2 
Reverse primer 10µM 0.2 
Nuclease free water - (up to 20µl) 
Total - 20 
Table 2.2: Standard PCR Cycling Condition 
Stage Temperature (°C) Duration Number of Cycle 
Initial Denaturation 95 2 min 1 
Denaturation 95 30 sec 25-40 
Annealing As appropriate for the 
primers used 
30 sec 
Extension 72 1 min 
Final Extension 72 5 min 1 
Incubation 4 Infinity 1 
 
2.1.3 Agarose Gel Electrophoresis 
PCR products and other nucleic acid samples were separated by electrophoresis on a 
0.8-1.0% agarose gel (Sigma-Aldrich) prepared in 100ml of 1× Tris Acetate-EDTA 
(TAE) buffer (Sigma-Aldrich), with 0.08mg/ml ethidium bromide (Sigma-Aldrich). 
6× DNA Gel Loading Dye (Thermo Scientific) was added to the samples to give 1× 
final concentration and 10µl was loaded for electrophoresis. 5µl of Gene Ruler DNA 
Ladder Mix (Thermo Scientific) was run in parallel with samples as a marker to 
determine the size of the samples. Gels were run in 1× TAE buffer at 120V for 30-45 
min and visualised under UV illumination using Syngene Gene Flash Bio Imaging 
Gel Documentation System.  
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2.1.4 Gel Extraction and Purification 
Gel extraction and purification were carried out using QIAEX II® Gel Extraction Kit 
(Qiagen). In brief, DNA bands were excised from agarose gel with a clean, sharp 
scalpel under UV illumination. Three volumes of Buffer QX1 and 10µl of QIAEX II 
beads were added to the excised gel fragment and incubated at 50°C for 10 min to 
solubilise the agarose and bind the DNA. The tube was vortexed every 2 min to keep 
QIAEX II beads in suspension. The sample was then centrifuged for 1 min and 
supernatant was carefully removed with a pipette. After that, the pellet was washed 
once with 500µl Buffer QXI to remove residual agarose contaminants and twice with 
500µl Buffer PE to remove residual salt contaminants. The pellet was air-dried for 
15-30 min until it turns white. To elute DNA, the dried pellet was resuspended with 
20µl of nuclease free water and incubated at room temperature for 5 min. Finally, the 
suspension was centrifuged at full speed for 1 min and the supernatant containing the 
purified DNA was carefully transferred to a clean tube. Purified DNA bands were 
stored at -20°C. 
2.2 Cloning 
2.2.1 Restriction Enzyme Digestion 
Restriction enzyme digestion was carried out in a reaction containing 2µl of 10× 
NEB buffer (1, 2, 3 or 4; New England Biolabs), 0.5µl of restriction enzyme (5-10U; 
New England Biolabs), 2µl of 10× bovine serum albumin (BSA; when needed; New 
England Biolabs), 300-1000ng of DNA and nuclease free water in a total volume of 
20µl. When two restriction enzymes were used simultaneously in a digestion 
reaction, the buffer indicating maximum activity for both enzymes was used or else a 
single digest was carried out initially with the enzyme requiring the lowest salt 
concentration followed by a second digest in the same mixture with the other 
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enzyme. 1M NaCl solution was added to adjust the concentration to the optimal salt 
concentration for the second enzyme digestion step. The reactions were incubated at 
37°C or 50°C (depending on restriction enzyme) for 1 to 2 hours and heat 
inactivation of enzymes was carried out at 65°C for 20 min. Digested plasmid DNA 
was then analysed by agarose gel electrophoresis. 
2.2.2 TOPO Cloning 
TOPO cloning was performed using TOPO® TA Cloning® Kit, Dual Promoter, with 
pCR®II-TOPO® Vector (Life Technologies; vector map see Appendix A1). TOPO 
cloning was carried out in a reaction consisting 0.5-2µl of insert, 0.5µl of TOPO 
vector, 0.5µl of salt (200mM NaCl, 10mM MgCl2) and nuclease free water in a total 
volume of 3µl and incubated at room temperature for 10 min followed by bacterial 
transformation.  
2.2.3 Ligation 
Ligations were performed with a vector:insert ratio of 1:1, 1:2 or 1:3, with 1µl of 
400U T4 DNA ligase (New England Biolabs), 1µl of 1× ligase buffer (New England 
Biolabs) and nuclease free water in a total volume of 10µl. Reactions were either 
incubated at room temperature for 1 to 2 hours or at 4°C overnight. A vector only 
ligation was also performed as a control.  
2.2.4 Transformation of Chemically Competent E. coli 
Transformations were performed using One Shot® TOP10 Chemically Competent E. 
coli (Life Technologies). 25µl of cells were mixed with 1µl of ligation mixture and 
incubated on ice for 30 min. Reactions were then heat shocked at 42°C for 30 sec 
and returned to ice for a further 2 min before the addition of 400µl SOC medium 
(Life Technologies) and incubated at 37°C for an hour. 100µl of the cells were then 
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plated on LB agar plates containing 50µg/ml of carbenicillin (Bioline) and incubated 
at 37°C overnight. For blue-white screening, 50µl of 20mg/ml X-Gal (Melford) was 
spread on the surface of the LB agar prior to plating the transformed bacterial cells.  
2.2.5 Small Scale Plasmid DNA Preparation 
Bacteria from a single colony were cultured overnight in 2ml of LB broth, 
supplemented with 50µg/ml carbenicillin, at 37°C in a shaking incubator (200rpm). 
Bacterial cultures were pelleted for 5 min and plasmid DNA was extracted using 
Wizard® Plus SV Minipreps DNA Purification System (Promega) according to the 
manufacturer’s instructions. In brief, cells were resuspended in 250µl of Cell 
Resuspension Solution before lysing in 250µl of Cell Lysis Solution and 10µl of 
Alkaline Protease Solution. After 5 min, the lysis reaction was stopped by the 
addition of 350µl Neutralization Solution. Protein and chromosomal DNA 
precipitate was pelleted (full speed, 10 min) and cleared supernatant was applied to a 
DNA binding Spin Column (full speed, 1 min). Columns were subsequently washed 
with 750µl of Wash Solution (full speed, 1 min) and again with 250µl of Wash 
Solution (full speed, 2 min). The plasmid DNA was then eluted from the column 
with 100µl of nuclease free water (full speed, 1 min) and stored at -20°C. 
2.2.6 Large Scale Plasmid DNA Preparation 
A starter culture was set up by culturing a single bacterial colony for 6-8 hours in 
5ml of LB broth supplemented with 50µg/ml of carbenicillin, at 37°C with shaking. 
The starter culture was then diluted 1:500 or 1:1000 in 150ml of LB broth 
supplemented with 50µg/ml of carbenicillin and cultured for 12-16 hours at 37°C 
with shaking. The overnight culture was pelleted (5000×g, 10 min) and plasmid 
DNA was then extracted using GenEluteTM HP Plasmid Maxiprep Kit (Sigma-
Aldrich) according to the manufacturer’s instructions. In brief, bacterial cells were 
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resuspended in 12ml of Resuspension Solution before lysing with 12ml of Lysis 
Solution at room temperature for 3-5 min. The lysis reaction was stopped with 12ml 
of chilled Neutralization Solution. 9ml of Binding Solution was added, mixed and 
the solution was poured into a filter syringe and was allowed to sit for 5 min to 
precipitate the protein. During the 5 min incubation, a GenElute HP Maxiprep 
Binding Column was placed into a 50ml collection tube and 12ml of Column 
Preparation Solution was added to the column and then centrifuged at 3000×g for 2 
min. Half of the cleared lysates was expelled into the binding column by holding the 
filter syringe barrel over the binding column and gently applying pressure to the 
plunger and then centrifuged at 3000×g for 2 min. The rest of the cleared lysate was 
processed similarly. Columns were washed with 12ml of Wash Solution 1 (3000×g, 
2 min) and with 12ml of Wash Solution 2 (3000×g, 5 min). The plasmid DNA was 
eluted with 3ml of Elution Solution (3000×g, 5 min). The plasmid solution was filter 
sterilised (0.2µm), aliquoted under sterile conditions and stored at -20°C. 
2.3 Sanger Sequencing 
Sanger sequencing was performed using BigDye® Terminator Cycle v3.1 
Sequencing Kit (Applied Biosystems). Cycle sequencing was first carried out to 
amplify the insert on a programmable thermal cycler (Applied Biosystems). 300ng of 
plasmid DNA was used as template DNA and two reactions (one with forward 
primer and another with reverse primer; primer details see Appendix B5) were 
carried out for each plasmid DNA sample in order to obtain both forward and reverse 
sequences for each sample. The reaction composition and cycling protocol are shown 
in Table 2.3 and Table 2.4.  
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Table 2.3: Reaction Composition for Cycle Sequencing 
Reagent Volume (µl) 
Plasmid DNA (300ng) x 
5× Sequencing Buffer 2 
BigDye® Terminator v3.1 Ready Reaction Mix 0.5 
Sequencing Primer (5ng/µl) 1 
Nuclease free water (up to 10µl) 
Total 10 
Table 2.4: Cycling Protocol for Cycle Sequencing 
Stage Temperature (°C) Time  Number of Cycle 
1 96 1 min 1 
2 96 10 sec 15 
55 5 sec 
60 1.15 min 
3 96 10 sec 5 
55 5 sec 
60 1.30 min 
4 96 10 sec 5 
55 5 sec 
60 2 min 
5 4 Infinity 1 
After cycle sequencing, purification of the extension products was carried out using 
BigDye® XTerminatorTM Purification Kit (Applied Biosystems) with shaking at 
2000rpm for 30 min. The reagents used are shown in Table 2.5.  
Table 2.5: Reagents for Purification of Extension Products in Sanger 
Sequencing 
Reagent Volume (µl) 
Extension products from cycle sequencing 10 
XTerminatorTM solution 10 
SAMTM solution 45 
Total 65 
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Capillary electrophoresis was then performed on an ABI 3130XL Genetic Analyzer 
with appropriate run module selected in the Data Collection software. Results were 
analysed using ABI Sequencing Analysis 5.2 software and the sequences obtained 
were blast analysed using NCBI Nucleotide Blast. 
2.4 Tissue Culture 
2.4.1 Culture of Adherent Cell Lines 
Adherent cell lines (MCF7, HeLa, HepG2, 293T and NIH/3T3) were cultured in 
Dulbecco’s Modified Eagle medium (DMEM) (Life Technologies) supplemented 
with 10% foetal bovine serum (FBS; Sigma-Aldrich) and 1% L-Glutamine-
Penicillin-Streptomycin solution (Sigma-Aldrich), under humidified conditions at 
37°C in 5% CO2. To passage and harvest the cells, DMEM medium was removed 
and an appropriate amount of 1× TrypLETM Express Enzyme (Life Technologies) 
was added, followed by incubation at 37°C for 5 min to detach the cells. The cell 
suspension was then centrifuged (300×g, 5 min) and the pellet was resuspended in an 
appropriate volume of medium and cells were either counted, seeded for expansion 
or collected for experiments.  
2.4.2 Culture of Suspension Cell Lines 
Suspension cell lines (Jurkat, K562, KG-1 NB-4, THP-1 and U937) were cultured in 
Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies) 
supplemented with 10% FBS (Sigma-Aldrich) and 1% Penicillin-Streptomycin 
solution (Sigma-Aldrich), under humidified conditions at 37°C in 5% CO2. Cells 
were passaged and harvested as described above but without trypsinisation. 
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2.4.3 Isolation of Peripheral Blood Mononuclear Cells and Primary T Cells  
Isolation of peripheral blood mononuclear cells (PBMCs) from leukocyte cones was 
carried out by density gradient centrifugation using Ficoll Histopaque (Sigma-
Aldrich). Blood sample from leukocyte cone was diluted with PBS containing 2% 
FBS up to a total of 40ml. The solution was slowly layered on top of the same 
volume of Ficoll Histopaque and then centrifuged at 560×g for 30 min. The 
interphase layer, which contains the PBMC, was carefully removed and washed with 
50ml of PBS (400×g, 5 min). Washing steps were repeated twice with 50ml of 2% 
FBS in PBS (200×g, 5 min). Cells were counted and either cryopreserved in liquid 
nitrogen for future use, stimulated and cultured in the presence of IL-2 to obtain a 
primary T cell population, or CD3+ T cells were isolated. 
Isolated PBMC were stimulated with 1µg/ml of anti-human CD3 (clone OKT3; 
eBioscience) and anti-human CD28 (clone 28.2; eBioscience), cultured in X-
VivoTM15 medium (Lonza) supplemented with 2% human AB serum (Sigma-
Aldrich) in the presence of 100U/ml recombinant human IL-2 (Peprotech) for 48 
hours. After stimulation and culture in the presence of human IL-2, the cell 
population consists mainly of T cells.  
Alternatively, CD3+ T cells were isolated from PBMC using Dynabeads® 
UntouchedTM Human T Cell Kit (Life Technologies). Briefly, isolated PBMC (5×108 
cells) were resuspended in 5ml of ice-cold 2% FBS in PBS and 1ml of antibody mix 
(5µl of 1mg/ml HLA-DR antibody, Abcam was added) was added and incubated on 
roller at 4°C for 20 min. The cells were then washed with 9ml of 2% FBS in PBS 
(500×g, 8 min) and resuspended in 45ml of 2% FBS in PBS with 5ml of pre-washed 
Dynabeads® (Dynabeads® was washed twice with 5ml of 2% FBS in PBS). After 
incubation on roller at room temperature for 15 min, the tube was placed on a 
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magnetic stand for 2 min and the supernatant containing the untouched human T 
cells were collected and pelleted (200×g, 5 min). Cells were then resuspended in 1ml 
of supplemented X-VivoTM15 medium (Lonza) and proceeded to cell counting for 
subsequent experiments. 
2.4.4 Culture of Primary T Cells 
Primary T cells were cultured in X-VivoTM15 medium (Lonza) supplemented with 
2% human AB serum (Sigma-Aldrich) and 100U/ml recombinant human IL-2 
(Peprotech), under humidified conditions at 37°C in 5% CO2. Cells were passaged 
and harvested as described in suspension cell lines above. 
2.4.5 Counting of Cells 
Cell suspensions were mixed with Trypan Blue (Lonza) in a 1:1 ratio and 10µl of the 
mixture was loaded onto Haemocytometer (Neubauer cell counting chamber, depth 
0.1µl). For PBMC cell counting, 1% acetic acid was also added to lyse the 
erythrocytes. Only live unstained cells from four corner squares were counted and 
the cell number per ml was determined with the following calculation. 
Cell Number/ml = Average Cell Count from 4 Squares × 104 × Dilution Factor 
2.4.6 Cryopreservation of Cells 
Suspension and adherent cell lines were resuspended in RPMI 1640 and DMEM 
freezing medium (containing 10% DMSO and 20% FBS) respectively at a density of 
2×106 cell/ml in 2ml cryogenic vials. For PBMC and primary T cells, cells were 
resuspended in Synth-a-Freeze® Cryopreservative Medium (Life Technologies) at a 
density of 10×106 cell/ml. The cryogenic vials were frozen at -80°C in a Freezing 
Container (Nalgene Mr Frosty) overnight and then transferred to liquid nitrogen for 
long term storage.  
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2.5 Cell Transfection 
2.5.1 Stable 
Stable transfection of cells with plasmid DNA (pBabePuro expressing miRNA) were 
carried out by nucleofection using either Amaxa® Cell Line Nucleofector® Kit V 
(Lonza) or Ingenio® Electroporation Kit (Mirus Bio LLC). 2×106 cells (MCF7, HeLa 
or Jurkat T cells) were pelleted and resuspended in 100µl of nucleofection (Lonza) or 
electroporation (Mirus Bio LLC) solution and 2µg of plasmid DNA was added. The 
solution was transferred to a cuvette and electroporated using a cell line specific 
program on the Nucleofector II device (Lonza). The programs used were P-020 for 
MCF7, I-013 for HeLa and X-001 for Jurkat T cells. The transfected cells were 
immediately transferred to tissue culture flasks or plates depending on cell number 
and experimental requirements and allowed to recover for 48 hours. Selection for 
stable transfected cells was done with appropriate antibiotics based on the selectable 
marker present in the plasmid (2µg/ml of puromycin, InvivoGen; 500µg/ml of 
zeocin, InvivoGen; or 12µM of ganciclovir, InvivoGen) for 10-15 days when cells 
were harvested for subsequent analysis. 
2.5.2 Transient  
Transient transfection of cells with siGENOME small interfering RNA (siRNA) 
against BRK1 (Dharmacon) or miRIDIAN miRNA hairpin inhibitors (Dharmacon) 
were performed by nucleofection as in the stable transfection described above. 
Sequences of siRNA and miRNA inhibitors are detailed in Appendix C2. 100nM of 
siRNA or miRNA inhibitors was used and transfected cells were cultured in 6-well 
plates before harvesting for further analysis at relevant time points (24h, 48h, 72h, 
96h or 120h). 
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2.6 Short Hairpin RNA Lentivirus Production and Transduction 
2.6.1 Oligonucleotide Annealing and Construction of pLKO.1-shBRK1 
Plasmid 
Long, complementary oligonucleotides encoding sequences of short hairpin RNA 
(shRNA) against BRK1 (details in Appendix C) (Wang et al., 2013a) were annealed 
to create double stranded DNA molecules for cloning into the pLKO.1-TRC cloning 
vector (Addgene; vector map see Appendix A4). shBRK1 oligonucleotides were 
annealed by mixing 5µl of 20µM forward oligo, 5µl of 20µM reverse oligo, 5µl of 
10× NEB buffer 2 and 35µl of nuclease free water. The mixture was incubated in a 
beaker with boiling water (98°C) and left to cool slowly to room temperature (2-3 
hours). The annealed double stranded oligonucleotides had appropriate overhangs 
was cloned into pLKO.1-TRC cloning vector. 
2.6.2 Lentivirus Production 
shRNA lentivirus were generated by co-transfection of human embryonic kidney cell 
line HEK293T with four plasmids, pMDG (envelope plasmid encoding VSV-G), 
pRRE (packaging plasmid encoding Gag & Pol), pREV (packaging plasmid 
encoding REV) and the shRNA plasmids (pLKO.1-shBRK1_1, pLKO.1-shBRK1_2 
or pLKO.1-scrambled shRNA) using Calcium Phosphate Transfection Kit (Life 
Technologies). 293T cells were seeded at a density of 1×107/1000cm in five layer 
flasks (T1000 flasks, Millipore) using DMEM medium supplemented with 10% FBS 
and 1% L-Glutamine-Penicillin-Streptomycin solution. The cells were incubated 
overnight at 37°C in 5% CO2. Four plasmids mixture containing pMDG (55µg), 
pRRE (91µg), pREV (45µg) and pLKO.1-shRNA (182µg) were mixed and diluted to 
a total volume of 3.96ml with nuclease free water. 540µl of 2M CaCl2 was then 
added to the mixture. Subsequently, the mixture was added drop wise to 4.5ml of 2× 
HEBS while vortexing and incubated at room temperature for 30 min in a total 
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volume of 9ml. The 9ml solution was mixed with 150ml of supplemented DMEM 
medium, added to the 293T cells in T1000 flasks and incubated for 16 hours at 37°C 
in 5% CO2. The medium was replaced with 180ml of fresh supplemented DMEM 
medium and incubated at 37°C for a further 24 hours after which the supernatants 
containing the lentivirus were harvested and stored at 4°C. 100ml of fresh 
supplemented DMEM medium was added to the flasks and incubated for another 24 
hours. The supernatant was again harvested and pooled with the 24 hours harvest. 
The pooled supernatant containing the lentivirus was concentrated by centrifugation 
at 8000rpm overnight at 6°C. The pellets were resuspended in 500µl of Opti-MEM®I 
Reduced Serum Medium (Life Technologies) and then aliquoted and stored at -80°C. 
2.6.3 Lentivirus Titration 
Titration of lentivirus (pLKO.1-scrambled shRNA, pLKO.1-shBRK1_1 and 
pLKO.1-shBRK1_2) was carried out by colony formation assay. HeLa cells were 
seeded at a density of 5×104/0.5ml per well in supplemented DMEM medium in 24-
well plates. After 24 hours, 0.1, 0.01, 0.001 and 0.0001µl (which corresponds to a 
final concentration of 10-4, 10-5, 10-6 and 10-7 ml) of lentivirus were added to the 
HeLa cells in triplicate, supplemented with 8µg/ml of polybrene (Sigma-Aldrich). 
After 24 hours incubation, 0.5ml of fresh supplemented DMEM medium was added 
to dilute the lentivirus. 5µg/ml of puromycin (InvivoGen) was added after 24 hours 
and cells were selected for 15 days when the cells were washed with HEPES buffer 
solution (Life Technologies) and stained with Commassie Blue. The colonies were 
counted and lentivirus titre was calculated using following equation. 
Colony Forming Units/ml (CFU/ml) = Number of Colony / Final Concentration of  
                                    Lentivirus Added 
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2.6.4 Lentivirus Transduction 
Cells were seeded in 24-well plates at a density of 6×105 (Jurkat T cells) or 1×106 
(anti-CD3/CD28 stimulated primary T cells) per well in 1ml of culture medium 
(supplemented RPMI 1640 medium for Jurkat T cells; X-VivoTM15 medium 
supplemented with 10% AB serum and 100U/ml IL-2 for primary T cells). 
Lentivirus with a multiplicity of infection (MOI) of 24 for Jurkat T cells and MOI of 
50 for primary T cells was added to the cells and supplemented with 4µg/ml of 
polybrene (Sigma-Aldrich). The plates were centrifuged at 800×g for 45 min at 32°C 
and incubated overnight. The next day, the plates were replaced with fresh 
supplemented culture medium. 2µg/ml of puromycin (InvivoGen) was added after 24 
hours and selected for 5-15 days when the cells were harvested for further functional 
analysis. MOI of lentivirus used for transduction was calculated with the following 
equation. 
Multiplicity of Infection (MOI) = Infectious Units (IFU) / Cell Number 
Infectious Units/ml (IFU/ml) = CFU/ml × Volume of Lentivirus Used 
2.7 DNA and RNA Extraction 
2.7.1 Genomic DNA Extraction 
Genomic DNA was extracted from cells using Quick-gDNA™ MiniPrep Kit (Zymo 
Research) according to the manufacturer’s instructions. In brief, cells were pelleted 
(500×g, 5 min) and lysed with 500µl of Genomic Lysis Buffer for 5-10 min at room 
temperature. The cell lysate was added to a Zymo-Spin™ Column (10000×g, 1 min), 
the column was washed with 200µl of DNA Pre-Wash Buffer and 500µl of g-DNA 
Wash Buffer (10000×g, 1 min). DNA was eluted with 50µl of DNA Elution Buffer 
or water, incubated for 2-5 min at room temperature and spun for 30 sec. Eluted 
genomic DNA was stored at -20°C. 
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2.7.2 RNA Extraction with TRIzol  
Total RNA was extracted from cells using TRIzol reagent (Life Technologies). 0.5-
1×106 cells were pelleted and resuspended in 500µl of TRIzol reagent before adding 
200µl of chloroform (Sigma-Aldrich) and mixing vigorously for 15 sec. After 
incubation for 2-3 min at room temperature, the sample was centrifuged at 12000×g 
for 15 min at 4°C and the upper colourless aqueous phase was carefully recovered in 
a fresh tube and mixed with 500µl of isopropanol (Sigma-Aldrich) and incubated for 
10 min at room temperature to precipitate RNA. Following centrifugation at 
12000×g for 10 min at 4°C, the pellet was washed with 1ml of 75% ethanol (7500×g, 
5 min, 4°C) and air-dried. The RNA was resuspended in 25-50µl nuclease free water 
and stored at -80°C. 
2.7.3 RNA Extraction with RNeasy Micro Kit 
Total RNA was extracted from primary T cells using RNeasy® Micro Kit (Qiagen) 
according to the manufacturer’s instructions. In brief, 5×105 cells were pelleted 
(300×g, 5 min), and disrupted and homogenised with 350µl of Buffer RLT by 
vortexing vigorously. Cell lysates were precipitated with 350µl of 70% ethanol and 
applied to RNeasy MinElute spin column (8000×g, 15 sec). Columns were washed 
with 350µl of Buffer RW1 (8000×g, 15 sec) and DNA contamination was removed 
by adding 80µl of DNase I incubation mix (10µl DNase I stock solution + 70µl 
Buffer RDD) directly to the column membrane and incubating at room temperature 
for 15 min. Columns were subsequently washed with 350µl of Buffer RW1 (8000×g, 
15 sec), 500µl of Buffer RPE (8000×g, 15 sec) and 500µl of 80% ethanol (8000×g, 2 
min) before ‘dry’ spinning the columns for 5 min to ensure all residual buffer was 
removed. RNA was eluted from the column with 14µl of RNase free water (full 
speed, 1 min) and stored at -80°C. 
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2.7.4 Nucleic Acid Quantification 
DNA and RNA samples were quantified using a NanoDrop 8000 Spectrophotometer 
(Thermo Scientific). 1.5µl of neat sample was pipetted onto the Nanodrop pedestal 
which directly measures and calculates the concentration in ng/µl. The ratio of 
absorbance at 260nm and 280nm is used to assess the purity of DNA and RNA. A 
ratio of approximately 1.8 is generally accepted as “pure” for DNA while 2.0 as 
“pure” for RNA. If the ratio is appreciably lower in either case, it may indicate the 
presence of protein, phenol or other contaminants that absorb strongly at or near 
280nm. 
2.8 Quantitative Real Time PCR (qPCR) 
2.8.1 qPCR – Probe Based Detection 
First strand cDNA synthesis was performed using SuperScript® VILO™ cDNA 
Synthesis Kit (Life Technologies). Total RNA was used to prepare cDNA in 10µl 
reaction consisting of 500ng of RNA, 2µl of 5× Reaction Mix and 1µl of 10× 
Superscript Enzyme. The reaction was incubated at 25°C for 10 min and 42°C for 2 
hours when the reaction was stopped by heat inactivating the reverse transcription 
(RT) enzyme at 85°C for 5 min. All cDNA samples were stored at -20°C. 
Probe based detection qPCR was then carried out using the FastStart Universal Probe 
Master (ROX; Roche Diagnostics) and Universal Library Probes (Roche 
Diagnostics), according to the manufacturer’s instructions. In brief, PCR reaction 
consisting 5µl of 1:50 diluted cDNA, 10µl of FastStart Universal Probe Master 
(ROX), 1µl of 20µM primer mix, 0.25µl of 25µM gene specific probe (primer and 
probe details in Appendix B3) and 3.75µl of nuclease free water was prepared in 
triplicate in MicroAmpTM Fast Optical 96-Well Reaction Plates (Life Technologies). 
Reactions were run on a StepOnePlus Real-Time PCR machine (Applied 
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Biosystems) using the following cycling conditions: 95°C for 10 min; then 40 cycles 
of 95°C for 15 sec and 60°C for 1 min. 
2.8.2 qPCR – DNA Dye Based Detection 
Reverse transcription (RT) of miRNA was carried out using Universal cDNA 
Synthesis Kit II (Exiqon). Total RNA was used to prepare cDNA in 10µl reaction 
consisting of 100ng of RNA, 2µl of 5× Reaction Buffer and 1µl of Enzyme Mix. The 
reaction was then incubated at 42°C for an hour before the reaction was stopped by 
heat inactivating the RT enzyme at 95°C for 5 min. All cDNA samples were stored at 
-20°C.  
DNA dye based detection qPCR was then carried out using ExiLENT SYBR® Green 
Master Mix (Exiqon) according to the manufacturer’s instructions. In brief, PCR 
reaction consisting 4µl of 20× diluted cDNA, 5µl of PCR Master Mix and 1µl of 
miRNA specific primer mix (details in Appendix B4) was prepared in triplicate in 
MicroAmpTM Fast Optical 96-Well Reaction Plate (Life Technologies). Reactions 
were run on a StepOnePlus Real-Time PCR machine (Applied Biosystems) using the 
following cycling condition: 95°C for 10 min; then 40 cycles of 95°C for 10 sec and 
60°C for 1 min. Melting curve analysis was included.  
2.8.3 qPCR Analysis – Relative Quantification 
Fluorescence signals were first normalised to that of the passive reference dye 
ROX™, included within the PCR master mix, to give a reporter normalised (Rn) 
value for each cycle of the reaction (no reference dye in DNA dye based detection). 
Next, a baseline signal was determined to account for background fluorescence and 
the Rn values baseline corrected to give ΔRn values. Finally, amplification curves 
were plotted using log (ΔRn) against cycle number and a threshold ΔRn value set to 
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intersect the exponential (or geometric) phase of the curves. The point of intersection 
determines the threshold cycle (Ct) number which is used as the basic measure of 
relative target concentration within the PCR. The Ct values for experimental and 
control samples were then used in subsequent calculations to achieve relative target 
quantification. Relative quantities were determined using the comparative Ct method 
described by Applied Biosystems. The amount of target was normalised to the 
GAPDH (probe based detection), miR-103a (DNA dye based detection, as 
recommended by Exiqon) or U6 (DNA dye based detection) reference and calculated 
relative to a designated calibrator sample using only Ct values in the mathematical 
formula 2-∆∆Ct as follows.  
∆∆Ct = ∆Cttarget - ∆Ctcalibrator 
∆Cttarget = Cttarget - Ctreference 
∆Ctcalibrator = Ctcalibrator - Ctreference 
Relative quantity = 2-∆∆Ct 
2.9 Immunoblotting 
2.9.1 Protein Extraction 
Whole cell protein extracts were prepared using Radio-Immunoprecipitation Assay 
(RIPA) Lysis Buffer (Santa Cruz Biotechnology) containing 1× TBS, 1% Nonidet P-
40, 0.5% sodium deoxycholate, 0.1% SDS and 0.004% sodium azide (NaN3), 
supplemented with 10µl of 200mM phenylmethylsulfonyl fluoride (PMSF) solution, 
10µl of 100mM sodium orthovanadate solution and 10µl of protease inhibitor 
cocktail solution. Cell pellets were lysed with 100µl of 1× RIPA lysis buffer and 
incubated on ice for 30 min. Cellular debris was pelleted (300×g, 5 min, 4°C) and 
supernatant containing the protein lysates were stored at -80°C.  
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2.9.2 Protein Assay 
Protein concentrations were measured using DCTM Protein Assay (Bio-Rad) 
according to the manufacturer’s instructions. BSA Protein Standard II (Bio-Rad) was 
used to create a standard curve by serial dilution from 1.4 to 0.175mg/ml. 5µl of 
BSA standards and 1:10 diluted protein lysates were first mixed with 25µl of 
working reagent A (20µl of reagent S has been added to each ml of reagent A), then 
200µl of reagent B and incubated at room temperature for 15 min. Colour change 
was measured by absorbance at 750nm on a microplate reader (BioTek ELx808) and 
protein concentration was calculated against the standard curve.  
2.9.3 Western Blotting 
Protein samples (typically 15-20µg) were prepared by addition of 1× NuPAGE® 
LDS Sample Buffer (Life Technologies) and 10% 1M dithiothreitol (DTT; Sigma-
Aldrich), and denatured at 100°C for 5 min. Samples were then loaded alongside a 
SpectraTM Multicolor Broad Range Protein Ladder (Thermo Scientific) on 
NuPAGETM NovexTM 4-12% Bis-Tris Protein Gel (1.0 mm; 10, 12 or 15 wells; Life 
Technologies) and run at a constant voltage of 200V for 40-50 min in 1× NuPAGE® 
MES SDS Running Buffer (Life Technologies). To transfer proteins from the gel to a 
PVDF membrane, the gel was placed under an immunoblot PVDF membrane (Bio-
Rad) and then sandwiched between blot paper (Bio-Rad) and nylon pads. Proteins 
were transferred from the gel to the membrane at 25V for 90-120 min at 4°C in 1× 
NuPAGE® Transfer Buffer (Life Technologies) after which the membrane was 
incubated in 5ml of blocking buffer (5% non-fat dried milk in 0.1% Tween 20/PBS 
buffer) for at least an hour to reduce non-specific antibody binding. An appropriate 
dilution of the primary antibody (details in Appendix D) was prepared in blocking 
buffer and added to the membrane and incubated overnight at 4°C. Membranes were 
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subsequently washed three times in 0.1% Tween 20/PBS buffer for 15 min before 
incubating with an appropriate dilution of horseradish peroxidase (HRP)-conjugated 
secondary antibody (details in Appendix D) in blocking buffer, for an hour at room 
temperature. Membranes were washed three times in 0.1% Tween 20/PBS buffer for 
15 min. The membranes were incubated in PierceTM ECL Western Blotting Substrate 
(Thermo Scientific) for 5 min, sealed in Saran wrap and secured in developing 
cassette. Proteins were exposed to CL-XposureTM Clear Blue X-ray Film (Thermo 
Scientific) for the preferable time using Photon Imaging Systems SRX-101A. 
Alternatively, images were acquired using Chemiluminescent Western Blot Imaging 
System (Azure Biosystems c300). The protein expression was then quantified by 
Image StudioTM Lite Version 5 software (LI-COR) against loading control according 
to the band intensity.  
2.10 Flow Cytometry 
2.10.1 Cell Cycle Analysis 
Cell pellets (1×106) were washed once with PBS and fixed in 1ml of 70% ice-cold 
ethanol for 30 min on ice. Fixed cells were then stained in 400µl of staining solution 
containing 40µg/ml of propidium iodide (PI) solution (Sigma-Aldrich) and 100µg/ml 
of RNase A (Sigma-Aldrich) in PBS for 30 min at 37°C before analysing using flow 
cytometry.  
2.10.2 Annexin V Staining 
Cell pellets (5×105) were washed with ice-cold PBS and 1× Cell-based Assay 
Annexin V Binding Buffer (Cayman Chemical Company) before staining with 2.5µl 
of APC Annexin V (BioLegend) and 2.5µl of PI staining solution (BioLegend) in 
50µl of 1× Binding Buffer at room temperature for 15 min in the dark. Stained cells 
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were subsequently washed twice with 1× Binding Buffer (300×g, 5 min) and 
resuspended in 400µl of 1× Binding Buffer before analysing using flow cytometry. 
2.10.3 T Cell Stimulation 
Prior to CD69, CD154 and F-actin staining, both Jurkat and primary T cells were 
stimulated, and results were analysed by comparison between unstimulated and 
stimulated cells. For Jurkat T cells, stimulation was performed with 10µg/ml of plate 
bound anti-human CD3 (clone OKT3; eBioscience) and 25ng/ml of Phorbol 12-
Myristate 13-Acetate (PMA; Sigma-Aldrich) in 24-well plates with 0.5×106 cells per 
well. Primary T cells were stimulated with 2µg/ml of plate bound anti-human CD3 
(clone OKT3; eBioscience) and 2µg/ml of soluble anti-human CD28 (clone 28.2; 
eBioscience) in 24-well plates with 1×106 cells per well. 
2.10.4 CD69 and CD154 Staining 
0.5×106 (Jurkat T cells) or 1×106 (primary T cells) cells were pelleted and washed 
with 1ml of FACS buffer (2.5% FBS in PBS). After washing, Jurkat T cells were 
stained with 5µl of anti-human CD69 PE (clone FN50; eBioscience) while primary T 
cells were stained with 5µl of Pacific BlueTM anti-human CD69 (clone FN50; 
BioLegend) and anti-human CD154 PE (clone 24-31; eBioscience) in FACS buffer 
for 30 min at room temperature in the dark. Primary T cells were also stained with 
5µl of APC anti-Human CD3 (clone OKT3; BioLegend) in addition to the T cell 
activation markers (CD69 and CD154) in order to confirm the T cell population. 
Stained cells were washed with 1ml of FACS buffer and resuspended in 400µl of 
FACS buffer before analysing the CD69 and CD154 expressions using flow 
cytometry. 
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2.10.5 F-actin Staining 
Cell pellets (1×106) were washed with 1ml of FACS buffer (2.5% FBS in PBS) and 
fixed with 200µl of 2% paraformaldehyde (Sigma-Aldrich) for 15 min at room 
temperature. Fixed cells were permeabilised with 100µl of 0.05% saponin (Sigma-
Aldrich) and 10% FBS in PBS for 30 min at room temperature before staining with 
5µl of rhodamine phalloidin (Life Technologies) for 30 min at room temperature in 
the dark. Stained cells were subsequently washed with 1ml of FACS buffer and 
resuspended in 400µl of FACS buffer. Total cellular F-actin content was then 
analysed using flow cytometry. 
2.10.6 Flow Cytometry – Data Acquisition and Analysis 
Samples were analysed on a BD FACSCanto II (BD Biosciences) flow cytometer 
using BD FACSDiva™ software v6.1.3 (BD Biosciences). PI, anti-CD69 PE, anti-
CD154 PE and rhodamine phalloidin stains were detected using the PE (blue) 
channel; anti-CD3 APC and APC Annexin V using the APC (red) channel; and 
Pacific Blue anti-CD69 using the BV421 (violet) channel. 10000 events were 
acquired for each sample and all data was collected from the side scatter (SSC) and 
forward scatter (FSC) as well as PE, APC or BV421 channels depending on 
experiment types for later analysis. FlowJo Version 9.7.7 or Version 10.1 software 
(Tree Star) was used to perform post acquisition analysis. 
2.11 Immunofluorescence Microscopy 
2.11.1 Spreading Assay 
24 hours prior to the spreading assay, each well of a 8-well chamber culture slide 
(BD Falcon) was coated with 200µl of 0.01% poly-L-lysine solution (Sigma-
Aldrich) for 15 min at room temperature, rinsed with sterile water and dried at room 
temperature for at least 2 hours. The wells were subsequently coated with 150µl of 
 93 
10µg/ml anti-human CD3 (clone OKT3; Bioscience) overnight at 4°C. The wells 
were washed three times with 500µl PBS and two times with 500µl of Chamber 
Buffer (10% FBS, 1% L-Glutamine-Penicillin-Streptomycin solution and 25mM 
HEPES buffer solution in RPMI 1640 medium without phenol red). 150µl of 
Chamber Buffer was placed in each well and the slide was pre-warmed at 37°C. 
0.5×106  (for 1 min of spreading) or 0.2×106 (for 3 and 5 min of spreading) cells were 
pelleted (300×g, 5 min) and resuspended in 50µl of Chamber Buffer. The cell 
suspensions were plated gently onto the slides by placing the pipette tip at the base of 
the well and expelling the cells in a single smooth motion onto the bottom of the 
well. The cells were allowed to spread for 1, 3 or 5 min and fixed with 200µl of 4% 
paraformaldehyde for 30 min. After rinsing three times with 500µl of 
PBS/FBS/NaN3 staining buffer (10% FBS and 0.02% sodium azide in PBS), fixed 
cells were permeabilised with 300µl of 0.1% Triton X-100 (Calbiochem) in PBS for 
5 min at room temperature and then again rinsed three times with 500µl of 
PBS/FBS/NaN3 staining buffer. Subsequently, it was blocked with 300µl of 5% goat 
serum (Sigma-Aldrich) in PBS/FBS/NaN3 staining buffer for an hour at room 
temperature before staining with 5µl of rhodamine phalloidin (Life Technologies) for 
30 min at room temperature in the dark. Stained cells were then washed three times 
with 500µl of PBS/FBS/NaN3 staining buffer before mounting with one drop of 
Vectashield Mounting Medium with DAPI (Vector Laboratories) and a coverslip was 
carefully placed on top of the slide. The slides were analysed using fluorescence 
microscope (Leica DM4500B) with a 100× oil objective, and images were acquired 
using Leica DFC365 FX monochrome digital camera and Leica LAS AF software. 
Percentage of spreading was calculated by counting at least 100 cells per 
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experimental condition. Cells that form a F-actin ring at the cell periphery were 
scored as positive while cells without an F-actin ring were scored as negative. 
2.11.2 Immunological Synapse Assay 
MEC-1 B cells were first stained with CellTracker Blue CMAC (Life Technologies) 
according to the manufacturer’s instructions and pulsed with 2µg/mL of a cocktail of 
staphylococcal superantigens (sAgs; SEA and SEB; Sigma-Aldrich) for 30 min at 
37°C. B cells (1×106) were centrifuged at 200×g for 5 min with an equal number of T 
cells (Jurkat or primary T cells) and incubated at 37°C for 15 min. Cells were 
transferred onto microscope slides (Menzel-Glaser Polysine slides; Thermo 
Scientific) using a cell concentrator (Cytofuge 2) and fixed with 3% methanol-free 
formaldehyde (TABB Laboratories) in PBS for 15 min at room temperature. 
Subsequently, cells were permeabilised with 0.3% Triton X-100 (Calbiochem) in 
PBS for 5 min and treated with blocking buffer (0.1% BSA in PBS) for 10 min. F-
actin was stained with 5µl of rhodamine phalloidin (Life Technologies). After 
washing, the cell specimens were sealed with 22mm×32mm coverslips using 
fluorescent mounting medium (Dako). Medial optical section images were captured 
by A1R (Nikon) confocal microscope using a 60×/1.40 oil objective with NIS-
elements imaging software (Nikon). Detectors were set to detect an optimal signal 
below saturation limits. Fluorescence was acquired sequentially to prevent passage 
of fluorescence from other channels (Multi-Track). Image sets to be compared were 
acquired during the same session using identical acquisition settings. Blinded 
confocal images were analysed using NIS-elements imaging software (Nikon). T 
cell-B cell conjugates were identified only when T cells were in direct contact 
interaction with B cells (blue fluorescent channel) and the total area (in square 
micrometre) of F-actin (red fluorescent channel) accumulation at all T cell contact 
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sites and synapses with B cell (minimum n=16; maximum n=30 per experimental 
condition) was measured.  
2.12 Migration Assay 
Migration assay of Jurkat T cells was performed using 96-well Boyden Chamber 
Chemotaxis Plate (5µm polycarbonate membrane, 3.2mm diameter; Receptor 
Technologies Ltd). Cells were harvested and incubated in migration medium (25mM 
HEPES buffer solution and 0.1% BSA in RPMI 1640 medium without phenol red, 
serum free) for 30 min at 37°C to starve the cells. Starved cells were stained with 
5µM of Calcein AM (Life Technologies) for 30 min at 37°C and washed twice with 
migration medium before resuspension at a density of 4×106 cells/0.5ml in migration 
medium. 25µl containing 2×105 cells were loaded on the upper chamber of the 
Boyden chamber in triplicate. In the lower chamber, 29µl of medium with serum 
(20% FBS, 25mM HEPES buffer solution and 0.1% BSA in RPMI 1640 medium 
without phenol red) was loaded. 25µl of migration medium was also loaded into 
lower chamber in triplicate as blank. Besides that, eight standards (ranging from 
1562.5 to 2×105 cells in 25µl) were also prepared using wild-type cells to generate a 
standard curve and 25µl of each standard was loaded into the lower chamber in 
triplicate. The plate was incubated at 37°C in 5% CO2 for 4 hours to allow the cells 
to migrate through the membrane to the lower chamber. The filter was wiped gently 
with cotton swab and flushed with PBS to remove any attached cells before 
centrifuging the plate at 400×g for 10 min to pull all the cells to the bottom of the 
well. Fluorescence intensity was measured with a fluorescence microplate reader 
(Tecan GENios Pro Multifunction Multimode Microplate Reader) with excitation 
wavelength of 485nm and emission wavelength of 535nm and cell number was 
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subsequently calculated against standard curve. The percentage of migration was 
estimated using the following equation. 
Percentage of Migration (%) = Number of Migrated Cell in Lower Chamber /  
  Total Number of Cell 
Total Number of Cell = Number of Non-migrated and Migrated Cells = 2×105  
2.13 Patient Samples 
BM derived CD3+ samples from five MDS patients associated with T-LGL 
leukaemia were obtained from King’s College London Haemato-Oncology Tissue 
Bank (Human Tissue Authority Licence Number 12223). The samples were 
collected, stored and used in accordance with donor consent given under the auspices 
of ethics approval, provided by the UK National Research Ethics Service (NRES) 
(Approval Reference 08/H0906/94). 
2.14 Statistical Analysis 
Statistical analysis was performed using Prism Version 5 software (GraphPad 
Software Inc). Statistical significance was calculated by P values using 
nonparametric, two tailed, unpaired t test.  
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3 Chapter 3 – Identification and Validation of miR-181c/d 
Target Genes 
3.1 Introduction 
miRNAs are short endogenous non-coding RNAs of 18-25 nucleotides in length 
which influence gene expression either by promoting mRNA degradation or 
translational inhibition (Ambros, 2001; Bartel, 2004). miRNAs have been shown to 
play pivotal roles in a diverse range of biological events in both normal and cancer 
cells [reviewed in (Ambros, 2004; Ghildiyal and Zamore, 2009)].  
Our study focused on the miR-181 family which has been demonstrated to play 
crucial roles in haematopoiesis. The expression of miR-181a and miR-181b has been 
reported to be upregulated during erythroid differentiation in human cord blood-
derived CD34+ cells (Choong et al., 2007; Lu et al., 2005). Overexpression of miR-
181 in both K562 cells and human cord blood-derived CD34+ progenitor cells was 
found to promote megakaryocytic differentiation by repressing Lin28 expression, 
disrupting the Lin28-Let-7 reciprocal regulatory loop and in turn upregulating Let-7 
(Li et al., 2012a). This finding is in contrast to a study performed by Garzon and 
colleagues where they reported that miR-181b and miR-181c were downregulated 
during in vitro megakaryocytic differentiation in CD34+ BM progenitors (Garzon et 
al., 2006). Furthermore, it has been shown that the miR-181 family inhibits 
granulocytic and macrophage-like differentiation in HL-60 cells and CD34+ HSPC 
by reducing the expression of PRKCD, CTDSPL and CAMKK1 (Su et al., 2015). 
Moreover, computational algorithms predicted that miR-181a regulates genes that are 
critical to very early steps in erythroid (MYB, CREBBP and AGTR2), myeloid (ERI-
1, ETS, MEIS-1 and HOXA5) and lymphoid (PU.1, MEF, SPI-B and MYB) 
differentiation, suggesting that miR-181a might be important in the early steps of 
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haematopoiesis (Georgantas et al., 2007). In addition, miR-181 was found to be 
preferentially expressed in B lymphoid cells in mouse BM and overexpression of 
miR-181 in HSPC caused an elevation in the fraction of B lineage cells both in vitro 
and in vivo, suggesting that miR-181 is a positive regulator of B cell differentiation 
(Chen et al., 2004a). Moreover, it has been demonstrated that miR-181a and miR-
181b promote the development of NK cells (Cichocki et al., 2011; Henao-Mejia et 
al., 2013). miR-181a/b-deficient mice were found to develop haematological defects 
including T cell proliferation and development as well as early B cell development 
(Henao-Mejia et al., 2013). Additionally, miR-181a has been shown to increase the 
TCR signalling strength and the sensitivity of T cells to antigens by repressing the 
expression of multiple negative regulators in the TCR signalling pathway 
(phosphatases PTPN22, SHP-2, DUSP5 and DUSP6) and increasing the basal level 
of LCK and ERK activation, thereby augmenting the TCR-mediated T cell activation 
(Li et al., 2007). Moreover, ectopic expression of miR-181c decreased both T cell 
activation and proliferation by reducing the expression of IL-2, suggesting that miR-
181c modulates T cell activation and proliferation (Xue et al., 2011). Taken together, 
multiple previous studies have shown that the miR-181 family plays an important 
role in haematopoietic development as well as T cell functions. 
Various computational algorithms have been developed to identify miRNA target 
genes in order to gain insight into the functions of miRNAs (Bentwich, 2005). 
However, a major drawback of these prediction models is an inevitable bias due to 
reliance on the complementarity between miRNA and target gene, resulting in a 
substantial false positive rate (Didiano and Hobert, 2006). Multiple studies showed 
that perfectly matched miRNA seed sequence with 3’UTR of target mRNA is not 
necessary for miRNA target gene regulation. miRNAs could bind to the 5’UTR of 
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target mRNA (Lytle et al., 2007) and also mRNA binding sites are present in the 
central region (Shin et al., 2010) or the 3’ end of miRNA (Grimson et al., 2007; Lal 
et al., 2009).  
As current miRNA target identification methods are often associated with a lack of 
sensitivity and specificity, we utilised a functional screening assay which has been 
developed in-house (Gäken et al., 2012) in this study to identify novel downstream 
targets of the miR-181 family members. This is a selection-based functional assay 
which allows rapid and specific detection of targets for a given miRNA. This 
strategy makes no assumptions based on previously identified sequences, but relies 
directly on downregulation, by a miRNA, of a thymidine kinase-zeocin (TKzeo) 
fusion gene expressed upstream of a cDNA library (Sigma-Aldrich, MREH01). This 
cDNA library, derived from multiple human tissues and 10 human cell lines, 
contains 16,923 unique genes. The main advantage of this assay is that it identifies 
miRNA targets that are downregulated either by mRNA degradation or translational 
repression and not merely relies on the binding of miRNA to putative targets. This 
assay predicts miRNA targets that are regulated by miRNA without seed-match 
pairing. Moreover, only targets that are significantly downregulated could be 
identified due to the nature of the assay and therefore the predicted targets are 
considered to be the most crucial targets of the investigated miRNA. Accordingly, 
the number of targets identified by this assay will be considerably smaller than 
predicted by computational algorithms. 
We aimed to identify possible downstream targets of the miR-181 family using this 
functional assay to elucidate the role of miR-181 in normal haematopoiesis. Our 
study started with the identification of miR-181c/d target genes in the first instance 




Figure 3.1: Principal of functional assay for miR-181c/d-mediated target genes 
identification. Human breast adenocarcinoma MCF7 cells which express low levels 
of miR-181c and miR-181d are first transfected with a cDNA library inserted 
downstream of a TKzeo fusion gene in the p3’TKzeo dual selection plasmid. During 
recovery period, constructs can integrate into the genome and express the encoded 
transcript and then zeocin selection results in a population of cells that express the 
TKzeo fusion gene from stably integrated library constructs. These cells are 
resistance to zeocin but sensitive to ganciclovir (GCV). Zeocin resistant cells are 
subsequently transfected with pBabePuro vector expressing miR-181c/d. After 
selection for stable integration with puromycin and cell expansion, cells are treated 
with GCV. Cells expressing TKzeo fusion gene that are not targeted by miR-181c/d 
will die, while cells that have downregulated the TKzeo fusion gene expression (cells 
containing library constructs which are targeted by miR-181c/d) either by 
translational repression or mRNA degradation will survive under GCV selection. 
Genomic DNA is then isolated from the GCV resistant cells and the cDNA 
containing miR-181c/d target sites is PCR amplified. PCR products are subjected to 
sequencing and sequences obtained are aligned against human genome to identify the 
putative miR-181c/d target genes [Adapted from (Gäken et al., 2012)].  
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3.2 Identification of miR-181c/d Targets Using A Functional Assay  
3.2.1 Construction of pBabePuro Plasmids Expressing miR-181a, miR-181b 
and miR-181c/d 
miR-181a (Figure 3.2a), miR-181b (Figure 3.2a) and miR-181c/d (Figure 3.2b) were 
first amplified from genomic DNA isolated from HeLa cells by PCR using designed 
primers (primer details in Appendix B1). miR-181c and miR-181d were amplified 
with a single primer pair as they are located close to each other at the chromosome. 
Due to the unspecific amplification (~400bp band) for miR-181c/d, we utilised the 
ApoI restriction site within the fragment of 808bp product to confirm the correct 
fragment was isolated. After digestion, two bands (~200bp and ~600bp) were shown 
(Figure 3.2c), confirming the correct amplification of miR-181c/d. 
Subsequently, miR-181 amplicons were cloned into TOPO vector to generate TOPO-
miR-181a, TOPO-miR-181b and TOPO-miR-181c/d plasmids, and then verified with 
EcoRI enzyme digestion, generating two fragments, ~4kb (TOPO vector) and 
~700bp  (PCR products of miR-181a, miR-181b and miR-181c/d) (Figure 3.3). In 
addition, TOPO-miR-181 plasmids were also validated by sequencing using M13 
primers (Life Technologies; primer details in Appendix B5). 
Next, the miR-181 was subcloned into pBabePuro retroviral vector (vector map see 
Appendix A2), a mammalian retroviral vector conferring puromycin resistance 
(Morgenstern and Land, 1990), using BamHI and EcoRI restriction sites to generate 
pBabe-miR-181a, pBabe-miR-181b and pBabe-miR-181c/d plasmids. Digestion of 
the plasmids with EcoRI and BamHI enzymes to check for the insertion of miR-181 
in the pBabePuro vector generated two fragments, ~5kb (pBabePuro vector) and 
~700bp (miR-181 inserts) (Figure 3.4). The plasmids were also verified by 
sequencing with designed primers (primer details in Appendix B5).  
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Figure 3.2: PCR amplification of miR-181a, miR-181b and miR-181c/d. (a) Gel 
image shows the PCR products of miR-181a (688bp, lane 1) and miR-181b (672bp, 
lane 2). (b) Gel image shows the PCR amplification of miR-181c/d using increasing 
annealing temperature (lane 1-6). The most specific amplified miR-181c/d (808bp, 
lane 6) was used in subsequent cloning. (c) Gel image shows the ApoI enzyme 
digestion of miR-181c/d PCR product. Lane 1: undigested product of 808bp; Lane 2: 






Figure 3.3: EcoRI enzyme digestion of TOPO-miR-181 plasmids. (a) Gel image 
shows the EcoRI enzyme digestion of TOPO-miR-181a and TOPO-miR-181b 
plasmids. Lane 1-3: undigested TOPO-miR-181a plasmids; Lane 4-6: undigested 
TOPO-miR-181b plasmids; Lane 7-9: digested TOPO-miR-181a plasmids; Lane 10-
12: digested TOPO-miR-181b plasmids. (b) Gel image shows the EcoRI enzyme 
digestion of TOPO-miR-181c/d plasmids. Lane 1-4: undigested TOPO-miR-181c/d 








Figure 3.4: EcoRI and BamHI enzyme digestion of pBabe-miR-181 plasmids. (a) 
Gel image shows the EcoRI and BamHI enzyme digestion of pBabe-miR-181a 
plasmids. Lane 1, 3, 5, 7 and 9: undigested plasmids; Lane 2, 4, 6, 8 and 10: digested 
plasmids. (b) Gel image shows the EcoRI and BamHI enzyme digestion of pBabe-
miR-181b plasmids. Lane 1 and 3: undigested plasmids; Lane 2 and 4: digested 
plasmids. (c) Gel image shows the EcoRI and BamHI enzyme digestion of pBabe-
miR-181c/d plasmids. Lane 1, 3, 5, 7 and 9: undigested plasmids; Lane 2, 4, 6, 8 and 
10: digested plasmids. 
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3.2.2 Transfection of MCF7 Cells with p3’TKzeo-library Plasmid and 
pBabePuro Plasmid Expressing miR-181c/d 
A panel of nine cell lines have previously been screened in-house for the expression 
levels of about 600 miRNAs and the MCF7 cell line expressed only low levels of 
miR-181c and miR-181d (Appendix F). Therefore, liquid nitrogen stock of MCF7 
cells transfected with p3’TKzeo-library (cDNA library from Sigma-Aldrich, 
MREH01 inserted between SfiI sites in the p3’TKzeo vector, vector map see 
Appendix A3) which have previously been produced in-house (by Dr Joop Gäken, 
Dr Heba Alkhatabi and Dr Austin Kulasekararaj) was used in subsequent miRNA 
transfection. Cells were first selected under zeocin for transfected cells but also 
remove silenced integrants and cDNAs targeted by endogenous miRNAs in essence 
self-cleaning the system. Subsequently, a large scale transfection, by electroporation, 
of the zeocin-selected MCF7 cells containing p3’TKzeo-library with pBabe-miR-
181c/d plasmid was perfomed (24 transfections with 2×106 cells per transfection). 
After transfection, cells were puromycin selected and after 48 hours, GCV was added 
for 10 days. Under GCV selection, cells expressing TKzeo fusion gene that are not 
targeted by miR-181c/d will die while cells downregulated the TKzeo fusion gene 
expression due to miR-181c/d targeting will survive. A total of 45 GCV resistant 
colonies was obtained from the 24 transfections and the colonies were expanded and 
then genomic DNA was extracted for target identification. 
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3.2.3 Targets Amplification and Detection 
PCR was carried out on the genomic DNA isolated from GCV resistant cells in order 
to amplify genes that are targeted by miR-181c/d, using p3’TKzeo specific primers 
flanking the SfiI cloning site (primer details in Appendix B2). Optimisation of the 
primer pairs showed that the primer pair of 3F and 10RTT was the most specific as 
other primer pairs showed amplification on negative control. Potential targets of 
miR-181c/d were amplified using primer pair of 3F and 10RTT (Figure 3.5). No 
template control and genomic DNA extracted from MCF7 cells transfected with 
empty pBabePuro vector were used as negative control during PCR amplification 
while genomic DNA extracted from MCF7 cells carrying cDNA library transfected 
with empty pBabePuro vector was used as positive control. There was no 
amplification in no template control as no DNA was present and also there were no 
bands observed in the negative control as there was no cDNA library present in the 
cells. The positive control showed a smear indicative of the amplification of the 
cDNA library.  
A total of 12 amplified bands were purified from the gel, cloned into TOPO vector 
and sequenced. Sequences were aligned against human genome and transcripts 
database in NCBI Nucleotide Blast and two transcripts with high homology were 
identified which are DHTKD1 and BRK1 (Appendix G). The detected targets 




Figure 3.5: Putative targets of miR-181c/d amplified by PCR. Gel image shows 
the PCR amplification of the genomic DNA isolated from GCV resistant cells. Lane 
1: no template control (NTC); Lane 2: negative control (genomic DNA from MCF7 
cells transfected with empty pBabePuro vector); Lane 3: positive control (genomic 
DNA from MCF7 cells carrying p3’TKzeo-library transfected with empty 
pBabePuro vector); Lane 4-11: genomic DNA from GCV resistant cells.  
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3.3 Prediction of miR-181c/d Targets by Computational Algorithms 
There are many prediction programs available that can be used to predict miRNA 
targets in silico. In this study, miRecords (http://c1.accurascience.com/miRecords/) 
which predict targets based on 11 prediction programs (DIANA, MicroInspector, 
miRanda, MirTarget2, miTarget, NBmiRTar, PicTar, PITA, Rna22, RNAhybrid and 
TargetScan) was used to predict the targets of hsa-miR-181c and hsa-miR-181d. 
More than 30 thousands predicted targets were found using all the 11 programs. 
Therefore, we filtered the results by reducing the number of prediction programs 
used. A total of 151 target genes for miR-181c were predicted by at least six 
programs, which are miRanda, MirTarget2, PicTar, PITA, RNAhybrid and 
TargetScan (Appendix H1). For miR-181d, a total of 222 targets were predicted by at 
least five programs, which include miRanda, MirTarget2, PITA, RNAhybrid and 
TargetScan (Appendix H2). Interestingly, the targets identified by our functional 




3.4 Validation of the Identified Targets of miR-181c/d 
3.4.1 Minimum Free Energy by RNAhybrid 
RNAhybrid (https://bibiserv2.cebitec.uni-bielefeld.de/rnahybrid) was used to 
determine the likelihood of miR-181c and miR-181d targeting DHTKD1 and BRK1. 
RNAhybrid is a computational algorithm that examines the degree of 
complementarity between miRNA and its target mRNA by determining the 
minimum free energy (mfe) of hybridisation between them. The lower the mfe 
values, the higher the degree of complementarity between miRNA and its target 
mRNA, indicating the increasing likeliness of the mRNA to be a target of the 
miRNA of interest. The hybridisation between mature miR-181c or miR-181d and 
DHTKD1 or BRK1 and their mfe values are shown in Figure 3.6. Interestingly, there 
is no seed-match pairing between miR-181c or miR-181d with both of their targets. 
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(c)                                                                     (d)  
 
 
Figure 3.6: Predicted hybridisation between miR-181c and miR-181d with their 
putative target genes, DHTKD1 and BRK1 by RNAhybrid. Hybridisation between 
(a) miR-181c and DHTKD1, (b) miR-181d and DHTKD1, (c) miR-181c and BRK1 as 
well as (d) miR-181d and BRK1. Green represents mature miRNA sequences and red 
represents target mRNAs. The predicted minimum free energy (mfe) values of the 

















mfe: -23.7 kcal/mol 
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3.4.2 Overexpression and Inhibition of miR-181c and miR-181d 
In order to select cell lines to perform validation experiments, the expression levels 
of endogenous miR-181c and miR-181d were examined in different cell lines, 
including HepG2, 293T, NIH/3T3, MCF7, HeLa, Jurkat, K562, KG1, NB4, THP-1 
and U937. Leukemic cell lines (Jurkat, K562, KG1, NB4, THP-1 and U937) have a 
relatively low expression of miR-181c and miR-181d as compared to adherent cell 
lines (HepG2, 293T, NIH/3T3, MCF7 and HeLa) (Figure 3.7). Two adherent cell 
lines, MCF7 and HeLa, which express lower level of miR-181c and miR-181d 
compared to other adherent cell lines, and one leukemic cell line, Jurkat T cells were 
chosen to perform validation experiments.  
Overexpression of miR-181c/d in MCF7, HeLa and Jurkat T cells was performed by 
transfecting pBabe-miR-181c/d plasmid using electroporation. As experimental 
controls, cells were mock transfected or transfected with empty pBabePuro vector. 
Relative to controls, miR-181c and miR-181d expression levels were increased by 
approximately 50 and 20 fold respectively in miR-181c/d overexpressing MCF7 
cells, almost 60 and 40 fold respectively in HeLa cells, and approximately 2000 and 
700 fold respectively in Jurkat T cells (Figure 3.8). Surprisingly, following ectopic 
expression of miR-181c/d, there were no changes in both the BRK1 and DHTKD1 
mRNA levels in all the three cell lines as compared to controls (Figure 3.9).  
Inhibition of miR-181c and miR-181d was also performed in miR-181c/d 
overexpressing MCF7, HeLa and Jurkat T cells by transfecting the cells with 
miRIDIAN hsa-miR-181c-5p-Hairpin Inhibitor and miRIDIAN hsa-miR-181d-5p-
Hairpin Inhibitor (Dharmacon; details see Appendix C2). Mock transfection and 
transfection using miRIDIAN Hairpin Inhibitor Negative Control (Dharmacon) were 
used as experimental controls. For DHTKD1 mRNA level, inconsistent results were 
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found between the three cell lines, where an increase in DHTKD1 mRNA level was 
seen in MCF7 cells following miR-181d inhibition, an decrease DHTKD1 mRNA 
expression was observed in HeLa cells following miR-181c and miR-181d inhibition, 
whereas the mRNA level of DHTKD1 remained unaltered in Jurkat T cells following 
both miR-181c and miR-181d inhibition (Figure 3.10a). However, BRK1 mRNA 
expression level remained unchanged following miR-181c or miR-181d inhibition in 
all the three cell lines, similar to miR-181c/d overexpression (Figure 3.10b).  
Given that overexpression and inhibition of miR-181c and miR-181d had no impact 
on the mRNA expression level of the target genes, we hypothesised that miR-181c 
and miR-181d might regulate the target genes by repressing their translation rather 
than by mRNA degradation and therefore the protein expressions were examined. 
Indeed, protein levels of BRK1 and DHTKD1 were substantially downregulated in 
miR-181c/d overexpressing MCF7, HeLa and Jurkat T cells as compared to controls 
(Figure 3.11a). The reduced protein expression of BRK1 and DHTKD1 in miR-
181c/d overexpressing cells could be reversed by miR-181c inhibition where a 
marked increase in DHTKD1 and BRK1 protein levels were observed (Figure 3.11b). 
Interestingly, inhibition of miR-181d had no impact on the protein expression of 
BRK1 and DHTKD1 (Figure 3.11b), indicating that BRK1 and DHTKD1 protein 





Figure 3.7: Endogenous expression of miR-181c and miR-181d in different cell 
lines. Figure shows qPCR analysis of miR-181c and miR-181d expression in HepG2, 
293T, NIH/3T3, MCF7, HeLa, Jurkat, K562, KG1, NB4, THP-1 and U937 cell lines. 









Figure 3.8: Expression of miR-181c and miR-181d following miR-181c/d 
overexpression. Figures show qPCR analysis of miR-181c and miR-181d expression 
in (a) MCF7, (b) HeLa and (c) Jurkat T cells transfected with pBabe-miR-181c/d 
plasmid (miR-181c/d) and empty pBabePuro vector (Control) as well as mock 
transfection (WT). Expression levels of miR-181c and miR-181d are calibrated to 
mock transfection and normalised to endogenous control miR-103a. Error bars 





































































































































Figure 3.9: mRNA expression levels of DHTKD1 and BRK1 following miR-
181c/d overexpression. Figures show qPCR analysis of (a) DHTKD1 and (b) BRK1 
mRNA expressions in MCF7, HeLa and Jurkat T cells following miR-181c/d 
overexpression. Relative DHTKD1 and BRK1 expression levels are calibrated to 
mock transfection and normalised to endogenous control GAPDH. Error bars 













































































































Figure 3.10: mRNA expression levels of DHTKD1 and BRK1 following miR-181c 
and miR-181d inhibition. Figures show qPCR analysis of (a) DHTKD1 and (b) 
BRK1 mRNA expressions in miR-181c/d overexpressing MCF7, HeLa and Jurkat T 
cells following miR-181c and miR-181d inhibition. Relative DHTKD1 and BRK1 
expressions are calibrated to mock transfection and normalised to endogenous 














































































































































































Figure 3.11: Protein expression of DHTKD1 and BRK1 following miR-181c and 
miR-181d overexpression and inhibition. (a) Western blot analysis of the protein 
expression of DHTKD1 and BRK1 in miR-181c/d overexpressing MCF7, HeLa and 
Jurkat T cells. (b) Western blot analysis of the protein expression of DHTKD1 and 
BRK1 in miR-181c/d overexpressing MCF7, HeLa and Jurkat T cells following miR-
181c and miR-181d inhibition. β-ACTIN level is used as a loading control and 
numbers represent the densitometric quantification of DHTKD1 and BRK1 protein 







    1      1.28      0.44 
    1       1.44      0.58 
   1      1.82    0.38 
  1       0.98    0.60 
    1       0.31     0.16 

































































  1     3.90    7.04    4.51 
   1     3.27    5.80   1.39 
  1     1.49    7.46   1.87 
  1     0.54    3.73   2.41 
  1     0.78   3.32   1.17 





























































Since the discovery of the first miRNA in 1993 (Lee et al., 1993), there have been 
rapid advances in the development of computational algorithms to predict miRNA 
targets, which have contributed to the identification of new miRNAs and a large 
number of predicted targets. The main obstacle in miRNA research is the accurate 
detection of target genes and it remains difficult and challenging to date due to the 
binding of miRNA to target with incomplete homology. Increasing evidence shows 
that base pairing between the miRNA seed region with the 3’UTR of target mRNA is 
not always required for miRNA regulation (Grimson et al., 2007; Lal et al., 2009; Lu 
et al., 2010; Lytle et al., 2007; Shin et al., 2010). In addition, the small size of 
miRNA provides only limited sequence information for their specificity. Moreover, a 
single miRNA is likely to influence the expression of a large number of mRNAs and 
also multiple miRNAs can act together to control an individual mRNA, which has 
further complicated the identification of miRNA target genes.  
Nevertheless, several miRNA target identification methods including computational 
algorithms, expression array and proteomic approaches have been developed and 
applied in miRNA studies. Undeniably, each of these approaches has their own 
benefits and limitations. Computational algorithms have been developed to predict 
the miRNA target sites in silico, predominantly based on the base pairing 
interactions between miRNA and target mRNAs. The commonly accepted rule for 
computational programs is the complementary pairing between 5’ seed sequence of 
miRNA and 3’UTR of target mRNA, which results in a high rate of false positive 
results (Didiano and Hobert, 2006). Given that individual miRNAs have the ability to 
regulate a number of genes, several experimental assays have evolved with the 
intention of screening a set of target genes, targeted by a specific miRNA. These 
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assays predict miRNA targets based on their differential expression at mRNA or 
protein level following overexpression or repression of the miRNA under 
investigation (Lewis et al., 2003; Thomson et al., 2011). The most widely used 
technique at the mRNA level is the gene expression profiling using expression array 
(microarray) or next generation sequencing. One of the caveats of using differential 
gene expression to identify miRNA targets is that it is unable to distinguish between 
direct and indirect targets (Lim et al., 2005) and it is associated with a false positive 
rate resulting from mishybridisation (Chiang et al., 2010; Thomson et al., 2004). In 
addition, this analysis is incapable to detect targets that are predominantly repressed 
by miRNA at the translational level. Thus, proteomic approaches such as stable 
isotope labelling with amino acids in cell culture (SILAC) are used to identify targets 
resulting from translational inhibition by a specific miRNA. SILAC is a high 
throughput method for quantitative proteomics in which relative protein abundance is 
measured by mass spectrometry of samples labelled with different isotopes. The 
drawbacks of SILAC assay are that this assay is expensive, very time-consuming and 
unable to distinguish between direct and indirect targets (Baek et al., 2008). 
Furthermore, co-immunoprecipitation of the RISC component, AGO has also been 
applied to identify miRNA targets (Hendrickson et al., 2008). This technique uses 
epitope-tagged AGO to co-immunoprecipitate the associated miRNA/mRNA pairs 
followed by microarray or high-throughput sequencing to identify the targets. The 
main limitation of this assay is that it may co-immunoprecipitate mRNA that 
interacts with AGO protein due to cell lysis, contributing to false positive results. 
Besides that, this method is technically challenging as it depends on the stable 
binding between miRNA/mRNA pairs and AGO protein (Mili and Steitz, 2004). 
Moreover, molecular techniques such as western blot, RT-qPCR and luciferase 
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reporter assay, are commonly used in validating individual targets of miRNA (Kuhn 
et al., 2008). Following overexpression or inhibition of a specific miRNA, western 
blot and RT-qPCR analysis are used to examine differential expression of target 
genes at protein and mRNA levels respectively. These methods are able to determine 
whether the regulation of miRNA on their targets is through translational repression 
or mRNA degradation. The disadvantages of these methods are that they only 
investigate a single miRNA target at a time and are unable to discriminate between 
direct and indirect targets (Zhang et al., 2007). On the other hand, the luciferase 
reporter assay is able to determine the direct target genes of a miRNA. This assay is 
dependent upon the cloning of binding sites of putative targets downstream of a 
luciferase reporter gene. Binding of endogenous or introduced miRNAs to the cloned 
target sequence will result in downregulation of luciferase expression. However, this 
technique requires prior knowledge about the correct target site and might involve a 
large amount of cloning work and therefore it might be time-consuming (Kong et al., 
2008; Lytle et al., 2007). Despite progress made within the field, many targets of 
miRNA have not been identified and experimentally validated due to the lack of 
highly sensitive and specific techniques.  
In the present study, the application of our functional assay allows an efficient 
identification of miRNA targets where miRNAs interact with or without a seed 
sequence with their target mRNAs. This assay has the potential to identify 
downregulated targets at both mRNA and protein levels and the identified number of 
putative targets by this assay is smaller than the number of targets predicted by 
computational algorithms, expression arrays or proteomic approaches. Besides that, 
this assay isolates only the targets that are significantly downregulated and therefore 
the identified targets are likely to be the most crucial targets. This functional assay 
 119 
relies on using a large cDNA library, representing approximately 77% of the human 
transcriptome, inserted downstream of a fusion gene (TKzeo). The presence of this 
large library will increase the possibility of identifying many targets for many 
miRNAs (Gäken et al., 2012). Using this functional assay, we identified two target 
genes of miR-181c/d which are BRK1 and DHTKD1. The chromosomal location and 
functions of BRK1 and DHTKD1 are shown in Table 3.1. 
Using RNAhybrid, we further strengthened the possibility that BRK1 and DHTKD1 
are targeted by miR-181c/d. We found that the mfe values of hybridisation between 
miR-181c and BRK1, miR-181c and DHTKD1, miR-181d and BRK1 as well as miR-
181d and DHTKD1 ranged from -21.5 to -25.1 kcal/mol. These mfe values are lower 
than the mfe value for hybridisation between miR-10a and its validated target, 
HOXA1 (-19.8 kcal/mol) as reported by a previous study (Garzon et al., 2006). 
Therefore, our data suggests that BRK1 and DHTKD1 are likely to be targeted by 
miR-181c/d based on the degree of complementarity predicted by mfe values using 
RNAhybrid. 
Besides validating the identified targets by RNAhybrid, BRK1 and DHTKD1 were 
also validated experimentally by examining their expression levels following 
overexpression and inhibition of miR-181c and miR-181d. To avoid differences in 
genetic background of the cell lines which may interfere with miRNA regulation of 
its target, we used three independent cell lines, MCF7, HeLa and Jurkat T cells in the 
validation experiments. Interestingly, our validation experiments showed that BRK1 
and DHTKD1 are regulated by miR-181c instead of miR-181d as inhibition of miR-
181d had no impact on the BRK1 and DHTKD1 protein expression levels. In 
addition, overexpression and inhibition of miR-181c had no impact on the mRNA 
expression but did in fact modulate protein expression, suggesting that miR-181c 
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regulates BRK1 expression by blocking the translation rather than by degrading the 
mRNA.  
According to literature reviews and miRTarBase Release 6.0 
(http://mirtarbase.mbc.nctu.edu.tw/), there are a number of miR-181c target genes 
which were validated experimentally by reporter assay, western blot or RT-qPCR 
analysis. Using RT-qPCR and western blotting analysis, Liu et al. showed that lower 
expression level of miR-181c in glioblastoma cells decreased PCAF expression, 
suggesting the role of miR-181c in reduction of the activation of major tumour 
suppressive pathways in glioblastoma (Liu et al., 2007a). Ruan et al. utilised the 
same methods, RT-qPCR and western blot and showed that miR-181c negatively 
regulates NOTCH2 in glioma cells (Ruan et al., 2015). Furthermore, Hashimoto et al. 
reported that epigenetically-silenced miR-181c plays an important role in the 
pathogenesis of gastric carcinomas through its target genes, NOTCH4, KRAS and 
MECP2, as identified by cDNA microarray analysis and validated by RT-PCR and 
western blot analysis in gastric carcinoma KATOIII cell line (Hashimoto et al., 2010; 
Hashimoto et al., 2013). Moreover, miR-181c was also found to negatively modulate 
T cell activation by targeting IL-2, as validated by luciferase reporter assay (Xue et 
al., 2011). Another study also utilised luciferase reporter assay and identified 
TRIM2, SIRT1 and BTBD3 as putative target genes of miR-181c, suggesting the 
potential function of miR-181c in brain homeostasis and disease pathogenesis 
(Schonrock et al., 2012). In addition, Zhang et al. showed that miR-181c directly 
targets the 3’UTR of TNF-α mRNA using luciferase reporter assay, and miR-181c 
regulates both TNF-α mRNA and protein expressions using RT-qPCR and western 
blot analysis in BV-2 microglial cell line, suggesting the regulation of TNF-α by 
miR-181c after ischemia/hypoxia and microglia-mediated neuronal injury (Zhang et 
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al., 2012). miR-181c was also found to regulate PDPK1 expression in brain 
endothelial cells using microarray analysis and it was validated by RT-qPCR and 
western blot analysis (Tominaga et al., 2015). Additionally, Ji et al. found that the 
miR-181 family directly targets CDX2, GATA6 and NLK, which are known 
regulators of hepatic cell differentiation in hepatocellular carcinomas using western 
blot analysis and luciferase reporter assay in Hep3B and HuH1 hepatocellular 
carcinoma cell lines (Ji et al., 2009). Zhu et al. reported that miR-181 family plays a 
key role in the development of multidrug resistance in both SGC7901 gastric and 
A549 lung cancer cell lines by modulation of apoptosis via regulation of BCL2, as 
validated by luciferase reporter assay (Zhu et al., 2010). Besides that, using 
luciferase reporter assay, RT-qPCR and western blot analysis, She et al. found that 
the miR-181 family targets RAP1B in glioblastoma U251 cell line (She et al., 2014). 
Moreover, it has also been recently shown that the miR-181 family inhibits 
granulocytic and macrophage-like differentiation of HL-60 and CD34+ HSPC by 
directly targeting PRKCD, CTDSPL and CAMKK1, as validated using luciferase 
reporter assay, RT-qPCR and western blot analysis (Su et al., 2015).  
However, none of these validated targets was identified by our functional assay in 
the present study. This might be attributed to the nature of the functional assay which 
is only able to identify targets that are significantly downregulated. The validated 
targets described above might not be downregulated sufficiently to be detected by 
this functional assay. In addition, the validated target genes of miR-181c might not 
be present in the cDNA library that we transfected into the MCF7 cells in this 
functional assay. Moreover, it might be due to the lower number of sequencing reads 
of these genes in the cDNA library. The number of sequencing reads in the cDNA 
library, obtained from Sigma-Aldrich’s website, for both the validated targets and the 
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targets detected in our study are shown in Table 3.2. The validated target genes of 
miR-181c which have low sequencing reads in the cDNA library include CDX2, 
GATA6, NOTCH4, BTBD3, RAP1B and PRKCD and hence there is a lower chance to 
identify these targets with the functional assay. 
Collectively, we confirm that BRK1 is a novel downstream target of miR-181c. We 
also showed that miR-181c regulates BRK1 by translational repression.  
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Table 3.1: Chromosomal Location and Functions of BRK1 and DHTKD1.  
Gene BRK1 DHTKD1 
Chromosomal 
Location 












• Contributes to Rac GTPase 
binding 
• No Data Available 
Molecular Function 
(UniProtKB) 
Involved in regulation of actin 
and microtubule organisation 
Part of a WAVE complex that 
activates the ARP2/3 complex 
The 2-oxoglutarate 
dehydrogenase complex 
catalyses the overall 
conversion of 2-oxoglutarate 
to succinyl-CoA and CO(2).  
Biological Processes 
(Gene Ontology) 
In utero embryonic 
development 
Small GTPase-mediated signal 
transduction 
RAC protein signal transduction 
Innate immune response 





Pathways Regulation of actin dynamics 
for phagocytic cup formation 
Regulation of actin cytoskeleton 
Immune system 
Signalling by Rho GTPases 
Interleukin-3, 5 and GM-CSF 
signalling 
Glyoxylate metabolism and 
glycine degradation  
Metabolism 
Viral mRNA translation 
Integrated breast cancer 
pathway 
(Adapted from http://www.genecards.org/) 
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Table 3.2: Number of Sequencing Reads of Validated and Detected Targets in 
cDNA Library (Adapted from Sigma-Aldrich) 























4 Chapter 4 – Roles of miR-181c-BRK1 Axis in T Cell 
Function 
4.1 Introduction 
Reorganisation of the actin cytoskeleton is a requisite event in controlling T cell 
activation and it is important for multiple aspects in T cell function (Holsinger et al., 
1998). The ability of T cells to polymerise actin is critical from the very first step of 
TCR triggering to the completion of a successful T cell activation. During T cell 
activation, multiple cellular processes including cellular polarisation, receptor 
sequestration and signalling, integrin-mediated adhesion, immunological synapse 
formation, and releases of cytokines and lytic granules are all dependent upon the 
proper regulated actin dynamics in T cells (Billadeau et al., 2007; Burkhardt et al., 
2008; Kumari et al., 2014; Yu et al., 2013).  
The miR-181 family has been demonstrated to be involved in T cell development, 
differentiation, proliferation and activation. miR-181a regulates T cell differentiation 
at a very early stage in human lymphopoiesis. miR-181a was found to regulate genes 
that are important in lymphoid differentiation including PU.1, MEF, SPI-B, MYB and 
CXCR4, suggesting that miR-181a might block the T cell differentiation in very early 
steps of haematopoiesis (Georgantas et al., 2007). Furthermore, miR-181a is an 
intrinsic modulator of the TCR signalling strength and the sensitivity of T cells to 
antigens during T cell development and function. miR-181a represses the expression 
of multiple negative regulators in the TCR signalling pathway such as phosphatases 
PTPN22, SHP-2, DUSP5 and DUSP6, and increases the basal level of LCK and 
ERK activation, thus reducing the amount of signal that is required for achieving full 
LCK and ERK activation upon antigen stimulation. This enhances the TCR 
signalling strength and sensitivity of T cells to antigens, thereby augmenting the 
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TCR-mediated T cell activation (Li et al., 2007). In addition, miR-181a and miR-
181b influence T cell proliferation and development as miR-181a/b-deficient mice 
showed reduced proliferative capacity and total number of T cells. This defect was 
found to be associated with impaired PI3K signalling pathway through modulation of 
the phosphatase PTEN expression by miR-181a and miR-181b (Henao-Mejia et al., 
2013). Moreover, miR-181c modulates T cell activation and proliferation by 
regulating the expression of IL-2. miR-181c was found to target IL-2 and ectopic 
expression of miR-181c reduced both T cell activation and proliferation  (Xue et al., 
2011). Although the miR-181 family has been demonstrated to be important in T 
cells, its role in actin polymerisation during T cell activation is still unknown. 
WAVE protein is a member of the WASP family that regulates actin cytoskeletal 
dynamics (Campellone and Welch, 2010; Padrick and Rosen, 2010; Pollitt and Insall, 
2009b). Among the three isoforms of WAVE, WAVE2 has been shown to be the 
major isoform expressed in T cells (Nolz et al., 2006; Zipfel et al., 2007) and 
increasing data indicate that it is an essential regulator of multiple actin cytoskeleton-
dependent processes during T cell activation (Nolz et al., 2006; Nolz et al., 2007; 
Nolz et al., 2008; Zipfel et al., 2007). Suppression of WAVE2 in Jurkat T cells has 
been shown to reduce the F-actin accumulation at the immunological synapse and 
decrease conjugate formation (Nolz et al., 2006; Zipfel et al., 2007). In addition, loss 
of WAVE2 also led to defect in stable lamellipodia generation and impairment in the 
regulation of Ca2+ in T cells (Nolz et al., 2006). Furthermore, depletion of WAVE2 
also caused reduction in IL-2 promoter activity (Nolz et al., 2007; Nolz et al., 2008) 
and defective integrin-mediated adhesion in response to TCR activation (Nolz et al., 
2006; Nolz et al., 2007; Nolz et al., 2008).  
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BRK1, a subunit of WAVE regulatory complex, has been found to be a downstream 
target of miR-181c in our study (see Chapter 3). BRK1 is a small protein of 9kDa 
with a presumed coiled-coil region that has been shown to be important in the 
stability and integrity of WAVE complex as loss of BRK1 led to degradation of the 
complex in both mammalian cell lines (Cai et al., 2009; Derivery et al., 2008; 
Escobar et al., 2010) and Drosophila (Kunda et al., 2003; Qurashi et al., 2007). 
Although much remains unknown regarding the functions of BRK1 in T cells, 
accumulating evidence indicate its important role in the actin cytoskeleton-dependent 
cellular processes. In HeLa cells, BRK1 was shown to be required for lamellipodia 
formation (Derivery et al., 2008; Eden et al., 2002). Moreover, suppression of BRK1 
in PG NSCLC cell line caused actin filament reorganisation, inhibited pseudopodia 
formation and blocked cell migration (Cai et al., 2009). Loss of BRK1 in SN12C and 
U031 renal cell carcinoma cell lines as well as U2OS osteosarcoma cell lines also 
resulted in defective directional migration and invasive growth, coupled with 
reduced cell proliferation (Escobar et al., 2010). Furthermore, BRK1 is also essential 
in actin dynamics and cell survival during embryo development as genetic ablation 
of Brk1 in mice resulted in dramatic defects in embryo compaction and development 
(Escobar et al., 2010). In addition, BRK1 also regulates actin dynamics during the 
processes of neurite outgrowth in human IMR-32 neuroblastoma cell line and 
primary rat hippocampal neurons (Wang et al., 2013a).  
Given the importance of the miR-181 family in T cells and the crucial roles of BRK1 
in the involvement of WAVE protein and in the regulation of actin reorganisation, 
we therefore focused our study on delineating the potential roles of miR-181c-BRK1 
axis in T cell functions. 
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4.2 Primary T Cell Activation Resulted in Downregulation of miR-181c 
Expression and Upregulation of BRK1 Protein Expression 
To investigate whether the regulation of BRK1 by miR-181c correlates with T cell 
activation, we examined the miR-181c expression and the BRK1 protein expression 
level in CD3+ T cells isolated from PBMC, before and after co-stimulation with CD3 
and CD28 antibodies. After stimulation, miR-181c expression was significantly 
reduced (P value=0.00038) (Figure 4.1a) while BRK1 protein expression was 
substantially elevated (Figure 4.1b) in CD3+ cells. This finding further strengthens 






Figure 4.1: Reduced miR-181c expression and increased BRK1 protein 
expression following primary T cell activation. (a) Figure shows the qPCR 
analysis of miR-181c expression in PBMC derived CD3+ T cells before and after 
stimulation. Co-stimulation of CD3+ cells was performed with 2µg/ml of plate-bound 
anti-human CD3 and soluble anti-human CD28 antibodies for 24h. Expression of 
miR-181c is normalised to endogenous control miR-103a. Error bars represent mean 
± SD of 4 independent experiments. *** P ≤0.001. (b) Western blot analysis of 
BRK1 protein expression in PBMC derived CD3+ T cells before and after 
stimulation. β-ACTIN level is used as a loading control and numbers represent the 
densitometric quantification of BRK1 protein expression level normalised to β-
ACTIN. Blot shown is representative of 3 independent experiments.  
  




















































4.3 Effects of miR-181c Overexpression in Jurkat T Cells 
4.3.1 Overexpression of miR-181c in Jurkat T Cells 
In order to study the roles of miR-181c in T cell function, we overexpressed miR-
181c in Jurkat T cells by transfecting the cells with pBabePuro plasmid expressing 
exogenous miR-181c (plasmid will be indicated as pBabe-miR-181c in the following 
text). The cloning of miR-181c into pBabePuro expression vector was carried out 
similar to the cloning of miR-181c/d into pBabePuro vector for miRNA target 
identification functional assay (see Chapter 2 and 3). Mock transfection and cells 
transfected with empty pBabePuro vector were used as experimental controls. 
Following transfection, an upregulation of miR-181c by approximately 600 fold in 
Jurkat T cells transfected with pBabe-miR-181c plasmid was observed when 
compared to controls (Figure 4.2). miR-181c overexpressing Jurkat T cells were used 
in subsequent functional assays.  
4.3.2 Overexpression of miR-181c in Jurkat T Cells Led to Reduced BRK1 
and WAVE2 Protein Expressions 
Before studying the roles of miR-181c in T cells, we examined the protein expression 
levels of BRK1 and WAVE2 following miR-181c overexpression in Jurkat T cells. 
As a result of miR-181c overexpression, BRK1 protein level was decreased as 
compared to controls (Figure 4.3), indicating that BRK1 is indeed a downstream 
target of miR-181c as identified and validated in Chapter 3. In addition, loss of 
BRK1 as a result of miR-181c overexpression also led to reduced WAVE2 protein 
expression (Figure 4.3), suggesting that BRK1 plays an important role in stabilising 





Figure 4.2: Overexpression of miR-181c in Jurkat T Cells. Figure shows the 
qPCR analysis of miR-181c expression in Jurkat T cells transfected with pBabe-miR-
181c plasmid (miR-181c), pBabePuro empty vector (Control) and mock transfected 
cells (WT). The data are calibrated to mock transfection and normalised to 






Figure 4.3: Overexpression of miR-181c in Jurkat T cells resulted in reduced 
BRK1 and WAVE2 protein expressions. Western blot analysis of BRK1 and 
WAVE2 protein expressions following miR-181c overexpression in Jurkat T cells. β-
ACTIN level is used as a loading control and numbers represent the densitometric 
quantification of protein expression levels normalised to β-ACTIN. Blot shown is 
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4.3.3 Overexpression of miR-181c in Jurkat T Cells Had No Impact on Cell 
Proliferation, Cell Cycle and Cell Viability 
To assess the effects of miR-181c overexpression on cell proliferation in Jurkat T 
cells, we used trypan blue exclusion to score the total number of cell at regular 
intervals. Trypan blue does not stain live cells with intact cell membrane but it 
traverses the cell membrane of dead cells, giving a distinctive blue colour under the 
microscope. The trypan blue exclusion results showed nearly identical cell counts in 
the controls and miR-181c overexpressing cells at all the time points (day1 to day6) 
(Figure 4.4a), suggesting that ectopic expression of miR-181c in Jurkat T cells has no 
influence on cell proliferation. 
Furthermore, we also examined the effect of miR-181c overexpression in Jurkat T 
cells on the changes of kinetics of cell cycle entry by flow cytometry analysis using 
propidium iodide (PI) staining. The percentage of cells in each cell cycle phase (G1, 
S and G2-M) was studied post-transfection. There was no substantial difference in 
the percentage of cells in the three phases of cell cycle between miR-181c 
overexpressing cells and controls (Figure 4.4b). 
In addition, the effect of miR-181c overexpression in Jurkat T cells on the cell 
viability was examined by Annexin V and PI staining. There was no difference in the 
percentages of live (~90% of Annexin V- PI- cells), early apoptotic (~6% of Annexin 
V+ PI- cells) and late apoptotic cells (~2% of Annexin V+ PI+ cells) between miR-









Figure 4.4: Overexpression of miR-181c in Jurkat T cells had no impact on cell 
proliferation, cell cycle and cell viability. (a) Plot shows the cell proliferation of 
miR-181c overexpressing cells (green), mock-transfected (WT, red) and empty 
pBabePuro vector-transfected cells (Control, blue). Cells were seeded and cultured in 
a 24-well plate and counted every day for 6 days post-transfection. Error bars 
represent mean ± SEM of 3 independent experiments. (b) Cell cycle profiles of 
Jurkat T cells overexpressing with miR-181c and controls. Samples were fixed with 
70% ethanol, stained with PI and analysed by flow cytometry. Y-axis indicates cell 
number and x-axis indicates PI staining. Plots are representative of 3 independent 
experiments. (c) APC Annexin V and PI staining of Jurkat T cells following miR-
181c overexpression. The percentage of live (Q4 = double negative for Annexin V 
and PI), early apoptotic (Q3 = positive Annexin V and negative PI) and late 
apoptotic (Q2 = double positive for Annexin V and PI) cells were analysed by flow 
cytometry. Y-axis indicates log fluorescence intensity of PI staining and x-axis 
indicates log fluorescence intensity of APC Annexin V staining.  




























4.3.4 Overexpression of miR-181c Repressed Jurkat T Cell Activation 
Since there was no effect on cell proliferation, cell cycle profile and cell viability 
following miR-181c overexpression in Jurkat T cells, we next investigated the 
influence of miR-181c in T cell activation. The expression of CD69, a marker for T 
cell activation, was examined by flow cytometry analysis, before and after co-
stimulation with CD3 antibody and PMA. After stimulation, the expression of CD69 
on the surface of Jurkat T cells in mock, empty pBabePuro vector and pBabe-miR-
181c transfections, were all elevated as compared to those before stimulation (Figure 
4.5). However, the upregulation of CD69 expression was lower in the cells 
overexpressed with miR-181c (72.6% CD69+ cells) than in mock transfected (90.3% 
CD69+ cells) and empty vector transfected cells (92.8% CD69+ cells) (Figure 4.5). 






Figure 4.5: Overexpression of miR-181c in Jurkat T cells repressed T cell 
activation. CD69 expression in miR-181c overexpressing Jurkat T cells and controls 
before (red) and after (blue) stimulation. Jurkat T cells were stimulated with 10µg/ml 
plate-bound anti-human CD3 antibody and 25ng/ml PMA for 24h. Y-axis indicates 
cell number and x-axis indicates log fluorescence intensity of CD69-PE staining. 
Plots are representative of 3 independent experiments. 
  




















































4.3.5 Overexpression of miR-181c in Jurkat T Cells Reduced Actin 
Polymerisation During Lamellipodia Generation and Immunological 
Synapse Formation 
Reorganisation of the actin cytoskeleton is requisite in the control of T cell activation 
(Holsinger et al., 1998). The finding of reduced T cell activation as a result of miR-
181c overexpression has led us to examine whether F-actin polymerisation during T 
cell activation is altered in miR-181c overexpressing cells. We assessed the ability of 
the cells to cap actin in response to T cell stimulation in order to define the roles of 
miR-181c in dynamic cytoskeletal regulation in Jurkat T cells.  
Firstly, the total cellular F-actin content was quantified by flow cytometry with the 
staining of F-actin using phalloidin, before and after stimulation with anti-CD3 and 
PMA. In controls, the total cellular F-actin content in the cells increased after 
stimulation while in miR-181c overexpressing cells, the total cellular F-actin content 
remained unaltered (Figure 4.6). To quantitatively determine the effect of miR-181c 
overexpression on actin polymerisation, the mean fluorescence intensity (MFI) was 
analysed, indicative of the total cellular F-actin content. After stimulation, miR-181c 
overexpressing Jurkat T cells had a significantly lower MFI as compared to the 
controls (Figure 4.6). This result indicates that ectopic expression of miR-181c in 
Jurkat T cells causes a marked reduction in actin polymerisation in response to 
stimulation. 
The generation of lamellipodia in T cells requires properly regulated actin dynamics 
and thus we next studied whether miR-181c overexpression reduces actin 
polymerisation during lamellipodia formation. Spreading of T cells on anti-TCR 
coated slide requires the formation of stable actin structures and the generation of 
lamellipodia (Bunnell et al., 2001). Therefore, we analysed the effect of miR-181c 
overexpression on the ability of Jurkat T cells to spread onto anti-CD3 coated slides 
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by performing a spreading assay. Cells were allowed to spread on anti-CD3 coated 
slides for 1, 3 and 5 minutes and then stained using phalloidin to visualise F-actin. 
During the spreading process, miR-181c overexpressing cells failed to spread whilst 
control cells were able to spread in a highly ordered fashion, forming a round 
lamellipodial interface containing radially-arrayed F-actin-rich structures at the 
periphery of the cells (Figure 4.7). At 1 minute, the percentages of spreading for all 
three experimental conditions were all very low (11.1%, 4.5% and 7.0% respectively 
for mock, empty vector and miR-181c transfected cells) as the cells have not started 
to spread yet. However, after 3 and 5 minutes of spreading, a significantly lower 
percentage of cells that have spread was observed in miR-181c overexpression 
(11.7% at 3 minutes and 14.6% at 5 minutes) as compared to mock (75.7% at 3 
minutes and 84.7% at 5 minutes) and empty vector (76.2% at 3 minutes and 92.4% at 
5 minutes) transfections (Figure 4.7). This data suggests that ectopic expression of 
miR-181c leads to defects in lamellipodia formation in response to TCR stimulation. 
The mutual recognition of T cell and APC results in the engagement and clustering 
of the TCR, and the formation of the T cell-APC interface, known as the 
immunological synapse. Regulation of actin polymerisation at the immunological 
synapse is crucial to initiate and sustain T cell activation. Hence, we next assessed 
whether miR-181c overexpression could impair actin polymerisation at the 
immunological synapse (T cell-B cell contact site). Our results showed that 
overexpression of miR-181c in Jurkat T cells led to severe impairment in actin 
polymerisation in response to stimulation with superantigen-pulsed MEC-1 B cells. 
A marked reduction of F-actin staining (red) at the T cell-B cell contact site was 
observed in miR-181c overexpressing Jurkat T cells in comparison to controls 
(Figure 4.8). To quantitatively determine the effect of miR-181c overexpression on 
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immunological synapse formation, we measured the total area (in square 
micrometre) of F-actin accumulation at the T cell contact sites and synapses with B 
cells. There was a significant reduction in the total area of F-actin accumulation at T 
cell-B cell contact site in miR-181c overexpressing cells as compared to cells in 
mock transfection (P value=0.0002) and cells transfected with empty vector (P 
value=0.0009) (Figure 4.8). This data suggests that in Jurkat T cells, miR-181c is 
essential for immunological synapse formation, a process that is highly dependent on 
proper regulation of actin cytoskeleton dynamics at the T cell-B cell conjugation site. 
4.3.6 Overexpression of miR-181c Had No Impact on Cell Migration in Jurkat 
T Cells 
To study whether ectopic expression of miR-181c in Jurkat T cells has an impact on 
migration, a process dependent upon actin polymerisation, we examined the ability 
of the cells to migrate towards a serum-rich condition. Our results showed that there 
was no difference in migration between cells overexpressed with miR-181c and the 
controls (Figure 4.9), indicating that enforced expression of miR-181c does not affect 




Figure 4.6: Overexpression of miR-181c in Jurkat T cells reduced actin 
polymerisation. F-actin staining of miR-181c overexpressing Jurkat T cells and 
controls, before (red) and after (blue) stimulation. Jurkat T cells were stimulated with 
10µg/ml plate-bound anti-human CD3 antibody and 25ng/ml PMA for 24h. Y-axis 
indicates cell number and x-axis indicates log fluorescence intensity of F-actin 
(rhodamine phalloidin) staining. Results are representative of 3 independent 
experiments. Chart shows the quantification of fold change in MFI before and after 
stimulation. Error bars represent mean ± SD of 3 independent experiments. * P 
≤0.05. 
  
Wild-type Control miR-181c 
Sample %
Jurkat_WT N3.fcs 84.1
Jurkat_WT N3 +.fcs 84.1
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Figure 4.7: Overexpression of miR-181c in Jurkat T cells caused defective 
lamellipodia formation in response to TCR stimulation during cell spreading. 
Microscopy images show the lamellipodia formation in miR-181c transfected Jurkat 
T cells and controls during cell spreading at 1, 3 and 5 min. Cells were fixed, 
permeabilised, blocked and stained with rhodamine phalloidin (red) and DAPI 
(blue), followed by analysis using fluorescence microscopy with a 100× objective. 
Images shown are representative of 3 independent experiments. Chart shows the 
percentage of spreading at 1, 3 and 5 min of spreading. Percentage of spreading was 
calculated by counting at least 100 cells per experimental condition. Cells that form a 
F-actin ring at the cell periphery were scored as positive while cells without an F-
actin ring were scored as negative. Statistical analysis is performed at 5 min time 





















































Figure 4.8: Overexpression of miR-181c in Jurkat T cells impaired 
immunological synapse formation. Confocal images show the immunological 
synapse formation between transfected Jurkat T cells (unstained) and superantigen-
pulsed MEC-1 B cells (blue). Equal number of Jurkat T cells and superantigen-
pulsed MEC-1 B cells were centrifuged, incubated, transferred to microscope slides, 
fixed, permeabilised and blocked. F-actin was stained using rhodamine phalloidin 
(red) and slides were analysed by confocal microscopy using a 60×/1.40 oil objective. 
Chart shows the quantification of the total area of F-actin at the T cell-B cell contact 
site (minimum conjugate measured n=16; maximum n=21) by NIS-elements imaging 
software and error bars represent mean ± SEM. *** P ≤0.001.  
  

































Figure 4.9: Overexpression of miR-181c in Jurkat T cells had no impact on cell 
migration. Percentage of migration in miR-181c overexpressing Jurkat T cells and 
controls. Cells were serum-starved, stained with Calcien AM, allowed to migrate 
towards serum-rich medium for 4h in a Boyden chamber. Number of migrated cells 
was determined by fluorescence intensity of Calcien AM using microplate reader and 
percentage of migration was calculated by the number of migrated cells relative to 
the total number of cells (non-migrated and migrated cells). Error bars represent 































4.4 Effects of Transient BRK1 Knockdown in Jurkat T Cells 
4.4.1 Transient Knockdown of BRK1 in Jurkat T Cells 
Our previous results showed that miR-181c plays a crucial role in T cell activation 
and actin polymerisation-dependent T cell functions including lamellipodia 
generation and immunological synapse formation. We therefore focused our study on 
ascertaining the roles of BRK1, a miR-181c target, in T cell functions. In order to 
evaluate the roles of BRK1 in T cell functions, a pool of four siRNAs targeting BRK1 
(Dharmacon; details see Appendix C2) was used to knockdown BRK1 in Jurkat T 
cells. siRNA negative control and mock transfections were used as experimental 
controls. Both mRNA and protein expression of BRK1 were assessed at 24, 48, 72, 
96 and 120 hours post-transfection. Successful reduction of BRK1 mRNA expression 
was achieved using siRNA in Jurkat T cells. The reduction of BRK1 expression was 
sustained for up to 120 hours post-transfection and the level of knockdown gradually 
reduced over this period, where 94.1% knockdown was achieved at 24 hours, 93.5% 
at 48 hours, 88.9% at 72 hours, 83% at 96 hours and 80.1% at 120 hours post-
transfection (Figure 4.10a). Similarly, the BRK1 protein levels were substantially 
reduced in the siRNA-treated samples from 24 to 120 hours post-transfection (Figure 
4.10b). Given that siBRK1 was able to silence BRK1 in Jurkat T cells up to 120 
hours post-transfection, we next examined the influence of BRK1 knockdown in T 







Figure 4.10: Transient knockdown of BRK1 in Jurkat T cells. (a) Figure shows 
the qPCR analysis of relative BRK1 expression in Jurkat T cells transfected with 
siRNA targeting BRK1 (siBRK1), siRNA negative control (Scr) and mock 
transfected cells (WT). mRNA expression of BRK1 was assessed at indicated time 
points after transfection. The data are calibrated to mock transfection and normalised 
to endogenous control GAPDH. Error bars represent mean ± SD of 3 independent 
experiments. (b) Western blot analysis of BRK1 protein expression in siBRK1-
transfected Jurkat T cells and controls. Total protein lysates were prepared at the 
indicated time points after transfection. β-ACTIN level is used as a loading control 
and numbers represent the densitometric quantification of BRK1 protein expression 
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4.4.2 Transient Knockdown of BRK1 in Jurkat T Cells Had No Impact on Cell 
Cycle Profile 
We next examined the effect of transient BRK1 knockdown in Jurkat T cells on the 
changes of kinetics of cell cycle entry. Similarly to miR-181c overexpression, there 
was no significant difference in the percentage of cells in the three phases of cell 
cycle (G1, S and G2-M) between the siBRK1-treated cells and the controls at the 
three time points measured (24, 48 and 72 hours post-transfection) (Figure 4.11). 
4.4.3 Transient Knockdown of BRK1 Had Mild Impact on Jurkat T Cell 
Activation 
To investigate whether BRK1 knockdown influences T cell activation as in miR-181c 
overexpression, the expression of CD69 in BRK1-suppressed Jurkat T cells was 
examined, before and after co-stimulation with CD3 antibody and PMA. After 
stimulation, the expression of CD69 on the surface of Jurkat T cells in mock, siRNA 
negative control and siBRK1 transfections, were all increased when compared to 
those before stimulation. However, similarly to ectopic expression of miR-181c, the 
upregulation of CD69 expression was slightly lower in the BRK1-knockdown cells 
(79.7% CD69+ cells) than in mock transfected (83.4% CD69+ cells) and siRNA 
negative control transfected cells (84.9% CD69+ cells) (Figure 4.12). This data 
indicates that in Jurkat T cells, consistent with miR-181c overexpression, transient 




Figure 4.11: Transient BRK1 knockdown had no impact on cell cycle profile in 
Jurkat T cells. Cell cycle profile of Jurkat T cells following siRNA-mediated 
knockdown of BRK1. Samples were fixed with 70% ethanol, stained with PI and 
analysed at 24, 48 and 72 hours post-transfection. Y-axis indicates cell number and 
x-axis indicates PI staining. Plots shown are representative of 3 independent 
experiments.  











Figure 4.12: Transient BRK1 knockdown had mild impact on Jurkat T cell 
activation. CD69 expression in siRNA-mediated BRK1 knockdown Jurkat T cells, 
before (red) and after (blue) stimulation. Jurkat T cells was stimulated at 48h post-
transfection with 10µg/ml plate-bound anti-human CD3 antibody and 25ng/ml PMA 
for 24h. Y-axis indicates cell number and x-axis indicates log fluorescence intensity 
of CD69-PE staining. Plots are representative of 3 independent experiments.  





















































4.4.4 Transient Knockdown of BRK1 Caused Defective Lamellipodia 
Formation in Jurkat T Cells 
Due to our finding of impaired lamellipodia formation following miR-181c 
overexpression in Jurkat T cells and previous reports from other groups which 
showed that WAVE2 protein is implicated in regulating the generation of 
lamellipodia in T cells (Nolz et al., 2006), we next analysed the effect of BRK1 
suppression on the ability of Jurkat T cells to spread onto anti-CD3 coated slides by 
performing a spreading assay. Consistent with miR-181c overexpression, BRK1-
knockdown cells failed to spread properly while in controls, cells were able to spread 
in a highly ordered fashion, forming a round lamellipodial interface containing 
radially-arrayed F-actin-rich structures at the cell periphery (Figure 4.13). At 1 
minute of spreading, the percentage of spreading for all experimental conditions 
were all very low while at 3 and 5 minute, a reduced percentage of spreading was 
observed in cells transfected with siBRK1 as compared to controls (Figure 4.13). 
This data suggests that in Jurkat T cells, similar to ectopic expression of miR-181c, 
transient BRK1 knockdown also results in defective lamellipodia generation in 





Figure 4.13: Transient BRK1 knockdown in Jurkat T cells resulted in defects in 
lamellipodia formation in response to TCR stimulation during cell spreading. 
Microscopy images show the lamellipodia formation in Jurkat T cells following 
siRNA-mediated BRK1 knockdown at 1, 3 and 5 min of cell spreading. Cells were 
fixed, permeabilised, blocked and stained with rhodamine phalloidin (red) and DAPI 
(blue), followed by analysis using fluorescence microscopy with a 100× objective. 
Images shown are representative of 3 independent experiments. Chart shows the 
percentage of spreading at 1, 3 and 5 min. Percentage of spreading was calculated by 
counting at least 100 cells per experimental condition. Cells that form a F-actin ring 
at the cell periphery were scored as positive while cells without an F-actin ring were 
scored as negative. Statistical analysis is performed at 5 min time point. Error bars 













































4.5 Effects of Stable BRK1 Knockdown in T Cells 
4.5.1 Stable Knockdown of BRK1 in T Cells 
Several limitations of using siRNA targeting BRK1 to achieve gene silencing have 
been faced in performing functional assays in T cells. Therefore, we employed 
lentiviral shRNA targeting BRK1 in the subsequent studies. The main reason of 
switching from siRNA to shRNA was the much higher number of cells required for 
various T cell functional assays, making the use of siRNA very costly. Furthermore, 
we found that there was poor consistency between experimental replicates using 
siRNA. In addition, we observed a high level of cell death after siRNA 
electroporation.  
Two lentiviral vectors targeting BRK1, pLKO.1-shBRK1_1 and pLKO.1-shBRK1_2 
were used to knockdown BRK1 in Jurkat and primary T cells. Scrambled shRNA 
(pLKO.1-scrambled shRNA, Addgene, plasmid #1864) and mock transduction were 
used as experimental controls. The lentiviral vectors were first titrated using colony 
formation assay in HeLa cells in order to calculate the amount of virus to be used in 
Jurkat and primary T cells transduction (Figure 4.14). Colony forming units/ml 
(CFU/ml) was calculated from number of colony as follows. 
Colony forming units/ml (CFU/ml) = Number of colony / Final concentration of  
          lentivirus added 
 
For scrambled shRNA, 
CFU/ml (for 10-6 final concentration) = 12.3/10-6 = 1.23×107 
CFU/ml (for 10-7 final concentration) = 2/10-7 = 2×107 
Average of CFU/ml from 2 concentrations = 1.615×107 
 
For shBRK1_1, 
CFU/ml (for 10-7 final concentration) = 9.7/10-7 = 9.7×107 
 
For shBRK1_2, 
CFU/ml (for 10-7 final concentration) = 16/10-7 = 1.6×108 
 
 151 
Jurkat T cells were transduced with lentivirus with an MOI of 24 to achieve a 
constitutive knockdown of BRK1. The BRK1 mRNA expression was drastically 
reduced in cells transduced with the two shBRK1 lentiviral vectors as compared to 
the controls. However, shBRK1_1 showed higher knockdown as compared to 
shBRK1_2, where BRK1 mRNA expression was reduced to less than 4% for the 
shBRK1_1 and 22% for the shBRK1_2 (Figure 4.15a). Similarly to BRK1 mRNA 
expression, BRK1 protein level was markedly reduced in both of the shBRK1-treated 
samples when compared to the controls (Figure 4.15b).  
To transduce primary T cells, lentivirus with an MOI of 50 was used to achieve 
constitutive BRK1 knockdown. Following transduction, mRNA and protein level of 
BRK1 were examined before and after stimulation with CD3 and CD28 antibodies. 
Comparable to Jurkat T cells, the BRK1 mRNA expression was decreased in both of 
the shBRK1-treated cells, before and after stimulation, as compared to the controls. 
The shBRK1_1 showed higher knockdown as compared to shBRK1_2. Before 
stimulation, BRK1 expression was reduced to less than 9% for the shBRK1_1 and 
33% for the shBRK1_2 while after stimulation, the percentage of BRK1 knockdown 
with shBRK1_1 was 92.26% and with shBRK1_2 was 60.84% (Figure 4.16a). 
Consistent with BRK1 mRNA expression, protein expression level of BRK1 was also 
substantially decreased in both shBRK1-treated samples before and after stimulation 
(Figure 4.16b). 
Given that we achieved good constitutive knockdown of BRK1 in both Jurkat and 





Figure 4.14: Lentivirus titration by colony formation assay. Figure shows the 
number of colony formed in HeLa cells transduced with the three lentiviral vectors 
(scrambled shRNA, shBRK1_1 and shBRK1_2). Cells were treated with puromycin 
to select for colonies with stable integration of lentiviral vectors. For scrambled 
shRNA, number of colony was counted from wells with 10-6 and 10-7 final 
concentrations while for shBRK1_1 and shBRK1_2, number of colony was counted 
from wells with 10-7 final concentration. Number of colony was scored from 
triplicate wells for each condition. Well 1, 2 and 3: 0.1µl of lentivirus added (final 
concentration 10-4); well 4, 5 and 6: 0.01µl of lentivirus added (final concentration 
10-5); well 7, 8 and 9: 0.001µl of lentivirus added (final concentration 10-6); well 10, 
11 and 12: 0.0001µl of lentivirus added (final concentration 10-7). Control: no 
lentivirus added. 
 
(a)                                                                 (b) 
 
Figure 4.15: Stable knockdown of BRK1 in Jurkat T cells. (a) Figure shows the 
qPCR analysis of relative BRK1 expression in Jurkat T cells following transduction 
with two independent shRNA targeting BRK1 (shBRK1_1 and shBRK1_2). The data 
are calibrated to mock transduction and normalised to endogenous control GAPDH. 
Numbers above the bar are indicative of the percentage of BRK1 knockdown. Error 
bars represent mean ± SD of 5 independent experiments. (b) Western blot analysis of 
BRK1 protein expression in Jurkat T cells transduced with shBRK1. β-ACTIN level 
is used as a loading control and numbers represent the densitometric quantification of 
BRK1 protein expression level normalised to β-ACTIN. Blot shown is representative 
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Figure 4.16: Stable knockdown of BRK1 in primary T cells. (a) Figures show the 
qPCR analysis of relative BRK1 expression in primary T cells transduced with 
shRNA targeting BRK1 (shBRK1_1 and shBRK1_2) before and after stimulation. 
Primary T cells were stimulated with 2µg/ml of plate bound anti-human CD3 and 
soluble anti-human CD28 for 24h. The data are calibrated to mock transduction and 
normalised to endogenous control GAPDH. Numbers above the bar are indicative of 
the percentage of BRK1 knockdown. Error bars represent mean ± SD of 4 
independent experiments. (b) Western blot analysis of BRK1 protein expression in 
shBRK1-transduced primary T cells before and after stimulation. β-ACTIN level is 
used as a loading control and numbers represent the densitometric quantification of 
BRK1 protein expression level normalised to β-ACTIN. Blot shown is representative 
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4.5.2 Stable Knockdown of BRK1 Led to Reduced Expressions of Other 
Proteins in the WAVE2 Complex 
Before studying the impact of BRK1 knockdown in T cells, we explored the role of 
BRK1 in the stability and integrity of WAVE2 protein in both Jurkat and primary T 
cells. Following BRK1 silencing in Jurkat and primary T cells, the stability of 
WAVE2 protein was investigated by examining the protein expressions of other 
members in the WAVE2 complex, including WAVE2, ABI1, SRA1 and HEM1. In 
addition, protein expression of ARP2 and ARP3, which have been shown to bind to 
the activated WAVE2 protein to carry out actin nucleation (Goley and Welch, 2006; 
Takenawa and Suetsugu, 2007), were also studied. Upon knockdown of BRK1 in 
both Jurkat and primary T cells, the protein expressions of WAVE2, ABI1 and SRA1 
were reduced as compared to controls while HEM1, ARP2 and ARP3 protein 
expression levels remained unchanged (Figure 4.17). This data suggests that BRK1 





Figure 4.17: Stable BRK1 knockdown in T cells reduced protein expressions of 
other members in the WAVE2 complex. Western blot analysis of BRK1, WAVE2, 
ABI1, SRA1, HEM1, ARP2 and ARP3 protein expressions in both Jurkat and 
primary T cells following shRNA-mediated BRK1 knockdown. β-ACTIN level is 
used as a loading control and numbers represent the densitometric quantification of 



















































Jurkat T Cell Primary T Cell 
   1    1.01   0.09   0.37  
   1    0.68   0.12   0.27  
   1    1.15   0.56   0.89  
   1    1.02   0.42   0.96  
   1    0.74   1.16   1.36  
   1    0.87   0.83   1.02  
   1    0.70   0.98     1  
    1   1.29    0.05   0.62  
    1   1.21   0.18    0.79  
    1   1.46   0.77    0.78  
    1    0.93   0.22   0.78  
    1    0.90   1.02   1.21  
    1     1.11   0.94  0.96  
    1    1.16   0.83   0.89  
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4.5.3 Stable Knockdown of BRK1 in T Cells Had Mild Impact on Cell 
Proliferation But Had No Impact on Cell Cycle and Cell Viability  
Trypan blue exclusion result showed that BRK1 knockdown had only a relatively 
mild impact on the proliferation with a slight reduction in total cell number at day 6 
as compared to controls, although the difference was not statistically significance 
(Figure 4.18). 
Moreover, we also examined the effect of BRK1 suppression in T cells on the 
changes of kinetics of cell cycle entry. In Jurkat T cells, cell cycle profiles showed 
that there was no change in the percentage of cells in the three phases of cell cycle 
(G1, S and G2-M) between shBRK1-treated cells and cells in the controls (Figure 
4.19a). The cell cycle of primary T cells was analysed before and after co-
stimulation with CD3 and CD28 antibodies. After stimulation, there was no change 
in the cell cycle profiles in cells with reduced expression of BRK1, as in Jurkat T 
cells. Before stimulation, there were not many cells detected in S and G2-M phases, 
indicating that the cells do not enter the cell cycle unless they are stimulated (Figure 
4.19b).  
In addition, the effect of BRK1 knockdown on cell viability was also examined in 
both Jurkat and primary T cells. In Jurkat T cells, there was no difference in the 
percentage of live (85-90% of Annexin V- PI- cells), early apoptotic (6-11% of 
Annexin V+ PI- cells) and late apoptotic cells (~3% of Annexin V+ PI+ cells) between 
BRK1-knockdown cells and controls (Figure 4.20a). Similarly to Jurkat T cells, there 
was no variation observed in the percentages of live, early apoptotic and late 
apoptotic cells between BRK1-knockdown primary T cells and controls, both before 
and after stimulation with CD3 and CD28 antibodies (Figure 4.20b). 
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Consistent with the results observed with the overexpression of miR-181c in Jurkat T 
cells, constitutive knockdown of BRK1 in both Jurkat and primary T cells did not 




Figure 4.18: Stable knockdown of BRK1 had mild impact on Jurkat T cell 
proliferation. Plot shows the cell proliferation of BRK1-knockdown Jurkat T cells 
(green and orange), mock transduced (WT, red) and scrambled shRNA transduced 
cells (Scr, blue). Cells were seeded and cultured in a 24-well plate and counted every 
day for 6 days. Error bars represent mean ± SEM of 3 independent experiments.  
  



























Figure 4.19: Stable BRK1 knockdown in Jurkat and primary T cells had no 
impact on cell cycle profile. Cell cycle profile of (a) Jurkat and (b) primary T cells 
following shRNA-mediated BRK1 knockdown. Samples were fixed with 70% 
ethanol, stained with PI and analysed by flow cytometry. For primary T cells, cell 
cycle profile was analysed before and after stimulation. Primary T cells were 
stimulated with 2µg/ml of plate bound anti-human CD3 and soluble anti-human 
CD28 antibodies for 24h. Y-axis indicates cell number and x-axis indicates PI 
staining. Plots are representative of 3 independent experiments.  
  
































Figure 4.20: Stable BRK1 knockdown in Jurkat and primary T cells had no 
impact on cell viability. APC Annexin V and PI staining of (a) Jurkat and (b) 
primary T cells following shRNA-mediated BRK1 knockdown. The percentage of 
live (Q4 = double negative for Annexin V and PI), early apoptotic (Q3 = positive 
Annexin V and negative PI) and late apoptotic (Q2 = double positive for Annexin V 
and PI) cells were analysed by flow cytometry. In primary T cells, Annexin V and PI 
staining were analysed before and after stimulation. Primary T cells were stimulated 
with 2µg/ml of plate bound anti-human CD3 and soluble anti-human CD28 for 24h. 
Y-axis indicates log fluorescence intensity of PI staining and x-axis indicates log 
fluorescence intensity of APC Annexin V staining.  
  



















4.5.4 Stable Knockdown of BRK1 Repressed T Cell Activation 
We next investigated the effects of BRK1 suppression on T cell activation. The 
surface expression of T cell activation markers, CD69 and CD154 were analysed by 
flow cytometry analysis. The levels of CD69 and CD154 were examined before and 
after stimulation with CD3 antibody and PMA for Jurkat T cells, and CD3 and CD28 
antibodies for primary T cells. Upon stimulation, the expression of CD69 on the 
surface of Jurkat T cells in mock, scrambled shRNA and shBRK1 transductions were 
all increased. However, the increase in CD69 expression was markedly reduced in 
the BRK1-knockdown cells (46.8% CD69+ cells for shBRK1_1 and 35.2% for 
shBRK1_2) as compared to mock transduced (86.3% CD69+ cells) and scrambled 
shRNA transduced cells (78.9% CD69+ cells) (Figure 4.21a). Consistent with the 
results observed in Jurkat T cells, the expression level of CD69 in primary T cells in 
all experimental conditions were elevated after stimulation as compared to before 
stimulation, but the increase of CD69 expression was lower in the BRK1-knockdown 
cells in comparison to controls (Figure 4.21b). To confirm the finding that BRK1 
knockdown causes reduction in primary T cell activation as shown by CD69 
expression, the expression of another T cell activation marker, CD154 was also 
examined in primary T cells. Similar results were observed and the increase in 
CD154 expression upon stimulation was lower in BRK1-suppressed cells (61.4% 
CD154+ cells for shBRK1_1 and 49.8% for shBRK1_2) as compared to mock 
transduced (85.3% of CD154+ cells) and scrambled shRNA transduced cells (80.9% 
of CD154+ cells) (Figure 4.21c). These data and the miR-181c overexpression studies 













Figure 4.21: Stable BRK1 knockdown in Jurkat and primary T cells repressed T 
cell activation. (a) CD69 expression in Jurkat T cells transduced with shRNA 
against BRK1 before (red) and after (blue) stimulation. Jurkat T cells were stimulated 
with 10µg/ml plate-bound anti-human CD3 antibody and 25ng/ml PMA for 24h. Y-
axis indicates cell number and x-axis indicates log fluorescence intensity of CD69-
PE staining. (b) CD69 expression in primary T cells following shBRK1 transduction 
before (red) and after (blue) stimulation. Primary T cells were stimulated with 
2µg/ml plate-bound anti-human CD3 and soluble anti-human CD28 antibodies for 
24h. Y-axis indicates cell number and x-axis indicates log fluorescence intensity of 
Pacific Blue CD69 staining. (c) CD154 expression in primary T cells following 
shRNA-mediated BRK1 knockdown, before (red) and after (blue) stimulation. Y-axis 
indicates cell number and x-axis indicates log fluorescence intensity of CD154-PE 
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4.5.5 Stable Knockdown of BRK1 Decreased Actin Polymerisation During 
Lamellipodia and Immunological Synapse Formation in T Cells 
Owing to the importance of reorganisation of the actin cytoskeleton in T cell 
activation (Holsinger et al., 1998) and our findings on the pivotal role of the miR-
181c-BRK1 axis in T cell activation, we next assessed whether BRK1 silencing in T 
cells has a similar effect as miR-181c overexpression on the regulation of actin 
polymerisation. As in miR-181c overexpression, total cellular F-actin content was 
first quantified in both BRK1-knockdown Jurkat and primary T cells, before and after 
stimulation. In both Jurkat (Figure 4.22a) and primary T cells (Figure 4.22b), the 
total F-actin content remained unaltered in BRK1-knockdown cells (shBRK1_1 and 
shBRK1_2) while in controls, the total cellular F-actin content increased after 
stimulation as compared to those before stimulation, as quantified by MFI. This data 
is consistent with those obtained with miR-181c overexpression, implying that miR-
181c-BRK1 axis is required for maximal actin polymerisation in T cells. 
The influence of miR-181c and its target BRK1 on the total cellular F-actin content 
upon stimulation have led us to determine whether constitutive knockdown of BRK1 
in T cells also has an effect on lamellipodia formation as in miR-181c 
overexpression. Generation of lamellipodia occurs during cell spreading upon TCR 
stimulation and it requires actin reorganisation. Therefore, as in miR-181c 
overexpression and transient BRK1 knockdown, spreading assay was performed to 
examine the ability of the cells to spread onto anti-CD3 coated slides following 
constitutive BRK1 knockdown. Our results were consistent with the findings in miR-
181c overexpression and transient BRK1 knockdown where we found that 
downregulation of BRK1 in both Jurkat (Figure 4.23a) and primary T cells (Figure 
4.23b) resulted in a defect in lamellipodia formation. Similar to miR-181c 
overexpression and transient knockdown of BRK1, no difference was seen at 1 
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minute of spreading between BRK1-knockdown T cells and controls while 
significant differences were observed at 3 and 5 minutes of spreading where 
depletion of BRK1 had significant impact on the cell ability to spread in response to 
anti-CD3 stimulation (Figure 4.23). This data suggests that the miR-181c-BRK1 axis 
is required for the generation of lamellipodia in response to TCR stimulation, a 
phenomenon requiring proper regulated actin polymerisation. 
Subsequently, we also examined whether BRK1 is required for actin polymerisation 
at the T cell-B cell contact site by performing immunological synapse assay 
following constitutive BRK1 knockdown in both Jurkat and primary T cells. 
Consistent with findings in the miR-181c overexpression studies, our results 
demonstrated that in both Jurkat (Figure 4.24a) and primary T cells (Figure 4.24b), 
knockdown of BRK1 resulted in a severe impairment in actin polymerisation in 
response to stimulation with superantigen-pulsed MEC-1 B cells as shown by 
significantly reduced F-actin staining (red) and total area of F-actin accumulation at 
the T cell-B cell contact site. Hence, consistent with miR-181c overexpression, this 
data indicates that reduced expression of BRK1 in T cells induced a defect in F-actin 
accumulation at the immunological synapse, suggesting that the miR-181c-BRK1 
axis is important in immunological synapse formation, a process that is highly 







Figure 4.22: Stable BRK1 knockdown in Jurkat and primary T cells reduced 
actin polymerisation. F-actin staining of (a) Jurkat and (b) primary T cells 
following BRK1 suppression before (red) and after (blue) stimulation. Jurkat T cells 
were stimulated with 10µg/ml plate-bound anti-human CD3 antibody and 25ng/ml 
PMA for 24h while primary T cells with 2µg/ml plate-bound anti-human CD3 and 
soluble anti-human CD28 antibodies for 24h. Y-axis indicates cell number and x-axis 
indicates log fluorescence intensity of F-actin (rhodamine phalloidin) staining. Plots 
are representative of 3 independent experiments. Charts show the quantification of 
fold change in MFI before and after stimulation. Error bars represent mean ± SD of 3 


































































































































































































































































Figure 4.23: Stable BRK1 knockdown in Jurkat and primary T cells led to 
defective lamellipodia formation in response to TCR stimulation during cell 
spreading. Microscopy images show the lamellipodia formation in (a) Jurkat and (b) 
primary T cells following BRK1 suppression at 1, 3 and 5 min of cell spreading. 
Cells were fixed, permeabilised, blocked and stained with rhodamine phalloidin (red) 
and DAPI (blue), followed by analysis using fluorescence microscopy with a 100× 
objective. Images shown are representative of 3 independent experiments. Charts 
show the percentage of spreading at 1, 3 and 5 min of spreading. Statistical analysis 
is performed at 5 min time point. Error bars represent mean ± SEM of 3 independent 





























































Figure 4.24: Stable BRK1 knockdown in Jurkat and primary T cells impaired 
immunological synapse formation. Confocal images show the immunological 
synapse formation between BRK1-knockdown (a) Jurkat or (b) primary T cells 
(unstained) and superantigen-pulsed MEC-1 B cells (blue). Equal number of T cells 
and superantigen-pulsed MEC-1 B cells were centrifuged, incubated, transferred to 
microscope slides, fixed, permeabilised and blocked. F-actin was stained using 
rhodamine phalloidin (red) and slides were analysed by confocal microscopy using a 
60×/1.40 oil objective. Charts show the quantification of the total area of F-actin 
accumulation at the T cell-B cell contact site (minimum conjugate measured n=16; 
maximum n=21 for Jurkat T cells and minimum n=14; maximum n=30 for primary T 
cells) by NIS-elements imaging software and error bars represent mean ± SEM. * P 















































































4.5.6 Stable Knockdown of BRK1 Had No Impact on Cell Migration in Jurkat 
T Cells 
To study the impact of BRK1 knockdown on migration of Jurkat T cells, a cellular 
process depending on actin cytoskeleton, the ability of the cells to migrate towards a 
serum-rich condition was examined. As in the miR-181c overexpression studies, 
constitutive BRK1 knockdown in Jurkat T cells did not influence cell migration 
because there was no difference in the percentage of migration between BRK1-




Figure 4.25: Stable knockdown of BRK1 had no impact on Jurkat T cell 
migration. Chart shows the percentage of migration in Jurkat T cells following 
BRK1 knockdown. Cells were serum-starved, stained with Calcien AM, allowed to 
migrate towards serum-rich medium for 4h. Number of migrated cells was 
determined by fluorescence intensity using microplate reader and percentage of 
migration was calculated by the number of migrated cells relative to the total number 
of cells (non-migrated and migrated cells). Error bars represent mean ± SEM of 2 




































Regulation of actin reorganisation is critical in T cell activation and multiple 
previous studies have suggested that actin-regulatory proteins are involved in this 
process. These include TCR-proximal signalling molecules such as PLCγ1, NCK1, 
ITK and VAV1 (Fuller et al., 2003); activator of ARP2/3 complex such as WASP 
(Cannon and Burkhardt, 2004; Sims et al., 2007; Snapper et al., 1998; Zhang et al., 
1999), WAVE2 (Nolz et al., 2006; Nolz et al., 2007; Nolz et al., 2008; Zipfel et al., 
2007), WASH (Gomez et al., 2012) and HS1(Gomez et al., 2006; Taniuchi et al., 
1995); actin severing proteins such as cofilin (Eibert et al., 2004) and coronin-1 
(Föger et al., 2006) as well as dynamin-2 (Gomez et al., 2005) and EZH2 (Su et al., 
2005). 
WAVE protein is a member of the WASP family that plays an important role in 
regulating actin cytoskeletal dynamics (Campellone and Welch, 2010; Padrick and 
Rosen, 2010; Pollitt and Insall, 2009b). It is well known that at the N-terminal of 
WAVE protein, it forms a WAVE regulatory complex consists of WAVE1/2/3, 
ABI1/2/3, SRA1, HEM1/2 and BRK1 (Chen et al., 2010; Gautreau et al., 2004). The 
integrity and stability of WAVE regulatory complex is dependent upon each of the 
members in the complex. Elimination of any of the members in the WAVE 
regulatory complex causes subsequent degradation of the complex in Dictyostelium 
(Blagg et al., 2003; Ibarra et al., 2006; Linkner et al., 2011; Pollitt and Insall, 2008; 
Pollitt and Insall, 2009a), Drosophila (Bogdan et al., 2004; Kunda et al., 2003; 
Qurashi et al., 2007; Rogers et al., 2003; Schenck et al., 2004), mammalian cell lines 
(Cai et al., 2009; Derivery et al., 2008; Escobar et al., 2010; Grove et al., 2004; Nolz 
et al., 2006; Steffen et al., 2004; Weiner et al., 2006) and mouse models (Dubielecka 
et al., 2011; Park et al., 2008; Rakeman and Anderson, 2006). In the present study, to 
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evaluate the importance of BRK1 in the stability and integrity of the WAVE2 
complex in T cells, we suppressed its expression in both Jurkat and primary T cells. 
Our data showed that silencing of BRK1 led to reduced protein expressions of 
WAVE2, SRA1 and ABI1, suggesting that BRK1 is required for the stability of other 
proteins in the WAVE2 complex in T cells. This finding is consistent with several 
previous studies which also showed that loss of BRK1 led to degradation of other 
proteins in the WAVE complex in Dictyostelium (Pollitt and Insall, 2009a), 
Drosophila (Kunda et al., 2003; Qurashi et al., 2007) and mammalian cell lines (Cai 
et al., 2009; Derivery et al., 2008; Escobar et al., 2010). In HeLa cells, Derivery and 
colleagues showed that siRNA knockdown of BRK1 caused reduction in the protein 
expressions of WAVE2, SRA1, NAP1 and ABI1 (Derivery et al., 2008) while in 
lung cancer PG cell line, Cai et al. reported that loss of BRK1 resulted in decreased 
expression of WAVE2 protein (Cai et al., 2009). Suppression of BRK1 in 
osteosarcoma U2OS cell line also contributed to decreased protein expressions of 
ABI1, WAVE1 and WAVE2 (Escobar et al., 2010). In Jurkat T cells, elimination of 
WAVE2 led to subsequent degradation of other members in the WAVE2 complex 
including HEM1, SRA1 and ABI2. Similarly, HEM1 suppression in Jurkat T cells 
also induced reduction in WAVE2, SRA1 and ABI2 protein expressions (Nolz et al., 
2006). In addition, thymocytes and T lymphocytes from Hem1-knockout mice also 
showed reduced protein expressions of WAVE2, ABI1, ABI2 and SRA1 (Park et al., 
2008). However, data published by Zipfel et al. contradicts our and multiple previous 
findings. In the Zipfel et al. study, knockdown of ABI1, ABI2, or both ABI1 and ABI2 
in Jurkat T cells had no impact on the stability of NAP1/HEM1/HEM2, SRA1, 
WAVE1 and WAVE2 proteins. The protein expression levels of 
NAP1/HEM1/HEM2, SRA1, WAVE1 and WAVE2 in primary thymocytes derived 
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from Abi1+/−Abi2−/− mice were also unchanged. Besides that, knockdown of WAVE 
proteins in Jurkat T cells also did not affect the ABI1 and ABI2 protein expressions 
(Zipfel et al., 2007). Interestingly, in our study, HEM1 protein level was not affected 
by BRK1 knockdown in both Jurkat and primary T cells. This might be due to the 
fact that BRK1 does not interact directly with HEM1. Previous studies have shown 
that BRK1 is a precursor in the assembly of WAVE-ABI-BRK1 heterotrimeric 
complex and in the subsequent binding of the heterotrimer to the SRA1-HEM1 dimer 
in order to form a functional WAVE regulatory complex. The binding of WAVE-
ABI-BRK1 heterotrimer to SRA1-HEM1 dimer is mainly via interaction between 
BRK1 and SRA1 (Chen et al., 2010; Derivery et al., 2008; Linkner et al., 2011). 
Thus, during the assembly of a WAVE regulatory complex, BRK1 interacts directly 
with WAVE, ABI and SRA1 proteins but not HEM1 protein. Furthermore, we also 
found that the ARP2 and ARP3 protein levels were not altered following suppression 
of BRK1, a expected result because ARP2/3 complex only interacts with activated 
WAVE2 protein at its C-terminal end (Goley and Welch, 2006; Takenawa and 
Suetsugu, 2007). Taken together, our results strongly suggest that BRK1 is an 
important component in regulating the stability of the WAVE2 regulatory complex. 
In this study, BRK1, a component of the WAVE protein, was identified as novel 
target of miR-181c. Although much is known about the importance of WAVE2 
complex in T cell activation, the role of BRK1 in the regulation of actin 
reorganisation in T cells is unknown. WAVE2 has been shown to be required for 
lamellipodia formation, immunological synapse formation, integrin activation, 
CRAC-mediated calcium entry and IL-2 production in T cells (Nolz et al., 2006; 
Nolz et al., 2007; Nolz et al., 2008; Zipfel et al., 2007). The miR-181 family has 
previously been reported to play pivotal roles in T cell functions including T cell 
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development, differentiation, proliferation and activation (Georgantas et al., 2007; 
Henao-Mejia et al., 2013; Li et al., 2007; Xue et al., 2011). Therefore, given the 
important role of the miR-181 family in T cell functions and the potential role of 
BRK1 in the regulation of actin polymerisation in T cells via its interaction with the 
WAVE2 complex, we investigated the influence of the miR-181c-BRK1 axis in T 
cell functions in this study. We found that upon stimulation of CD3+ T cells, the 
expression of miR-181c was significantly reduced but the protein expression of 
BRK1 was markedly elevated. This finding further strengthens our hypothesis that 
the miR-181c-BRK1 axis might be important in T cell activation. Our data is in 
agreement with another previous study which showed that Jurkat and PBMC derived 
CD4+ T cell activation resulted in the downregulation of miR-181c expression (Xue 
et al., 2011).  
In order to assess the impact of the miR-181c-BRK1 axis on T cell activation, we 
downregulated BRK1 and overexpressed miR-181c in Jurkat and primary T cells. 
Although suppression of BRK1 and overexpression of miR-181c had no impact on 
cell proliferation, cell cycle profile and cell viability in T cells, we have 
demonstrated that the miR-181c-BRK1 axis plays pivotal roles in regulating the actin 
polymerisation-dependent processes in T cells. We showed that BRK1 suppression 
repressed T cell activation with reduced expressions of CD69 and CD154 in BRK1-
knockdown cells. Subsequently, to investigate whether BRK1 negatively regulates T 
cell activation through modulation of actin polymerisation in T cells, we examined 
the total cellular F-actin content. Indeed, reduced total cellular F-actin content was 
seen in cells with BRK1 depletion following stimulation. We therefore studied 
whether BRK1 regulates processes in T cells that are dependent on actin 
cytoskeleton, including lamellipodia generation, immunological synapse formation 
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and cell migration. In fact, silencing of BRK1 contributed to defects in the generation 
of stable lamellipodia as the BRK1-suppressed cells failed to accumulate F-actin at 
the leading edge of spreading T cell. Moreover, BRK1-knockdown cells also failed to 
accumulate F-actin at the T cell-B cell conjugation site, indicating that reduced 
expression of BRK1 in T cells results in impairment in immunological synapse 
formation. Nonetheless, suppression of BRK1 in Jurkat T cells did not influence cell 
migration. This finding is in contrast to published data which showed that in solid 
tumour cell lines, suppression of BRK1 in NSCLC cell line (Cai et al., 2009) as well 
as renal cell carcinoma and osteosarcoma cell lines (Escobar et al., 2010) resulted in 
defective cell migration. This discrepancy might be attributed to the different cell 
types where BRK1 might not play a role in cell migration in haematopoietic cells. 
Together, our data demonstrated that suppression of BRK1 is important in T cell 
activation and specifically disrupts the processes in T cells that are dependent on 
actin reorganisation, including lamellipodia generation and immunological synapse 
formation. 
To date, there are no published studies on the role of BRK1 in actin polymerisation-
mediated T cell activities and our data demonstrated these important roles of BRK1 
in T cells. Nevertheless, BRK1 is known to participate in the WAVE2 complex 
which has been shown to be important in T cell activation by regulating the actin 
cytoskeletal remodelling in T cells. The first published study on the roles of WAVE2 
in regulating multiple pathways leading to T cell activation was by Nolz and 
colleagues. Their data revealed that WAVE2 protein is a critical component in the 
actin regulatory machinery in T cells (Nolz et al., 2006). They showed that WAVE2 
suppression led to reduction in the conjugation formation and the F-actin 
accumulation at the T cell-B cell site. This is consistent with our finding where we 
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showed that BRK1 suppression also impaired immunological synapse formation. 
Furthermore, in their study, they demonstrated that WAVE2 was required for the 
generation of stable lamellipodia in response to anti-TCR ligation and this is in line 
with our results showing that silencing of BRK1 induced defects in lamellipodia 
formation in spreading T cells in response to TCR stimulation (Nolz et al., 2006). A 
year later, another study reported a novel mechanism of ABI/WAVE complex in the 
regulation of TCR-mediated T cell activation (Zipfel et al., 2007). They showed that 
ABI proteins localise to the sites of dynamic actin polymerisation, which include the 
leading edge of spreading T cells (lamellipodia) and the T cell-B cell conjugation site 
(immunological synapse). In addition, WAVE proteins (WAVE1 and WAVE2) also 
co-localised with ABI proteins and F-actin at the T cell-B cell conjugation site. 
Furthermore, they also showed that primary T cells derived from Abi1/Abi2-deficient 
mice exhibited a reduction in actin polymerisation after T cell activation (Zipfel et 
al., 2007) and this is in agreement with our finding in BRK1-suppressed Jurkat and 
primary T cells where decreased total cellular F-actin content was observed 
following T cell stimulation. Besides that, the other two members of the WAVE2 
complex, ABI2 and HEM1, have also been found to be essential for conjugate 
formation. Previous study showed that ABI2 and HEM1 are recruited to the 
immunological synapse site together with WAVE2 and F-actin (Nolz et al., 2006). 
Moreover, Hem1 deficiency in mice has been shown to result in impaired T cell 
activation, adhesion and development as well as defective F-actin polymerisation and 
actin cap formation in lymphocytes (Park et al., 2008). Our findings on the roles of 
BRK1 in T cells together with multiple previous studies on the other members of the 
WAVE complex have demonstrated that BRK1 and WAVE2 complex are important 
in the regulation of actin polymerisation-mediated T cell functions.  
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We also revealed the indispensable role of miR-181c in actin polymerisation-
mediated T cell functions. The impact of ectopic expression of miR-181c in Jurkat T 
cells on disruption of the T cell functions that are dependent on actin reorganisation 
phenocopy the impact seen in BRK1 suppression studies. Similar to downregulation 
of BRK1, overexpression of miR-181c in Jurkat T cells also contributed to reduction 
in T cell activation and actin polymerisation coupled with defects in lamellipodia 
generation and immunological synapse formation, hence confirming the important 
roles of the miR-181c-BRK1 axis in T cell activation. Our finding on repressed T cell 
activation as a result of miR-181c overexpression is consistent with data published by 
Xue et al. who reported that miR-181c mimics were able to reduce CD25, CD69 and 
CD154 expressions in Jurkat and CD4+ T cells, indicating the reduction in T cell 
activation (Xue et al., 2011). Although the role of miR-181c in the regulation of actin 
reorganisation in T cells is poorly studied, there are a few previous studies which 
showed that the miR-181 family is involved in T lymphocyte development, 
differentiation, proliferation and activation. miR-181a acts as an intrinsic modulator 
in TCR signalling pathways through the downregulation of different phosphatases 
such as PTPN22, SHP-2, DUSP5 and DUSP6 that dampen LCK and ERK signalling, 
in turn enhancing the T cell activation (Li et al., 2007). Moreover, miR-181a is 
highly expressed at the CD4+CD8+ stage of thymocyte maturation in comparison 
with previous CD4-CD8- stages or mature CD4+ or CD8+ T cells (Neilson et al., 
2007). Furthermore, Georgantas et al. also predicted, using computational 
algorithms, that miR-181a regulates molecules such as PU.1, MEF, SPI-B and MYB 
as well as regulating CXCR4 as shown by a reporter assay. These molecules are 
critical to very early steps in haematopoiesis and thus miR-181a might inhibit T 
lymphocytes differentiation through modulation of these molecules (Georgantas et 
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al., 2007). In addition, reduced proliferative capacity and total number of T cells 
were seen in miR-181a/b-deficient mice suggesting that miR-181a and miR-181b 
might be important in T cell proliferation and development (Henao-Mejia et al., 
2013). Besides that, Xue et al. showed that overexpression of miR-181c in Jurkat and 
CD4+ T cells reduced T cell activation and proliferation by reducing the expression 
of IL-2 (Xue et al., 2011). Collectively, these data suggest that miR-181 plays 
essential roles in T cells and in the present study, we demonstrated that miR-181c is 
indeed an important mediator of actin reorganisation during T cell activation by 
modulating the expression of BRK1.  
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5 Chapter 5 – Correlation of miR-181c and BRK1 in 
Myelodysplastic Syndromes with T Cell Large Granular 
Lymphocytic Leukaemia  
5.1 Introduction 
MDS is a heterogeneous group of clonal haematopoietic stem cell malignancies, 
characterised by cytopenias, myeloid cell dysplasia and defective haematopoiesis 
(Adès et al., 2014; Corey et al., 2007; Nimer, 2008). Several studies have reported 
the association of MDS with T-LGL leukaemia, a rare and indolent disorder 
involving inappropriate expansion of the large granular cytotoxic T lymphocytes 
(Bassan et al., 1987; Dhodapkar et al., 1994; Huh et al., 2009; Saunthararajah et al., 
2001; Zhang et al., 2016). Dhodapkar and colleagues identified five patients with the 
coexistence of MDS and T-LGL (Dhodapkar et al., 1994) while Saunthararajah et al. 
and Huh et al. described nine patients each (Huh et al., 2009; Saunthararajah et al., 
2001). More recently, Zhang et al. showed that MDS patients with T-LGL cell 
proliferation exhibit more frequent BM hypocellularity and lineage hypoplasia, 
particularly erythroid hypoplasia, as compared to MDS patients without T-LGL 
proliferation (Zhang et al., 2016). Although increasing evidence indicate that T-LGL 
leukaemia is frequently associated with BM failure syndromes including MDS 
(Bassan et al., 1987; Dhodapkar et al., 1994; Huh et al., 2009; Saunthararajah et al., 
2001; Zhang et al., 2016), but there is limited data on the clinicopathological features 
of T-LGL cell proliferation in MDS patients, and the mechanism of the interference 
between T-LGL cells and the BM haematopoietic and stromal niches. 
The miR-181 family plays essential roles in haematopoiesis and its aberrant 
expression has been implicated in haematological malignancies including MDS. 
Expression of miR-181a was upregulated in advanced MDS cases but downregulated 
in early MDS. In addition, the expression level of miR-181a was found to increase 
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steadily from controls to MDS to AML (Pons et al., 2009). Furthermore, the 
expression of miR-181 family members was significantly elevated in high risk MDS 
patients as compared to low risk patients. Moreover, elevated expression levels of 
miR-181 family members were found to be associated with shorter survival in low 
risk MDS patients (Sokol, et al., 2011). On the contrary, the expression of miR-181a 
was reported to be decreased in MSC from MDS patients when compared with 
normal controls (Santamaría et al., 2012).  
However, there are no published studies on the expression of miR-181 family in 
MDS patients associated with T-LGL leukaemia. Our data on the important role of 
the miR-181c-BRK1 axis in T cell functions as well as previous findings by other 
groups on differential expression of miR-181 family members in MDS have led us to 
analyse the miR-181c expression and BRK1 protein expression in BM derived CD3+ 
T cells from MDS patients associated with T-LGL leukaemia in order to study the 
correlation of miR-181c and BRK1 in this specific group of MDS patients. 
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5.2 Clinical Features of MDS Patients with T-LGL Leukaemia 
Five MDS patients associated with T-LGL leukaemia were analysed for their miR-
181c and BRK1 expression levels. Both samples in TRIzol and cell pellets of BM 
derived CD3+ cells were obtained from the King’s College London Haemato-
Oncology Tissue Bank (Human Tissue Authority Licence Number 12223). The 
samples were collected, stored and used in accordance with donor consent given 
under the auspices of ethics approval, provided by the UK National Research Ethics 
Service (NRES) (Approval Reference 08/H0906/94).  
The median age of the patient group was 60 and two of the five patients were male. 
All five patients were classified as RCMD according to the MDS WHO classification 
system. Moreover, all of the patients had a normal karyotype and none of them had a 
STAT3 mutation. BM cellularity was normal in three patients and decreased in two 
patients. One of the patients had anaemia, neutropenia and thrombocytopenia, three 
patients had anaemia and neutropenia; and another patient had anaemia only. In 
addition, lymphocytosis was seen in three of the five patients. One of the five 
patients had mild splenomegaly and associated with coeliac disease. The 
immunophenotyping of the T-LGL population is shown in Table 5.1. 
Table 5.1: Clinical Characteristics of MDS Patients Associated with T-LGL 
Leukaemia 
Patient Age Sex Diagnosis Immunophenotype of T-LGL population 
P1  79 M RCMD CD2+ CD3+ CD8+ CD16+ CD56- CD57- 
P2  60 M RCMD CD2+ CD3+ CD8+ CD16+ CD56- CD57(weak) 
P3 72 F RCMD CD2+ CD3+ CD8+ CD7(weak) CD56- CD57- 
P4  36 F RCMD CD2+ CD3+ CD8+ CD16+ CD56+ CD57- 




5.3 Increased miR-181c and Decreased BRK1 Protein Expressions in MDS 
Patients with T-LGL Leukaemia 
To study the correlation of miR-181c and BRK1 in MDS patients associated with T-
LGL leukaemia, we examined the miR-181c expression and BRK1 protein 
expression in the BM derived CD3+ cells from five patients using qPCR and western 
blot analysis respectively. In comparison to three healthy controls, four out of five 
patients had increased expression of miR-181c (Figure 5.1a). However, the 
difference was not statistically significant (P value=0.2407) and this might be due to 
the small number of samples studied.  
For BRK1 protein expression analysis, one of the samples (P4) was degraded and 
protein was undetectable by western blot and was excluded from further western blot 
analysis. A significant decrease in the protein expression level of BRK1 (P 
value=0.0302) was detected in all four patient samples, as compared to three healthy 
controls (Figure 5.1b). Given that BRK1 is a component of the WAVE2 complex, 
WAVE2 protein level was also examined in these patients to assess whether reduced 
BRK1 expression would have an impact on WAVE2. Indeed, significant reduction in 
the WAVE2 protein expression (P value=0.0002) was detected in all of the four 
patient samples in comparison to three healthy controls (Figure 5.1b).  
Subsequently, we studied the correlation of miR-181c expression with BRK1 and 
WAVE2 protein expression levels by performing Pearson correlation analysis. miR-
181c expression level was found to be negatively correlated with protein expression 
levels of BRK1 (r = -0.6848) and WAVE2 (r = -0.7323) (Figure 5.1c). Nonetheless, 
the correlation between miR-181c expression and BRK1 (P value=0.0896) as well as 
WAVE2 (P value=0.0587) protein expressions were not statistically significant 
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Figure 5.1: Increased miR-181c but decreased BRK1 protein expression levels in 
BM derived CD3+ T cells from MDS patients with T-LGL leukaemia. (a) Figure 
shows the qPCR analysis of relative miR-181c expression in five MDS patients with 
T-LGL leukaemia (T-LGL) and three healthy controls (normal). RNA was extracted 
from the TRIzol stock of BM derived CD3+ cells, reversed transcribed to cDNA and 
analysed by qPCR. miR-181c expression is normalised to endogenous control U6 and 
error bars represent mean ± SEM. (b) Western blot analysis of BRK1 and WAVE2 
protein expressions in four MDS patients with T-LGL leukaemia (P1-P3, P5) and 
three healthy controls (N1-N3). Total protein lysates were obtained from the cell 
pellets of BM derived CD3+ cells. β-ACTIN level is used as a loading control and 
numbers represent the densitometric quantification of BRK1 and WAVE2 protein 
expression levels normalised to β-ACTIN. Data are presented in charts and error bars 
represent mean ± SD. * P ≤0.05, *** P ≤0.001. (c) Scatter plots show the Pearson 
correlation analysis of miR-181c expression with BRK1 and WAVE2 protein 
expressions. Blue dots represent healthy controls while red dots represent MDS 
patients associated with T-LGL leukaemia. The Pearson correlation coefficient r was 




To date, the mechanism of the occurrence of T-LGL leukaemia in MDS remains 
elusive. Nonetheless, Saunthararajah et al. have proposed two possible mechanisms 
of the association of T-LGL with MDS where the T-LGL might arise from a clonally 
rearranged MDS stem cell or alternatively, the T-LGL could represent an 
autoimmune response to an antigen presented by normal or MDS marrow cells 
(Saunthararajah et al., 2001). We focused on analysing the expression patterns of 
miR-181c and its target BRK1 in MDS patients associated with T-LGL leukaemia, 
because we anticipated that this analysis might provide new information relating to 
the disease pathogenesis and development. Indeed, our data demonstrated that the 
expression of miR-181c was increased but the protein expression levels of BRK1 and 
WAVE2 were decreased in BM derived CD3+ cells from MDS patients associated 
with T-LGL leukaemia.  
There are several publications reporting the aberrant expression of miR-181 in MDS 
patients. However, these studies involved MDS patients without focus on a specific 
group of patients and also different cell types were used. For instance, Pons and 
colleagues evaluated the expression of 25 mature miRNAs in BM mononuclear cells 
of 25 MDS patients and 12 healthy controls by using RT-qPCR analysis and found 
that miR-181a was downregulated in early MDS but upregulated in advanced MDS 
(Pons et al., 2009). Similarly, Sokol et al. also used BM mononuclear cells from 44 
MDS patients and 17 normal controls to examine miRNA expression by microarray 
profiling. They reported the upregulation of miR-181a, miR-181b, miR-181c and 
miR-181d in high risk MDS patients in comparison to low risk patients as validated 
by RT-qPCR analysis (Sokol, et al., 2011). Intriguingly, Santamaria et al. profiled 
the miRNA expression in MSC from 21 low risk MDS with the use of low density 
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arrays and found that the expression of miR-181a was reduced in MSC from MDS 
patients when compared with normal controls (Santamaría et al., 2012). 
In this study, we also showed that the miR-181c expression was negatively correlated 
with protein expressions of BRK1 and WAVE2 in CD3+ T cells from both patients 
and healthy controls. This data confirms our finding on the negative regulation of 
BRK1 expression by miR-181c at the translational level and suggests the negative 
correlation of miR-181c and BRK1 expression in a proportion of RCMD patients 
with T-LGL leukaemia.  
Taken together, we demonstrated that in a proportion of RCMD patients with T-LGL 
leukaemia, the miR-181c and BRK1 expression was negatively correlated where the 
miR-181c expression was upregulated but the BRK1 protein expression was 
downregulated. Despite the small sample size, our finding provides insight into the 
possible implication of miR-181c in the disease mechanism via the regulation of its 
novel target, BRK1, which requires further evaluation and investigation. 
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6 Chapter 6 – Conclusion 
6.1 Conclusion 
This study aimed to identify the target genes of miR-181 family members and to 
study its biological functions in order to provide insight into the roles of miR-181 in 
haematopoiesis and haematological malignancies. Currently available miRNA target 
identification methods lack sensitivity and specificity as most of the target 
identification methods rely predictive algorithms that mainly concentrate on the 
complementary binding between the miRNA seed sequence and the 3’UTR of target 
mRNA (Didiano and Hobert, 2006). Therefore, a functional assay based on an 
optimised and enriched cDNA library and a dual selection strategy which has 
previously been developed in-house (Gäken et al., 2012), was applied in this study to 
identify biologically relevant targets of the miR-181 family members. This method 
makes no assumptions on previously identified sequences, but relies directly on 
miRNA mediated downregulation of a thymidine kinase-zeocin (TKzeo) fusion gene 
upstream of a cDNA library which act as 3’UTR. This assay is able to identify 
miRNA targets that are downregulated by mRNA degradation or translational 
repression and not merely relies on the complementary binding of miRNA to 
putative targets. In this project, we focused on the identification of miR-181c/d-
regulated target genes. One such target was BRK1, a component of the WAVE2 
complex that has been shown to play a pivotal role in actin polymerisation 
(Takenawa and Suetsugu, 2007). Subsequent validation experiments showed that 
BRK1 was regulated by miR-181c but not miR-181d. Overexpression and inhibition 
of miR-181c had no impact on BRK1 mRNA expression but did in fact alter the 
protein expression levels, suggesting that BRK1 is modulated by miR-181c through 
translational repression. In addition, in MDS patients associated with T-LGL 
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leukaemia, the expression of miR-181c was negatively correlated with protein 
expression of BRK1 in BM derived CD3+ T cells. Increased expression of miR-181c 
and decreased BRK1 protein expression were observed in these cells, suggesting the 
modulation of BRK1 protein expression by miR-181c in this group of MDS patients.  
It has previously been demonstrated that the miR-181 family plays a key role in T 
cell development, differentiation, proliferation and activation (Georgantas et al., 
2007; Henao-Mejia et al., 2013; Li et al., 2007; Xue et al., 2011). Nevertheless, the 
role of miR-181c in actin polymerisation in T cells is still unknown. In addition, the 
role of BRK1 in the regulation of actin dynamics in T cells remains to be elucidated. 
Multiple studies have shown that the WAVE2 complex plays a crucial role in 
regulation of the actin cytoskeleton in T cells. The WAVE2 complex regulates 
immunological synapse formation, lamellipodia formation, calcium entry, integrin 
adhesion and IL-2 production in T cells (Nolz et al., 2006; Nolz et al., 2007; Nolz et 
al., 2008; Zipfel et al., 2007). Given the important role miR-181 plays in T cell 
activity and the potential role of BRK1 in the involvement in WAVE2 complex and 
actin polymerisation in T cells, we next focused our study on ascertaining the 
influence of the miR-181c-BRK1 axis in several T cell functions. In order to study 
the role of miR-181c and its target BRK1, we overexpressed miR-181c in Jurkat T 
cells and downregulated BRK1 by shRNA in Jurkat and primary T cells. Although 
ectopic expression of miR-181c and suppression of BRK1 had no impact on T cell 
proliferation, cell cycle profile and cell viability, we showed that the miR-181c-
BRK1 axis did in fact regulate actin polymerisation-dependent processes during T 
cell activation. Firstly, we showed that upon stimulation of CD3+ T cells derived 
from PBMC by CD3 and CD28 antibodies, the expression of miR-181c was reduced 
but the protein expression of BRK1 was upregulated. This data further strengthens 
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our hypothesis that the miR-181c-BRK1 axis might be important in T cell activation. 
Subsequently, we showed that overexpression of miR-181c in Jurkat T cells 
repressed T cell activation as indicated by decreased expression of CD69. In 
addition, we observed no increase in total cellular F-actin content in miR-181c 
overexpressing cells upon stimulation, indicating the involvement of miR-181c in 
actin polymerisation in T cells. Moreover, miR-181c overexpressing cells also failed 
to accumulate F-actin at the leading edge of spreading T cells, indicating the 
defective formation of lamellipodia, a process highly dependent upon actin 
reorganisation. Ectopic expression of miR-181c in Jurkat T cells also resulted in 
reduction in the F-actin accumulation at the T cell-B cell conjugation site, suggesting 
an impairment in immunological synapse formation. Similarly to miR-181c 
overexpression, we found that knockdown of BRK1 in both Jurkat and primary T 
cells led to reduction in T cell activation as shown by decreased expression of CD69 
and CD154. Depletion of BRK1 in Jurkat and primary T cells also contributed to a 
reduction in total cellular F-actin content upon stimulation, decreased F-actin 
accumulation at the T cell-B cell conjugation site, and impaired lamellipodia 
formation during T cell spreading on anti-CD3 coated slides. Additionally, our data 
in Jurkat and primary T cells showed that suppression of BRK1 resulted in decreased 
protein expressions of WAVE2, ABI1 and SRA1, suggesting that BRK1 has 
additional functions in regulating the stability of the proteins involved in the 
WAVE2 complex. This is in concordance with previous studies which demonstrated 
that loss of BRK1 led to degradation of other proteins in the WAVE complex in 
Dictyostelium (Pollitt and Insall, 2009a), Drosophila (Kunda et al., 2003; Qurashi et 
al., 2007) and mammalian cell lines (Cai et al., 2009; Derivery et al., 2008; Escobar 
et al., 2010).  
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In conclusion, we have identified BRK1 as a novel target of miR-181c and validated 
that miR-181c regulates BRK1 by repressing its translation. In addition, we have 
highlighted the important role of the miR-181c-BRK1 axis in impaired actin 
polymerisation-dependent T cell functions and T cell activation. Furthermore, we 
showed the deregulation of miR-181c-BRK1 axis in a proportion of MDS patients 
with T-LGL leukaemia, suggesting the potential role of miR-181c-BRK1 axis in the 
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Appendix A: Vectors 
 




A2: pBabePuro Vector 
 















































A3: p3’TKzeo Dual Selection Vector (Adapted from Sigma-Aldrich) 
 
The human cDNA library was inserted directionally downstream of a TKzeo fusion 




A4: pLKO.1-TRC Cloning Vector (Taken from Addgene) 
 
The shRNA against BRK1 was inserted into pLKO.1-TRC cloning vector via its 







Appendix B: Oligonucleotides  
 
B1: Oligonucleotides used to amplify miR-181 from human genomic DNA  
 
Oligo Sequence 5’-3’ Incorporated Restriction 



























B2: Oligonucleotides used to amplify putative targets of miR-181c/d 
 
Several primers designed to flank the SfiI sites in the p3’TKzeo vector were used in 
optimisation of amplification of putative miR-181c/d target genes. 
 
Oligo Sequence 5’-3’ Annealing 
Temperature (°C) 
3 Forward (3F) GGGTCGACCTCGAATCCTTA 62 
9 Forward (9F) CAAGTTGACCAGTGCCGTTC 61 
11 Forward (11F) CCTTAGGCCATTAAGGCC 61 
14 Forward (14 F) TCGACCTCGAATCCTTAG 56 
15 Forward (15 F) GGGTCGACCTCGAATCC 55 
10 Reverse 
(10RTTT) 
CGAGGCGGCCGACATGTTT 55, 56, 61 or 62 
(depending on forward 
primer) 
 
Primers Alignment in p3’UTR of TKzeo Vector 
 
 
Reverse Primer of 10RTTT  
 



























B3: Oligonucleotides for qPCR (Probe Based Detection) 
 
Oligo Sequence 5’-3’ Probe 
GAPDH_F AGCCACATC GCTCAGACAC 60 
GAPHD_R GCCCAATACGACCAAATCC 60 
BRK1_F AGTACATTGAAGCTCGGGTGA 3 
BRK1_R GGCCTGTGTTGTGTAAAGCA 3 
DHTKD1_F TGTCGAAACTAATGCTGGAATC 49 
DHTKD1_R TCCATATCGCTTCACTGTCG 49 
 
B4: Oligonucleotides for qPCR (DNA Dye Based Detection – SYBR® Green) 
 









B5: Oligonucleotides for Sanger Sequencing  
 
Oligo Sequence 5’-3’ 
pLKO.1_Seq CAAGGCTGTTAGAGAGATAATTGGA 
M13 Forward (-20) GTAAAACGACGGCCAG 








Appendix C:  
 
C1: Oligonucleotides of shRNA Directed Against BRK1 
 


















C2: Sequences of miRNA Inhibitors, siRNA and shRNA 
 








































shRNA Target Sequence Supplier 
shBRK1_1 GACTTTCTCAACTCGTTCGAT NA 
shBRK1_2 CTTGTCGTTCAAGACTTGCAA NA 
Scrambled shRNA CCTAAGGTTAAGTCGCCCTCG Addgene 
NA: not applicable 
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Appendix D: Antibodies for Western Blotting 
 
Primary Antibody Description Source (Cat No) Working 
Dilution  
Anti-β-ACTIN Mouse monoclonal Abcam (ab8226) 1:1000 
Anti-DHTKD1 Rabbit polyclonal 
antibody 
Abgent (AP10715c) 1:500 
 
Anti-BRK1 Mouse monoclonal Generous gift from 
Professor Stradal Theresia 
1:3 
Anti-WAVE2 (H-110) Rabbit polyclonal 
antibody 
Santa Cruz Biotechnology 
(sc-33548) 
1:500 
Anti-ABI1 (C-1) Mouse monoclonal 
antibody 
Santa Cruz Biotechnology 
(sc-398554) 
1:500 
Anti-PIR121-1/Sra-1 Rabbit polyclonal 
IgG 
Millipore (07-531) 1:500 
Anti-HEM1 (Q-12) Goat polyclonal 
antibody 
Santa Cruz Biotechnology 
(sc-107591) 
1:200 
Anti-ARP2 (H-84) Rabbit polyclonal 
antibody 






Millipore (07-272) 1:500 
Secondary Antibody Description Source (Cat No) Working 
Dilution  





Anti-mouse IgG HRP-linked 
antibody 
Promega (W4021) 1:1000 or 
1:5000 
Rabbit anti-goat IgG Polyclonal HRP-
linked antibody 









pBabePuro Dr Joop Gäken 
pMDG (envelope plasmid encoding VSVG) Dr David Darling 
pREV (packaging plasmid encoding REV) Dr David Darling 
pRRE (packaging plasmid encoding Gag & Pol) Dr David Darling 
p3’TKzeo-library Dr Joop Gäken 
pLKO.1-scrambled shRNA Addgene (plasmid #1864) 
pLKO.1-TRC cloning vector Addgene (plasmid #10878) 
 
E2: Cell Lines 
 
Cell Line Cell Source Provider 
MCF7 Breast adenocarcinoma Dr Joop Gäken 
HeLa Cervical adenocarcinoma Dr Joop Gäken 
Jurkat Acute T cell leukaemia Dr Terry Gaymes 
HepG2 Hepatocellular carcinoma Dr Joop Gäken 
293T Human embryonic kidney Dr David Darling 
NIH/3T3 Mouse embryo fibroblast Dr Joop Gäken 
K562 Chronic myelogenous leukaemia Dr David Darling 
KG-1 Acute myelogenous leukaemia Dr Terry Gaymes 
NB-4 Acute promyelocytic leukaemia Dr Terry Gaymes 
THP-1 Acute monocytic leukaemia Dr Terry Gaymes 
U937 Histiocytic lymphoma Dr Terry Gaymes 




Appendix F: miRNA Profiling of Cell Lines 
 
Cell Line miR-181c Expression miR-181d Expression 
293T 2966.093018 75.01759338 
HeLa 10684.79199 60.73740768 
CHO 894.2407837 370.772583 
MCF7 1155.665527 1 
COS7 7059.505371 41.21817398 
NIH/3T3 1782.085938 344.5409851 
TE761 935.8190918 8.6062603 
HepG2 387.5531311 1 
Saos2 6478.030273 326.6053162 
 
miRNA profiling was performed using Illumina bead assay by the company 
Geneservice. Normalised expression levels of miRNA were between 1 (no 
expression) and 60,000. A 500 fold change was used as the cut-off point where 
expression below 500 was considered low while above 500 was considered high. 
This was based on the qPCR results of the miRNA expression, which have shown a 
strong correlation between the qPCR and the array profiling data. This work was 
performed by Dr Joop Gäken before the start of this project.  
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Appendix G: Alignment of forward and reverse sequences against human 
genome and transcripts database in NCBI Nucleotide Blast 
 
G1.1: Forward sequence that aligned to DHTKD1 mRNA transcript 
 
Score Expect Identities Gaps Strand 
649 bits(351) 0.0 356/358(99%) 1/358(0%) Plus/Plus 
 
Query  1     gggtggggtggcacatgcctgtaatcccagcactttgggaggccaaggctggtggatcac  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2931  GGGTGGGGTGGCACATGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGCTGGTGGATCAC  2990 
 
Query  61    ctgaggtcaggagttcgagaccagcctggccaacacggtgaaaccccgcctctactaaaa  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2991  CTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACACGGTGAAACCCCGCCTCTACTAAAA  3050 
 
Query  121   atacaaaaaatagccgggtgtggtggtgggcacctgtgatcccagcttcctgggaggctg  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3051  ATACAAAAAATAGCCGGGTGTGGTGGTGGGCACCTGTGATCCCAGCTTCCTGGGAGGCTG  3110 
 
Query  181   aggcaagagaatcgcttgaatctggggggcggaggttgcagtgagccaggatcacaccat  240 
             |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Sbjct  3111  AGGCAAGAGAATCGCTTGAATCTGGGAGGCGGAGGTTGCAGTGAGCCAGGATCACACCAT  3170 
 
Query  241   tgctgtccagcctgggtgacagagcaagactgcgtttcaaaaaaaaaaaaaaaaaaaCCC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3171  TGCTGTCCAGCCTGGGTGACAGAGCAAGACTGCGTTTCAAAAAAAAAAAAAAAAAAACCC  3230 
 
Query  301   ATTAAAAGAGGCCTCCTTCCTCCACTCTCTCAACCCCTCTGTTGGGGTAACATGAAAA  358 
             |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct  3231  ATTAAAAGAGGCCTCCTTCCTCCACTCTCTCAACCCCTCTGTTGGG-TAACATGAAAA  3287 
 
G1.2: Reverse sequence that aligned to DHTKD1 mRNA transcript 
 
Score Expect Identities Gaps Strand 
610 bits(330) 8e-172 465/528(88%) 18/528(3%) Plus/Minus 
 
Query  5     ttttttttttttttttttttttttttttttttttttccctatttctaccatcacACCTTC  64 
             ||| ||||||| || || ||||| |||| || |||||| ||||||||||||||||||||| 
Sbjct  3459  TTTCTTTTTTTGTTATTGTTTTTCTTTTGTTGTTTTCC-TATTTCTACCATCACACCTTC  3401 
 
Query  65    AAGGAAAAATTTGCTGGTTGCATTCACATATTCATAACCAGTTCCCCTGGTTATTCCACC  124 
             ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3400  AAGGATAAATTTGCTGGTTGCATTCACATATTCATAACCAGTTCCCCTGGTTATTCCACC  3341 
 
Query  125   TATTGCAAATTAAATCACGTATATCAATCCCAACATCTTAAAGGAATACAGTCTTTTCAT  184 
             ||||||| |||||||||||||||||||||||||||||||| ||||||||||||||||||| 
Sbjct  3340  TATTGCAGATTAAATCACGTATATCAATCCCAACATCTTAGAGGAATACAGTCTTTTCAT  3281 
 
Query  185   GTTACCCAACAAAGGGGTTGAAAAAGGGGAGGAAGGAGGCCTCTTTTAAGGGGttttttt  244 
             ||||||||||| ||||||||| | || |||||||||||||||||||||| |||||||||| 
Sbjct  3280  GTTACCCAACAGAGGGGTTGAGAGAGTGGAGGAAGGAGGCCTCTTTTAATGGGTTTTTTT  3221 
 
Query  245   ttttttttttttgaa-cgcaatcttggtctgtcacccagggtgggcagcaagggtgtgaa  303 
             ||||||||||||||| |||| ||||| ||||||||||||| ||| |||||| |||||||  
Sbjct  3220  TTTTTTTTTTTTGAAACGCAGTCTTGCTCTGTCACCCAGGCTGGACAGCAATGGTGTGA-  3162 
 
Query  304   tctttgctcatggaaacctc-gcccccaagattcaagcgattctcttgcctcagcctccc  362 
             || | |||||  | |||||| ||| || |||||||||||||||||||||||||||||||| 
Sbjct  3161  TCCTGGCTCACTGCAACCTCCGCCTCCCAGATTCAAGCGATTCTCTTGCCTCAGCCTCCC  3102 
 
Query  363   aggaagctgggatcacaggtgccccccac-acacccggctattttt-gtttttatagaaa  420 
             |||||||||||||||||||||||| |||| |||||||||||||||| || ||| ||| |  
Sbjct  3101  AGGAAGCTGGGATCACAGGTGCCCACCACCACACCCGGCTATTTTTTGTATTTTTAGTAG  3042 
 
Query  421   ag-cgggg-ttcaccgtggggggcagggggggctcga-ctcc-gaacttaggtgatc-ac  475 
             || ||||| |||||||||  || ||||  || ||||| |||| || || |||||||| || 
Sbjct  3041  AGGCGGGGTTTCACCGTGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGGTGATCCAC  2982 
 
Query  476   -agtcttggc-tctcaaag--ctgtgat-acagAAA-GTGTCCACCCC  517 
              || |||||| || |||||  ||| ||| ||||  | ||| ||||||| 
Sbjct  2981  CAGCCTTGGCCTCCCAAAGTGCTGGGATTACAGGCATGTG-CCACCCC  2935 
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G2.1: Forward sequence that aligned to BRK1 mRNA transcript 
 
Score Expect Identities Gaps Strand 
771 bits(417) 0.0 424/427(99%) 1/427(0%) Plus/Minus 
 
Query  31   agagcccaaaggccacacttttgaaaaaagaaaaaCAAGAATAAGCCCTGTTGCTCTTTA  90 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  432  AGAGCCCAAAGGCCACACTTTTGAAAAAAGAAAAACAAGAATAAGCCCTGTTGCTCTTTA  373 
     
Query  91   AGGAGAAAGGAAGGAGCTGAAGGCTGCTGGGGCCTTTCCCATGTGGCCTGTGTTGTGTAA  150 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  372  AGGAGAAAGGAAGGAGCTGAAGGCTGCTGGGGCCTTTCCCATGTGGCCTGTGTTGTGTAA  313 
 
Query  151  AGCAACTTCCCAGCAGCAGCACGGCACTGTTCTAGGTGAGTGTCTCACCTTTTGTCACCC  210 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  312  AGCAACTTCCCAGCAGCAGCACGGCACTGTTCTAGGTGAGTGTCTCACCTTTTGTCACCC  253 
 
Query  211  GAGCTTCAATGCACTCTATTCTCCGTTCAAGGGCTGTCAATTTCTCGTTTAGTGTTGCAA  270 
            ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  252  GAGCTTCAATGTACTCTATTCTCCGTTCAAGGGCTGTCAATTTCTCGTTTAGTGTTGCAA  193 
 
Query  271  GTCTTGAACGACAAGACATATCGAACGAGTTGAGAAAGTCTGCGATTTTCTTGATGCTGC  330 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  192  GTCTTGAACGACAAGACATATCGAACGAGTTGAGAAAGTCTGCGATTTTCTTGATGCTGC  133 
 
Query  331  TGGTGATTATCTCAATGTACTCCCGGTTAGCCCAGTCCTGGTGAATCTCCCGCTGCACCG  390 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  132  TGGTGATTATCTCAATGTACTCCCGGTTAGCCCAGTCCTGGTGAATCTCCCGCTGCACCG  73 
 
Query  391  GATCCTCCTGTCCCGCCATGGCCGCCGCCTGAGGAAAAGCGACTGCGCAGGCGCCCCGAC  450 
            |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||| 
Sbjct  72   GATCCTCCTGTCCCGCCATGGCCGCCGCCTGAGGAAGAGCGACTGCGCAGGCGCCCCGAC  13 
 
Query  451  C-TACAG  456 
            | ||||| 
Sbjct  12   CCTACAG  6 
 
G2.2: Reverse sequence that aligned to BRK1 mRNA transcript 
 
Score Expect Identities Gaps Strand 
782 bits(423) 0.0 429/432(99%) 0/432(0%) Plus/Plus 
 
Query  5    GAGGACTGTAGGGTCGGGGCGCCTGCGCAGTCGCTTTTCCTCAGGCGGCGGCCATGGCGG  64 
            |||| |||||||||||||||||||||||||||||| |||||||||||||||||||||||| 
Sbjct  1    GAGGCCTGTAGGGTCGGGGCGCCTGCGCAGTCGCTCTTCCTCAGGCGGCGGCCATGGCGG  60 
 
Query  65   GACAGGAGGATCCGGTGCAGCGGGAGATTCACCAGGACTGGGCTAACCGGGAGTACATTG  124 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GACAGGAGGATCCGGTGCAGCGGGAGATTCACCAGGACTGGGCTAACCGGGAGTACATTG  120 
 
Query  125  AGATAATCACCAGCAGCATCAAGAAAATCGCAGACTTTCTCAACTCGTTCGATATGTCTT  184 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AGATAATCACCAGCAGCATCAAGAAAATCGCAGACTTTCTCAACTCGTTCGATATGTCTT  180 
 
Query  185  GTCGTTCAAGACTTGCAACACTAAACGAGAAATTGACAGCCCTTGAACGGAGAATAGAGT  244 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GTCGTTCAAGACTTGCAACACTAAACGAGAAATTGACAGCCCTTGAACGGAGAATAGAGT  240 
 
Query  245  GCATTGAAGCTCGGGTGACAAAAGGTGAGACACTCACCTAGAACAGTGCCGTGCTGCTGC  304 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  ACATTGAAGCTCGGGTGACAAAAGGTGAGACACTCACCTAGAACAGTGCCGTGCTGCTGC  300 
 
Query  305  TGGGAAGTTGCTTTACACAACACAGGCCACATGGGAAAGGCCCCAGCAGCCTTCAGCTCC  364 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  TGGGAAGTTGCTTTACACAACACAGGCCACATGGGAAAGGCCCCAGCAGCCTTCAGCTCC  360 
 
Query  365  TTCCTTTCTCCTTAAAGAGCAACAGGGCTTATTCTTGtttttcttttttcaaaagtgtgg  424 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  TTCCTTTCTCCTTAAAGAGCAACAGGGCTTATTCTTGTTTTTCTTTTTTCAAAAGTGTGG  420 
 
Query  425  cctttgggctct  436 
            |||||||||||| 
Sbjct  421  CCTTTGGGCTCT  432 
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Appendix H: Predicted Targets of miR-181c and miR-181d Using miRecords 
 
H1: A list of 151 miR-181c targets predicted by miRanda, MirTarget2, PicTar, PITA, 
RNAhybrid and TargetScan 
 
Symbol Description Symbol Description 
SENP1 SUMO1/sentrin specific peptidase 1 ESR1 estrogen receptor 1 
PI4K2B phosphatidylinositol 4-kinase type 2 beta ATP2B1 
ATPase, Ca++ transporting, plasma 
membrane 1 
CTTNBP2
NL CTTNBP2 N-terminal like EIF4A2 
eukaryotic translation initiation factor 
4A, isoform 2 
PCDHAC1 protocadherin alpha subfamily C, 1 ETV6 ets variant gene 6 (TEL oncogene) 
PCDHAC2 protocadherin alpha subfamily C, 2 ACSL1 
acyl-CoA synthetase long-chain 
family member 1 
PCDHA1 protocadherin alpha 1 HLF hepatic leukemia factor 
PCDHA12 protocadherin alpha 12 ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 
PCDHA13 protocadherin alpha 13 ITGB8 integrin, beta 8 
PCDHA2 protocadherin alpha 2 KPNA1 karyopherin alpha 1 (importin alpha 5) 
PCDHA3 protocadherin alpha 3 KPNB1 karyopherin (importin) beta 1 
PCDHA4 protocadherin alpha 4 LBR lamin B receptor 
PCDHA5 protocadherin alpha 5 MAP2K1 mitogen-activated protein kinase kinase 1 
PCDHA7 protocadherin alpha 7 PTPN9 protein tyrosine phosphatase, non-receptor type 9 
PCDHA8 protocadherin alpha 8 RBBP7 retinoblastoma binding protein 7 
SLC38A2 solute carrier family 38, member 2 CLIP1 
CAP-GLY domain containing linker 
protein 1 
CCNJ cyclin J STC1 stanniocalcin 1 
PCNP PEST proteolytic signal containing nuclear protein UBE2B 
ubiquitin-conjugating enzyme E2B 
(RAD6 homolog) 
FLJ20160 FLJ20160 protein ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 
INOC1 INO80 complex homolog 1 (S. cerevisiae) ACVR2A activin A receptor, type IIA 
FAM13B1 family with sequence similarity 13, member B1 CYR61 cysteine-rich, angiogenic inducer, 61 
KIAA0182 KIAA0182 NR3C1 
nuclear receptor subfamily 3, group 
C, member 1 (glucocorticoid 
receptor) 
TOX thymocyte selection-associated high mobility group box ATXN1 ataxin 1 
DAZAP2 DAZ associated protein 2 TIMP3 
TIMP metallopeptidase inhibitor 3 
(Sorsby fundus dystrophy, 
pseudoinflammatory) 
KIAA0528 KIAA0528 IL1A interleukin 1, alpha 
GLS glutaminase PAM peptidylglycine alpha-amidating monooxygenase 
BTBD3 BTB (POZ) domain containing 3 ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 
USP33 ubiquitin specific peptidase 33 LMO3 LIM domain only 3 (rhombotin-like 2) 
KIAA0423 KIAA0423 C16orf87 chromosome 16 open reading frame 87 
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Symbol Description Symbol Description 
HIC2 hypermethylated in cancer 2 AFTPH Aftiphilin 
GPD1L glycerol-3-phosphate dehydrogenase 1-like OSBPL8 oxysterol binding protein-like 8 
KANK1 KN motif and ankyrin repeat domains 1 LIN28B lin-28 homolog B (C. elegans) 
DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 13 KLF6 Kruppel-like factor 6 
CLASP1 cytoplasmic linker associated protein 1 EN1 engrailed homeobox 1 
OSBPL3 oxysterol binding protein-like 3 EN2 engrailed homeobox 2 
GAPVD1 GTPase activating protein and VPS9 domains 1 NR6A1 
nuclear receptor subfamily 6, group 
A, member 1 
HECA headcase homolog (Drosophila) B4GALT1 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 1 
LRRN1 leucine rich repeat neuronal 1 ZIC3 Zic family member 3 heterotaxy 1 (odd-paired homolog, Drosophila) 
PKNOX2 PBX/knotted 1 homeobox 2 CUL3 cullin 3 
MPP5 
membrane protein, palmitoylated 




CDC42 binding protein kinase alpha 
(DMPK-like) 
RNF145 ring finger protein 145 MAT2A methionine adenosyltransferase II, alpha 
RNF182 ring finger protein 182 DYNC1LI2 
dynein, cytoplasmic 1, light 
intermediate chain 2 
C7orf41 chromosome 7 open reading frame 41 PBX3 pre-B-cell leukemia homeobox 3 
EED embryonic ectoderm development PDGFRA platelet-derived growth factor receptor, alpha polypeptide 
FLJ38973 hypothetical protein FLJ38973 ARFGEF2 
ADP-ribosylation factor guanine 
nucleotide-exchange factor 2 
(brefeldin A-inhibited) 
POM121 POM121 membrane glycoprotein (rat) NFAT5 
nuclear factor of activated T-cells 5, 
tonicity-responsive 
CNTN4 contactin 4 LRBA LPS-responsive vesicle trafficking, beach and anchor containing 
ANKRD43 ankyrin repeat domain 43 SOX5 SRY (sex determining region Y)-box 5 
ZNF800 zinc finger protein 800 NR4A3 nuclear receptor subfamily 4, group A, member 3 
C3orf59 chromosome 3 open reading frame 59 TARDBP TAR DNA binding protein 
RSPO2 R-spondin 2 homolog (Xenopus laevis) SIRT1 
sirtuin (silent mating type 




ADAM metallopeptidase with 
thrombospondin type 1 motif, 6 G3BP2 
GTPase activating protein (SH3 
domain) binding protein 2 
SS18L1 synovial sarcoma translocation gene on chromosome 18-like 1 YWHAG 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
gamma polypeptide 
OTUD4 OTU domain containing 4 SSX2IP synovial sarcoma, X breakpoint 2 interacting protein 
ADAMTS
18 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 18 KLF15 Kruppel-like factor 15 
FBXO33 F-box protein 33 NPTXR neuronal pentraxin receptor 
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Symbol Description Symbol Description 
MBOAT2 
membrane bound O-
acyltransferase domain containing 
2 
MAP1B microtubule-associated protein 1B 
SLITRK1 SLIT and NTRK-like family, member 1 ST8SIA4 
ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 4 
CNTNAP3 contactin associated protein-like 3 LPP LIM domain containing preferred translocation partner in lipoma 
HOXC8 homeobox C8 PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 
GPBP1 GC-rich promoter binding protein 1 BHLHB2 
basic helix-loop-helix domain 
containing, class B, 2 
C17orf39 chromosome 17 open reading frame 39 IRS2 insulin receptor substrate 2 
DERL1 Der1-like domain family, member 1 PCAF p300/CBP-associated factor 
LIN28 lin-28 homolog (C. elegans) AKAP6 A kinase (PRKA) anchor protein 6 
RNF34 ring finger protein 34 DUSP5 dual specificity phosphatase 5 
CPEB4 cytoplasmic polyadenylation element binding protein 4 RAB11A 
RAB11A, member RAS oncogene 
family 
ANKRD13
C ankyrin repeat domain 13C NMT2 N-myristoyltransferase 2 
C6orf62 chromosome 6 open reading frame 62 CDYL chromodomain protein, Y-like 
SPRY4 sprouty homolog 4 (Drosophila) ATG5 ATG5 autophagy related 5 homolog (S. cerevisiae) 
PPP1R12B protein phosphatase 1, regulatory (inhibitor) subunit 12B TBPL1 TBP-like 1 
FOXP1 forkhead box P1 ZFP36L1 zinc finger protein 36, C3H type-like 1 
ADO 2-aminoethanethiol (cysteamine) dioxygenase SEL1L 
sel-1 suppressor of lin-12-like (C. 
elegans) 
SYNE1 spectrin repeat containing, nuclear envelope 1 ETS1 
v-ets erythroblastosis virus E26 
oncogene homolog 1 (avian) 
PURB purine-rich element binding protein B PRKCE protein kinase C, epsilon 
DOCK7 dedicator of cytokinesis 7 LRRC32 leucine rich repeat containing 32 
E2F7 E2F transcription factor 7 LEMD3 LEM domain containing 3 




H2: A list of 222 miR-181d targets predicted by miRanda, MirTarget2, PITA, 
RNAhybrid and TargetScan 
 
Symbol Description Symbol Description 
PCDHA6 protocadherin alpha 6 CD69 CD69 molecule 
GAPVD1 GTPase activating protein and VPS9 domains 1 QSER1 glutamine and serine rich 1 
OSBPL3 oxysterol binding protein-like 3 C14orf43 chromosome 14 open reading frame 43 
CLASP1 cytoplasmic linker associated protein 1 SLC9A6 
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 6 
TRIM2 tripartite motif-containing 2 MTMR12 myotubularin related protein 12 
DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 13 PAPD5 PAP associated domain containing 5 
DMXL2 Dmx-like 2 NKAIN2 Na+/K+ transporting ATPase interacting 2 
HISPPD1 histidine acid phosphatase domain containing 1 FAM3C 
family with sequence similarity 3, 
member C 
TBC1D1 TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 TCERG1 transcription elongation regulator 1 
PHF3 PHD finger protein 3 CREBZF CREB/ATF bZIP transcription factor 
GPD1L glycerol-3-phosphate dehydrogenase 1-like PALM2 paralemmin 2 
HIC2 hypermethylated in cancer 2 ARL5A ADP-ribosylation factor-like 5A 
PHF20L1 PHD finger protein 20-like 1 KIAA1553 KIAA1553 
CDON Cdon homolog (mouse) ACVR2B activin A receptor, type IIB 
SEMA4G 
sema domain, immunoglobulin 
domain (Ig), transmembrane 




PCDHA5 protocadherin alpha 5 ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 
PCDHA3 protocadherin alpha 3 ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 
PCDHA2 protocadherin alpha 2 ADRBK1 adrenergic, beta, receptor kinase 1 
PCDHA13 protocadherin alpha 13 ACVR2A activin A receptor, type IIA 
PCDHA10 protocadherin alpha 10 CYR61 cysteine-rich, angiogenic inducer, 61 
PCDHA1 protocadherin alpha 1 EN2 engrailed homeobox 2 
PCDHAC1 protocadherin alpha subfamily C, 1 S1PR1 sphingosine-1-phosphate receptor 1 
CTTNBP2
NL CTTNBP2 N-terminal like DPYSL2 dihydropyrimidinase-like 2 
C10orf6 chromosome 10 open reading frame 6 DDX3X 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, X-linked 
FIGN fidgetin CPD carboxypeptidase D 
TMEM16
A transmembrane protein 16A KLF6 Kruppel-like factor 6 
BTBD3 BTB (POZ) domain containing 3 FOXK1 forkhead box K1 
TBC1D4 TBC1 domain family, member 4 YTHDC1 YTH domain containing 1 
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Symbol Description Symbol Description 
TSC22D2 TSC22 domain family, member 2 AP1G1 adaptor-related protein complex 1, gamma 1 subunit 
GREM1 
gremlin 1, cysteine knot 
superfamily, homolog (Xenopus 
laevis) 
ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 
G3BP2 GTPase activating protein (SH3 domain) binding protein 2 ITSN1 intersectin 1 (SH3 domain protein) 
SIRT1 
sirtuin (silent mating type 
information regulation 2 
homolog) 1 (S. cerevisiae) 
PAM peptidylglycine alpha-amidating monooxygenase 
ILF3 interleukin enhancer binding factor 3, 90kDa GRM5 glutamate receptor, metabotropic 5 
MIP major intrinsic protein of lens fiber GABRA1 
gamma-aminobutyric acid (GABA) 
A receptor, alpha 1 
TARDBP TAR DNA binding protein FKBP1A FK506 binding protein 1A, 12kDa 
KLHL2 kelch-like 2, Mayven (Drosophila) CD4 CD4 molecule 
UBL3 ubiquitin-like 3 GPD2 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 
ADAMTS
5 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 5 
(aggrecanase-2) 
TIMP3 
TIMP metallopeptidase inhibitor 3 
(Sorsby fundus dystrophy, 
pseudoinflammatory) 
SOX5 SRY (sex determining region Y)-box 5 TGFBI 
transforming growth factor, beta-
induced, 68kDa 
CALM1 calmodulin 1 (phosphorylase kinase, delta) NR3C1 
nuclear receptor subfamily 3, group 
C, member 1 (glucocorticoid 
receptor) 
LRP12 low density lipoprotein-related protein 12 LMO3 
LIM domain only 3 (rhombotin-like 
2) 
BAZ2B bromodomain adjacent to zinc finger domain, 2B GRB10 
growth factor receptor-bound protein 
10 
SSX2IP synovial sarcoma, X breakpoint 2 interacting protein PPARA 
peroxisome proliferator-activated 
receptor alpha 
DAZAP2 DAZ associated protein 2 TNRC6B trinucleotide repeat containing 6B 
TOX thymocyte selection-associated high mobility group box ABI1 abl-interactor 1 
DOCK4 dedicator of cytokinesis 4 GOLGA8E 
golgi autoantigen, golgin subfamily 
a, 8E 
DOCK10 dedicator of cytokinesis 10 ATP11C ATPase, class VI, type 11C 
UBE3C ubiquitin protein ligase E3C KIAA2022 KIAA2022 
BRD1 bromodomain containing 1 ENAH enabled homolog (Drosophila) 
UBP1 upstream binding protein 1 (LBP-1a) CTDSPL 
CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide A) 
small phosphatase-like 
RABGEF1 RAB guanine nucleotide exchange factor (GEF) 1 LMBRD2 LMBR1 domain containing 2 
GHITM growth hormone inducible transmembrane protein 
SLC25A2
5 
solute carrier family 25 
(mitochondrial carrier; phosphate 
carrier), member 25 
LEMD3 LEM domain containing 3 LIN28B lin-28 homolog B (C. elegans) 
KLF15 Kruppel-like factor 15 LYCAT lysocardiolipin acyltransferase 
LRBA 
LPS-responsive vesicle 
trafficking, beach and anchor 
containing 
ESR1 estrogen receptor 1 
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Symbol Description Symbol Description 
SLC38A2 solute carrier family 38, member 2 EIF4A2 
eukaryotic translation initiation factor 
4A, isoform 2 
E2F7 E2F transcription factor 7 NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive 
MAMDC2 MAM domain containing 2 SEL1L sel-1 suppressor of lin-12-like (C. elegans) 
EED embryonic ectoderm development ZFP36L1 zinc finger protein 36, C3H type-like 1 
CPNE2 copine II ONECUT2 one cut homeobox 2 
MIER3 mesoderm induction early response 1, family member 3 ATG5 
ATG5 autophagy related 5 homolog 
(S. cerevisiae) 
LONRF1 LON peptidase N-terminal domain and ring finger 1 NMT2 N-myristoyltransferase 2 
ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 KIF3B kinesin family member 3B 
SYNPR synaptoporin RAB11A RAB11A, member RAS oncogene family 
MBOAT2 
membrane bound O-
acyltransferase domain containing 
2 
TGFBR1 
transforming growth factor, beta 
receptor I (activin A receptor type II-
like kinase, 53kDa) 
DCBLD2 discoidin, CUB and LCCL domain containing 2 
RPS6KA
3 
ribosomal protein S6 kinase, 90kDa, 
polypeptide 3 
SLITRK1 SLIT and NTRK-like family, member 1 DUSP5 dual specificity phosphatase 5 
BRWD1 bromodomain and WD repeat domain containing 1 AKAP6 A kinase (PRKA) anchor protein 6 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 GATA6 GATA binding protein 6 
POM121 POM121 membrane glycoprotein (rat) PRKCE protein kinase C, epsilon 
DIP2B DIP2 disco-interacting protein 2 homolog B (Drosophila) TOM1L1 target of myb1 (chicken)-like 1 
ADAMTS
18 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 18 
ARFGEF
2 
ADP-ribosylation factor guanine 
nucleotide-exchange factor 2 
(brefeldin A-inhibited) 
OTUD4 OTU domain containing 4 PRKCD protein kinase C, delta 
SS18L1 synovial sarcoma translocation gene on chromosome 18-like 1 
DYNC1L
I2 
dynein, cytoplasmic 1, light 
intermediate chain 2 
ZC3H6 zinc finger CCCH-type containing 6 RNF6 ring finger protein (C3H2C3 type) 6 
SRPK2 SFRS protein kinase 2 MAT2A methionine adenosyltransferase II, alpha 
RSPO2 R-spondin 2 homolog (Xenopus laevis) ST8SIA4 
ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 4 
C3orf59 chromosome 3 open reading frame 59 NFIB nuclear factor I/B 
WDR40B WD repeat domain 40B LPP LIM domain containing preferred translocation partner in lipoma 
PPM1B 
protein phosphatase 1B (formerly 
2C), magnesium-dependent, beta 
isoform 
INPP5A inositol polyphosphate-5-phosphatase, 40kDa 
ANKRD43 ankyrin repeat domain 43 HOXA1 homeobox A1 
CNTN4 contactin 4 LRRC32 leucine rich repeat containing 32 
CNTNAP3 contactin associated protein-like 3 PCAF p300/CBP-associated factor 
  
 231 
Symbol Description Symbol Description 
DOCK7 dedicator of cytokinesis 7 CCNK cyclin K 
FOXP1 forkhead box P1 RNMT RNA (guanine-7-) methyltransferase 
PKNOX2 PBX/knotted 1 homeobox 2 PAWR PRKC, apoptosis, WT1, regulator 
SEC24A SEC24 related gene family, member A (S. cerevisiae) 
TNFRSF1
1B 
tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 
RBM25 RNA binding motif protein 25 NOVA1 neuro-oncological ventral antigen 1 
ZBTB4 zinc finger and BTB domain containing 4 MAP3K3 
mitogen-activated protein kinase 
kinase kinase 3 
LRRN1 leucine rich repeat neuronal 1 ADAM11 ADAM metallopeptidase domain 11 
SIPA1L2 signal-induced proliferation-associated 1 like 2 LBR lamin B receptor 
KIAA1219 KIAA1219 IPO5 importin 5 
SPIRE1 spire homolog 1 (Drosophila) KPNA1 karyopherin alpha 1 (importin alpha 5) 
PLEKHA3 
pleckstrin homology domain 
containing, family A 
(phosphoinositide binding 
specific) member 3 
ITGB8 integrin, beta 8 
CCNJ cyclin J HMGB2 high-mobility group box 2 
ZFAND6 zinc finger, AN1-type domain 6 ACSL1 acyl-CoA synthetase long-chain family member 1 
MPP5 
membrane protein, palmitoylated 
5 (MAGUK p55 subfamily 
member 5) 
PLAG1 pleiomorphic adenoma gene 1 
HOXC8 homeobox C8 MAPK1 mitogen-activated protein kinase 1 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) MAP2K1 
mitogen-activated protein kinase 
kinase 1 
SCOC short coiled-coil protein IRS2 insulin receptor substrate 2 
FAM160A
2 
family with sequence similarity 
160, member A2 BHLHB2 
basic helix-loop-helix domain 
containing, class B, 2 
PPP1R12B protein phosphatase 1, regulatory (inhibitor) subunit 12B PIK3R3 
phosphoinositide-3-kinase, 
regulatory subunit 3 (gamma) 
SPRY4 sprouty homolog 4 (Drosophila) PPFIA1 
protein tyrosine phosphatase, 
receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), 
alpha 1 
C6orf62 chromosome 6 open reading frame 62 
CDC42B
PA 
CDC42 binding protein kinase alpha 
(DMPK-like) 
ANKRD13
C ankyrin repeat domain 13C CUL3 cullin 3 
CPEB4 cytoplasmic polyadenylation element binding protein 4 ZIC3 
Zic family member 3 heterotaxy 1 
(odd-paired homolog, Drosophila) 
LPCAT1 lysophosphatidylcholine acyltransferase 1 UBE2B 
ubiquitin-conjugating enzyme E2B 
(RAD6 homolog) 
LIN28 lin-28 homolog (C. elegans) STC1 stanniocalcin 1 
DERL1 Der1-like domain family, member 1 CLIP1 
CAP-GLY domain containing linker 
protein 1 
C17orf39 chromosome 17 open reading frame 39 PTPN9 
protein tyrosine phosphatase, non-
receptor type 9 
RIN2 Ras and Rab interactor 2 ETV6 ets variant gene 6 (TEL oncogene) 
 
 
 
